Page last updated: 2024-08-24

zanamivir and Grippe

zanamivir has been researched along with Grippe in 733 studies

Research

Studies (733)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	61 (8.32)	18.2507
2000's	280 (38.20)	29.6817
2010's	341 (46.52)	24.3611
2020's	51 (6.96)	2.80

Authors

Authors	Studies
He, PL; Jiang, H; Li, J; Li, T; Liu, H; Tang, W; Zheng, M; Zhu, W; Zuo, JP	1
Bailey, KW; Barnard, DL; Day, CW; Furuta, Y; Morrey, JD; Sidwell, RW; Smee, DF; Wong, MH	1
Li, YH; Li, ZR; Liu, ZY; Shao, HY; Wang, B; Yi, H; You, XF; Zhao, LX	1
Kakuta, M; Kubo, S; Nasu, H; Tokumitsu, A; Tomozawa, T; Yamashita, M	1
Demmler-Harrison, GJ; Deyde, VM; Gubareva, LV; Klimov, AI; Okomo-Adhiambo, M; Sheu, TG; Xu, X	1
Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG	1
Cheng, YS; Fang, JM; Lee, PS; Liu, KC; Wang, SY; Wong, CH	1
Cheng, TJ; Cheng, YS; Fang, JM; Huang, WI; Tsai, KC; Tseng, YC; Wang, PC; Wang, SY; Wong, CH	1
Hao, C; Jiang, T; Wang, W; Yin, R; Yu, R; Zhang, L; Zhang, M	1
Barrett, S; Hader, S; McKimm-Breschkin, JL; Pilling, PA; Streltsov, VA; Watts, AG	1
Chen, F; Chen, Q; Dong, C; Han, X; Jin, M; Lan, K; Liang, J; Liu, X; Wu, S; Xu, Z; Yu, L; Yu, Y; Zhou, HB	1
Feng, IJ; Hua, YM; Shih, MF; Su, HC; Tang, HJ	1
Fujiwara, M; Hara, A; Hara, K; Kobayashi, C; Komeda, T; Miyazawa, S; Ogura, E; Urushihara, H; Yoshida, M	1
Bandera, A; Castelli, V; Gori, A; Lombardi, A; Palomba, E; Renisi, G	1
Jayabalan, T; Joshi, A; Miller, I; Oliver, A; Peppercorn, A; Wang-Jairaj, J; Zammit-Tabona, P	1
Ding, P; Guo, Y; Li, Y; Ping, J; Suzuki, Y; Yu, M; Zhang, H; Zhang, Y; Zheng, Y	1
Chan, KA; Fang, CT; Huang, CT; Su, CP	1
Aziz, A; Barr, IG; Baz, M; Brown, SK; Tseng, YY	1
Bando, T; Chong, Y; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Shindo, S; Takasaki, Y; Tani, N	1
Lai, CC; Wei, JCC	1
Chang, R; Chen, HY; Hung, YM; Sun, CK	1
Tian, Y; Wang, K; Zhang, H	1
Dandekar, T; Sarukhanyan, E; Shanmugam, TA	1
Aziz, A; Barr, IG; Baz, M; Brown, SK; Deng, YM; Kuba, M; Lau, H; O'Neill, G; Peck, H; Soppe, S; Subbarao, K	1
Mehta, N; Peppercorn, AF; Watson, HA; Yates, PJ	1
Adlhoch, C; Bossuyt, N; Brytting, M; Carnahan, A; Delgado-Sanz, C; Domegan, L; Gomes Dias, J; Guiomar, R; Kynčl, J; Larrauri, A; Maistre Melillo, J; Marbus, SD; Melillo, T; O'Donnell, J; Olsen, SJ; Popovici, O; Redlberger-Fritz, M; Slezak, P; Thomas, I; van Gageldonk-Lafeber, AB	1
Chan, KKP; Hui, DSC	1
Aoki, S; Chon, I; Kakuya, F; Kawashima, T; Kitano, A; Kodo, N; Li, J; Minato, M; Nagata, N; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shimada, Y; Sun, Y; Suzuki, E; Tanaka, T; Wagatsuma, K; Watanabe, H	1
Kumar, R; Sagar, R; Tyagi, R; Yadav, Y	1
Angioletti-Uberti, S; Baumgardt, M; Bhatia, S; Haag, R; Herrmann, A; Hocke, AC; Hönzke, K; Khatri, V; Ludwig, K; Nie, C; Parshad, B; Rimondi, A; Schlecht, MN; Schneider, P; Wolff, T	1
Bart Tarbet, E; Bejster, I; Brown, AN; Chadderdon, A; Donnelly, RF; Drusano, GL; Harteg, C; Hidayat Bin Sabri, A; Kurnia Anjani, Q; Lipka, E; Reyna, D; Vora, LK; Westover, J	1
Cuanalo-Contreras, K; Islas, AA; Martinez-Laguna, Y; Scior, T	1
Balligand, T; Carpenet, C; Liu, X; Ploegh, HL	1
Govorkova, EA; Ivachtchenko, AV; Ivanenkov, YA; Ivashchenko, AA; Jones, JC; Karapetian, RN; Pascua, PNQ; Penaflor, MK; Shkil, DO	1
Barr, IG; Bobbitt, ME; Brown, SK; Chanthalavanh, P; Dapat, C; Deng, YM; Diefenbach-Elstob, TR; Peck, H; Rynehart, C; Spirason, N; Subbarao, K	1
Barreca, GS; Bruni, A; Garofalo, E; Giancotti, A; Liberto, MC; Longhini, F; Matera, G; Mazzitelli, M; Navalesi, P; Quirino, A; Serapide, F; Torti, C; Trecarichi, EM	1
Barth, A; Collins, J; Hossain, M; Okour, M; Peppercorn, A; Roberts, G; Shortino, D; Watson, HA; Yates, P; Zuo, P	1
Abed, Y; Boivin, G; Carbonneau, J; Checkmahomed, L; Fage, C; Giannotti, F; Goncalves, AR; Kaiser, L; Schibler, M; Venable, MC	1
Martin-Loeches, I; O'Sullivan, S; Rodriguez, A; Torres, A	1
Han, N; Kim, IW; Oh, JM	1
Miyazaki, C; Momoi, MY; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K	1
Best, T; Breuer, J; Illingworth, CJR; Lumby, CK; Oporto, M; Shah, D; Tutill, H; Veys, P; Williams, R; Worth, A; Zhao, L	1
Gubareva, L; Mohan, T	1
Barr, IG; Brown, SK; Chow, MK; Patel, M; Peck, H; Price, OH; Rynehart, C; Soppe, S; Spirason, N; Todd, A	1
Cao, R; Dai, Q; Guo, X; Li, W; Li, X; Li, Y; Xia, Q; Xu, K; Yan, Y; Yang, J; Yang, K; Zhao, L; Zhong, W; Zou, G	1
Adams, SE; Bovin, NV; Donnelly, RP; Ilyushina, NA; Kan, A; Lugovtsev, VY	1
Bhatia, S; Cheng, C; Haag, R; Kerkhoff, Y; Nie, C; Oehrl, A; Parshad, B; Stadtmüller, M; Wolff, T	1
Akimoto, M; Fujisaki, S; Hasegawa, H; Kaido, T; Kishida, N; Kuwahara, T; Miura, H; Morita, H; Nagata, S; Nakamura, K; Sato, A; Shirakura, M; Sugawara, H; Takashita, E; Watanabe, S; Yasui, Y	1
Bulgakova, VA; Gorodin, VN; Kareva, EN; Pshenichnaya, NY; Selkova, EP; Volchkova, EV	1
Chung, YS; Kang, C; Kim, HM; Kim, MS; Lee, N	1
Atkins, E; Bao, P; Barclay, WS; Bentham, M; Claridge, JK; Cook, GP; Elderfield, R; Evans, S; Foster, R; Foster, TL; Goldhill, DH; Griffin, S; Kankanala, J; Loundras, E; McKimmie, CS; Pingen, M; Schnell, JR; Scott, C; Simmons, K; Stilwell, PR; Targett-Adams, P; Tathineni, R; Thompson, J	1
Bo, H; Dong, J; Huang, WJ; Li, XY; Liu, J; Tang, J; Wang, DY; Xin, L; Yang, L; Zhang, J; Zhang, SX; Zhou, JF; Zou, SM	1
Slain, D	1
Chen, Y; Chi, YM; Du, JF; Du, WX; Han, GC; Li, M; Liu, F	1
Aaron, JG; DiMango, EA; Laplante, JM; Macesic, N; Miko, BA; Pereira, MR; Reshef, R; St George, K	1
Jansson, M; Rello, J; Solé-Lleonart, C; Tejada, S	1
Botelho-Nevers, E; Cantais, A; Cizeron, A; Gagneux-Brunon, A; Pillet, S; Saunier, F	1
Laghdir, Z; Quach, C; Tadount, F	1
Lee, YG; Liu, X; Low, PS; Luo, W; Shahriar, I; Srinivasarao, M; Zhang, B	1
Chiba, T; Chikada, S; Matsuoka, Y; Nakano, T; Shiosakai, K; Yamaguchi, H	1
Govorkova, EA; Gubareva, LV; Hay, AJ; Hayden, FG; Ison, MG; McKimm-Breschkin, JL; Takashita, E	1
Chiu, HY; Lee, JA; Lin, SH; Liu, JW; Wang, LC	1
Blanchon, T; Charlois-Ou, C; Chevret, S; Duval, X; Flicoteaux, R; Leport, C; Lina, B; Mosnier, A; Protopopescu, C; Tibi, A; Werf, SV	1
Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N	8
Asai, N; Furui, T; Hagihara, M; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakata, M; Takahashi, T; Yamagishi, Y	1
Besselaar, TG; Daniels, RS; Fry, A; Gregory, V; Gubareva, LV; Huang, W; Hurt, AC; Jorquera, PA; Lackenby, A; Leang, SK; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Wang, D; Zhang, W	1
Fujii, T; Higashiguchi, M; Matsumoto, T	1
Buettner, I; Chow, MK; Lau, H; Leang, SK; Leung, VK; Spirason, N	1
Baranovich, T; Davis, CT; Gubareva, LV; Guo, Z; Hodges, E; Sleeman, K; Stevens, J; Yang, H	1
Boikos, C; Doll, MK; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N	1
Ahn, SJ; Baek, YH; Chae, HB; Choi, WS; Choi, YK; Govorkova, EA; Hwang, J; Jeong, JH; Kim, CJ; Kim, MH; Kwon, HI; Kwon, JJ; Lloren, KKS; Song, MS; Webby, RJ	1
Adams, B; Blumer, JL; Bradley, JS; DeBiasi, RL; Hossain, M; Kimberlin, DW; Michaels, MG; Munoz, FM; Pahud, B; Peppercorn, A; Roberts, G; Romero, JR; Shortino, D; Yamamoto, G; Yates, PJ	1
Ishii, H; Ishimoto, H; Kadota, JI; Mukae, H; Nishida, C; Noguchi, S; Sakamoto, N; Umeki, K; Yamasaki, K; Yatera, K	1
Behzadian, F; Kananizadeh, P; Moeini, S; Mozhgani, SH; Pakzad, R; Zarei Ghobadi, M	1
Hasegawa, T; Hirotsu, N; Saisho, Y; Shishido, T	1
Uyeki, TM	2
Christiansen, CB; Fischer, TK; Trebbien, R	1
Bailly, B; Borbás, A; Dirr, L; Dyason, JC; Gao, GF; Hadházi, Á; Li, L; Maggioni, A; Martin, G; Pascolutti, M; Thomson, RJ; Ve, T; von Itzstein, M	1
Akutsu, Y; Aoyagi, H; Ariga, T; Arioka, H; Azuma, K; Furuyama, H; Hatae, Y; Hazama, K; Inagawa, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kawamura, N; Kikuta, H; Koike, A; Konno, M; Koseki, N; Kumita, Y; Matsuzono, Y; Morita, K; Murashita, M; Nagano, N; Oba, K; Odagawa, Y; Okamura, A; Sawada, Y; Shibata, M; Shida, S; Tabata, Y; Takada, K; Tobise, C; Togashi, T; Tsubakihara, K; Tsuchida, A; Tsuchiyama, A; Uetsuji, K; Watanabe, T; Yamanaka, T; Yamazaki, S; Yasoshima, K; Yasuda, K; Yoshioka, M	1
Fushimi, K; Matsui, H; Michihata, N; Miyairi, I; Morisaki, N; Okubo, Y; Shoji, K; Uda, K; Yasunaga, H	1
Bradbury, N; Lim, WS; Nguyen-Van-Tam, J	1
Chan, KH; Hung, IFN; Kao, RYT; Lee, ACY; Li, C; To, KKW; Yuen, KY; Zhang, AJX; Zhang, RR; Zhu, H	1
Ikematsu, H; Ishikawa, Y; Iwaki, N; Kashiwagi, S; Kawai, N; Shiosakai, K; Yamaguchi, H	1
Bakulina, AY; Durymanov, AG; Goncharova, NI; Ilyicheva, TN; Kolosova, NP; Maksyutov, RA; Marchenko, VY; Pyankova, OG; Ryzhikov, AB; Sobolev, IA; Susloparov, IM; Svyatchenko, SV	1
Albati, F; Chilundo, J; Daniels, R; Gudo, E; Machalele, L; Mateonane, E; Mavale, S; McCauley, J; Mussá, T; Muteto, D; Nacoto, A; Nguenha, N; Pale, M; Salência, J; Tivane, A	1
Cocoros, NM; Haug, N; Maher, C; Panucci, G; Reichman, M; Toh, S	1
Chand, M; Cleary, PR; Crofts, J; Parry-Ford, F; Phin, N	1
Escuret, V; Gaymard, A; Javouhey, E; Josset, L; Lina, B; Malcus, C; Massenavette, B; Millat, G; Monneret, G; Morfin-Sherpa, F; Picard, C; Pichon, M; Renard, C; Simon, B; Valette, M	1
Beard, KR; Brendish, NJ; Clark, TW	1
Ben-Hamouda, N; Jahns, FP; Kirsch, M; Liaudet, L; Roumy, A	1
Asai, K; Fujioka, M; Hirata, K; Kimura, T; Kureya, Y; Shinataku, H; Tocino, Y; Yoshi, N	1
Block, S; Herrmann, A; Lauster, D; Müller, M; Wildenauer, HHK	1
Miyazaki, C; Momoi, M; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K	1
Calistri, A; Del Vecchio, C; Franchin, E; Marini, G; Nicolè, S; Palù, G; Parolin, C; Salata, C; Sgarabotto, D; Solimbergo, E	1
Arinaga-Hino, T; Hirai, S; Ide, T; Kawaguchi, T; Nagamatsu, H; Shimizu, M; Takata, A; Tanikawa, K; Tateishi, H; Tokushige, T; Torimura, T	1
Bassetti, M; Carnelutti, A; Castaldo, N	1
Betsuyaku, T; Ogawa, T; Ohgino, K; Omori, N; Sayama, K; Tanaka, K	1
Buettner, I; Chow, MK; Iannello, P; Kaye, M; Lau, H; Leung, VK; Roe, M; Tolosa, MX; Zakis, T	1
Cheng, Y; Huang, W; Li, X; Tang, J; Wang, D; Wei, H; Xin, L; Yang, L; Zhang, J; Zhou, J; Zhu, W; Zou, S	1
Abed, Y; Boivin, G; Pizzorno, A; Samson, M	1
Cabral, E; Carratalá, J; Cordero, E; Cruzado, JM; Delgado, JF; Gavaldá, J; Gómez-Bravo, MÁ; López-Medrano, F; Marcos, MÁ; Pérez-Romero, P; Sabé, N	2
Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M	1
Coenen, S; Michiels, B; Van Puyenbroeck, K; Verhoeven, V; Vermeire, E	1
Ishizuka, H; Kubo, Y; Yoshihara, K	1
Gubareva, LV; Klimov, AI; Li, Y; Lysén, C; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Xu, X	1
Kubo, T; Minakami, H; Nakai, A; Saito, S; Unno, N; Yoshimura, Y	1
Jones, LS; Lou, Y; Ng-Cashin, J; Peppercorn, A; Weller, S	1
Devalapally, H; Holmes, EH; Li, L; Ostrander, GK; Perdue, ML	1
Booy, R; Dixit, R; Ilgoutz, S; Khandaker, G; Rashid, H	1
Jones, LS; Lou, Y; Ng-Cashin, J; Peppercorn, A; Piscitelli, S; Weller, S	1
Awamura, S; Ikematsu, H; Ishida, K; Kashiwagi, S; Okamoto, T; Uemori, M; Watanabe, A	1
Ihashi, M; Inoue, Y; Kaneno, H; Kase, T; Mizoguchi, Y; Okabe, N; Shimotsuji, T; Yamamoto, K; Yamamoto, T	1
Baranovich, T; Dapat, C; Dapat, IC; Kondo, H; Saito, K; Saito, R; Shobugawa, Y; Suzuki, H; Suzuki, Y	1
Cheung, PP; Choy, KT; Guan, Y; McKimm-Breschkin, JL; Ng, IH; Peiris, JS; Webby, RJ; Webster, RG; Wong, DD; Yen, HL; Zhou, J; Zhu, H	1
Gubareva, LV; Guo, L; Marjuki, H; Mishin, VP; Okomo-Adhiambo, M; Sheu, TG; Sleeman, K; Xu, X	1
Hargraves, J; Patel, DM; Pitts, SR	1
Ariga, T; Ishiguro, N; Kaiho, M; Kikuta, H; Koseki, N; Oba, K; Togashi, T	1
Kakuta, M; Kubo, S; Tanaka, M; Tobiume, S; Tomozawa, T; Yamashita, M	1
Alvarez-Lerma, F; Brealey, D; Francois, B; Garot, D; Lorente, JA; Man, CY; Mánez, R; Marty, FM; Peppercorn, AF; Thamlikitkul, V; van der Horst, C; Weller, S; Yates, PJ; Zhao, HH	1
Baranovich, T; Burnham, AJ; Govorkova, EA	1
Akl, EA; Alonso-Coello, P; Brozek, J; Chen, YL; Cheung, A; Flottorp, SA; Hopkins, JP; Hovhannisyan, G; Hsu, J; Ivanova, L; Mustafa, R; Saeterdal, I; Santesso, N; Schünemann, HJ; Smaill, F; Tian, J; Uyeki, TM; Wong, AD	2
Hubbard, RJ; Li, J; Meyer, AE; Miller, PE; Mounts, AW; Penn, CR; Rambachan, A; Rolfes, MA; Stephens, P	2
Farrukee, R; Hurt, AC; Mosse, J	1
Cao, B; Hayden, FG	1
Kobayashi, N; Makau, JN; Watanabe, K	1
Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S	1
Chong, M; Henry, B; Kendall, P; Marra, F; Patrick, DM	1
Long, B; Malaisree, M; McIntosh-Smith, S; Mulholland, AJ; Woods, CJ	1
Hashimoto, K; Honzumi, K; Hosoya, M; Kawasaki, Y; Miyazaki, K; Sato, M; Sato, T; Watanabe, M	2
Kmietowicz, Z	2
Herxheimer, A; McGettigan, P; Pollock, A	1
Dunstan, HJ; Mill, AC; Stephens, S; Thomas, SH; Yates, LM	1
Chan, JF; To, KK; Yuen, KY	1
Kidd, M	1
Chan, JF; Chan, KH; Cheng, VC; Ho, PL; Sin, WC	1
Kanda, T; Mizuno, S; Mizuno, T	1
Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ	2
Torjesen, I	1
Doshi, P; Jefferson, T	2
Barr, IG; Hurt, AC; Kelso, A; Kwok, S; Leang, SK; Maurer-Stroh, S; Sullivan, SG	1
Butler, D	2
Godlee, F	1
Nguyen-Van-Tam, JS	2
Leonardi-Bee, J; Myles, PR	2
Jones, M	1
Belluz, J	1
Heneghan, CJ; Jefferson, T; Jones, M; Onakpoya, I; Spencer, EA; Thompson, M	1
Krumholz, HM	1
Fry, AM	1
Al Khuwaitir, TS; Al Mamun, A; Amine, IL; Anovadiya, AP; Azziz-Baumgartner, E; Báez, C; Bassetti, M; Beovic, B; Bertisch, B; Bonmarin, I; Booy, R; Borja-Aburto, VH; Burgmann, H; Cao, B; Carratala, J; Denholm, JT; Dominguez, SR; Duarte, PA; Dubnov-Raz, G; Echavarria, M; Fanella, S; Gao, Z; Gérardin, P; Giannella, M; Gubbels, S; Herberg, J; Hoger, PH; Hu, X; Iglesias, AL; Islam, QT; Jiménez, MF; Kandeel, A; Keijzers, G; Khalili, H; Knight, M; Kudo, K; Kusznierz, G; Kuzman, I; Kwan, AM; Langenegger, E; Lankarani, KB; Leo, YS; Leonardi-Bee, J; Linko, R; Liu, P; Madanat, F; Mayo-Montero, E; McGeer, A; Memish, Z; Metan, G; Mickiene, A; Mikić, D; Mohn, KG; Moradi, A; Muthuri, SG; Myles, PR; Nguyen-Van-Tam, JS; Nymadawa, P; Oliva, ME; Ozkan, M; Parekh, D; Paul, M; Polack, FP; Rath, BA; Rodríguez, AH; Sarrouf, EB; Seale, AC; Sertogullarindan, B; Siqueira, MM; Skręt-Magierło, J; Stephan, F; Talarek, E; Tang, JW; To, KK; Torres, A; Törün, SH; Tran, D; Uyeki, TM; Van Zwol, A; Vaudry, W; Venkatesan, S; Vidmar, T; Yokota, RT; Zarogoulidis, P	1
Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T	1
Bamba, M; Ichikawa, M; Ide, Y; Kawakami, C; Kawaoka, Y; Mitamura, K; Sakai-Tagawa, Y; Sugaya, N; Yamaguchi, Y; Yamazaki, M; Yasuhara, R	1
Nguyen-Van-Tam, JS; Nicholson, KG; Openshaw, PJ	1
Moynihan, R	1
Ak, Ö; Alan, S; Aslan, T; Badur, S; Balkan, II; Benzonana, N; Ceylan, B; Ciblak, M; Dokucu, AI; Engin, D; Eraksoy, H; Ergönül, Ö; Fincancı, M; Gencer, S; Göktaş, P; Gulhan, E; Gündüz, A; Inan, A; Kantürk, A; Midilli, K; Nazlıcan, O; Öncül, O; Özer, S; Özgüneş, N; Ozyurt, M; Saltoğlu, N; Sargın, F; Şimşek, F; Uzun, N; Yazıcı, S; Yıldırmak, T	1
Adams, O; Gkioule, C; Grund, S; Kobbe, G; Pfeifer, N; Termos, T; Verheyen, J	1
Cheng, CK; Fang, JM; Shie, JJ; Tsai, CH	1
Antes, G; Meerpohl, JJ	1
Del Mar, C; Hama, R; Jones, M	1
Leonardi-Bee, J; Muthuri, SG; Myles, PR; Nguyen-Van-Tam, JS; Venkatesan, S	1
Schumacher, M; Wolkewitz, M	1
Ebell, MH	2
Cueno, ME; Imai, K; Kamio, N; Ochiai, K; Saito, Y; Shimizu, K; Tamura, M	1
Dhawane, A; Dinh, H; He, Y; Iyer, SS; Sweeney, J; Yang, Y; Zhang, X	1
Calderon, A; Cañizares, A; Casas, I; Cuesta, I; Gonzalez, M; Gonzalez-Velasco, C; Lackenby, A; Lopez-Miragaya, I; Molinero, M; Monzon, S; Perez-Sautu, U; Pozo, F; Rey, S; Rodriguez, G	1
Almeida-Santos, MM; Correia, V; Gíria, M; Rebelo-de-Andrade, H; Santos, LA	1
Besselaar, T; Correia, V; Daniels, RS; Drager-Dayal, R; Fry, A; Gregory, V; Gubareva, L; Hurt, AC; Kageyama, T; Lackenby, A; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Wong, S; Zhang, W	1
Toniolo Neto, J	1
Kubo, T; Minakami, H; Nakai, A; Saito, S; Unno, N	1
Chi, HC; Hsiao, NW; Lin, CY; Shih, KC; Tang, CY; Zhou, J	1
Król, E; Rychłowska, M; Szewczyk, B	1
Brydak, LB; Nitsch-Osuch, A	2
Michiels, B	1
Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, A; Li, Y; Rosenfeld, P; Rotstein, C; Savchenko, A; Shalhoub, S; Stogios, PJ	1
Chen, Q; Guo, Y; Wei, YN; Zhang, C	1
Ali, Z; Dapat, C; Dapat, IC; Dbaibo, G; Ghanem, S; Kayali, G; Kondo, H; Lteif, M; Saito, K; Saito, R; Suzuki, H; Zaraket, H	1
Li, Y; Ma, D; Tian, J; Zhong, J	1
Millard, PS	1
Zambon, M	1
Furukawa, H; Murayama, M; Soutome, T; Watanabe, A; Yates, PJ	1
Arastoo, M; Khorshid, HR	1
Coleman, BL; Drews, SJ; Fadel, SA; Hatchette, TF; McGeer, AJ	1
Cao, B; Chan, PK; Cheung, CS; Gu, L; Hui, DS; Kyaw, WM; Lee, N; Leo, YS; Li, H; Liu, Y; Liu, Z; Qu, J; Tam, WW; Uyeki, TM; Yung, IM	1
Birnkrant, DB; Chan-Tack, KM; Kim, C; Moruf, A	1
Ison, MG	1
Fairbanks, AJ; Fee, CJ; Fredericks, R; Hall, RJ; Somasundaram, B; Watson, AJ	1
Garrison, S; Kolber, MR; Korownyk, C	1
Campbell, AP; DeBiasi, RL; Fry, AM; Gubareva, LV; Loechelt, B; Mishin, VP; Okomo-Adhiambo, M; Tamura, D; Wiedermann, BL	1
Abed, Y; Boivin, G; Boquete-Suter, P; Bouhy, X; Chalandon, Y; Cordey, S; Kaiser, L; L'Huillier, AG; Petty, TJ; Schibler, M; Simon, A; Thomas, Y; van Delden, C; Zdobnov, E	1
Boucher, CA; Cowling, BJ; Ip, DK; Schutten, M; Tong, X; van der Vries, E; Wojtowicz, K; Zhang, JD	1
Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY	1
Cheng, Y; Guo, J; Huang, W; Li, X; Shu, Y; Tan, M; Wang, D; Wang, Z; Wei, H; Xiao, N; Zhao, X	1
Hawkes, N	1
Aoyagi, Y; Chishiki, M; Endo, K; Hosoya, M; Ito, N; Kawasaki, Y; Momoi, N; Sato, M	1
Abed, Y; Ann, J; Beaulieu, E; Boivin, G; Bouhy, X; Carbonneau, J; Dubé, K; Hamelin, ME; Joly, MH; Mallett, C	1
Baas, C; Barr, IG; Butler, J; Harrower, B; Hurt, AC; Leang, SK; Little, K; Mosse, J	1
Buckeridge, DL; Charland, KM; DE Serres, G; Papenburg, J	1
Chiang, SY; Lin, SM; Pao, SI; Weng, TH	1
Kossyvakis, A; Lytras, T; Mentis, A	1
Bischoff, A	1
Barr, IG; Chow, MK; Kelso, A; Sullivan, SG	1
Dapat, C; Fujii, K; Hassan, MR; Hibino, A; Kondo, H; Okazaki, M; Otsuka, T; Saito, R; Shobugawa, Y; Yagami, R	1
Alame, MM; Ghulmiyyah, LM; Mirza, FG; Nassar, AH; Zaraket, H	1
Catchpole, M; Penttinen, P	1
Adams, T	1
Dor, D; Handel, A; Pawelek, KA; Salmeron, C	1
Haraki, M; Hishiki, H; Inoue, N; Ishiwada, N; Kameoka, Y; Kurosaki, T; Nagasawa, K; Naito, S; Someya, T; Suzuki, K	1
Awamura, S; Ikematsu, H; Kashiwagi, S; Uemori, M; Watanabe, A	1
Bastien, N; Chaudhry, A; Drews, SJ; Li, Y; Pabbaraju, K; Scott, A; Stewart, D; Wong, S	1
Fang, JM; Lin, LZ	1
Man, CY; Mehta, N; Peppercorn, AF; Raimonde, DS; Steel, HM; Yates, PJ; Zhao, HH	1
Abed, Y; Boivin, G; Carbonneau, J; Kaiser, L; L'Huillier, AG	1
Kitazawa, T; Koga, I; Ota, Y; Seo, K; Yoshino, Y	1
Antalis, E; Kalliaropoulos, A; Karakitsos, P; Kossyvakis, A; Lytras, T; Meijer, A; Mentis, AA; Mentis, AF; Pogka, V; Tryfinopoulou, K; Tsiodras, S	1
Azuma, T; Hisamatsu, K; Hosomaru, K; Ishida, M; Kunitou, M; Mikata, S; Mino, Y; Otomo, K; Shimizu, M; Yunoki, A	1
Ishiwada, N; Isobe, K; Nakano, T; Sumitani, T; Uemori, M	1
Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Kurt-Yilmaz, N; Özen, A; Prachanronarong, KL; Schiffer, CA; Thayer, KM; Wang, JP; Yilmaz, LS; Zeldovich, KB	1
Ariza-Heredia, EJ; Chemaly, RF; Shahani, L	1
Chapman, MJ; Clark, C; Garot, D; Gupta, SK; Husa, P; Jacobs, F; Marty, FM; Merino, E; Peppercorn, AF; Rodriguez-Noriega, E; Shortino, D; Vidal-Puigserver, J; Watson, HA; Yates, PJ	1
Fischer, TK; Franck, KT; Pedersen, SS; Trebbien, R; Vorborg, K	1
Das, A; Dholakia, D; Goyal, S; Grover, A; Jamal, S; Singh, A	1
Boikos, C; Caya, C; Delisle, G; Doll, MK; Dolph, M; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N	1
Kolber, MR; Korownyk, C	1
Koyfman, A; Long, B; Simon, E	1
Das, S; Mandal, RS; Panda, S	1
Chidiac, C	1
Nüesch, R	1
Ichikawa, M; Kawakami, C; Kawaoka, Y; Mitamura, K; Sugaya, N; Tamura, D; Yamazaki, M	1
Monto, AS	2
Osterhaus, AD; Pistoor, F; Simon, J; Stittelaar, KJ; Tisdale, M; van Amerongen, G; van Lavieren, RF	1
Glezen, WP	1
Bresee, JS; Broder, K; Cox, NS; Fiore, AE; Iskander, JK; Mootrey, G; Shay, DK; Uyeki, TM	1
Brydak, LB; Nitsch-Osuch, A; Wardyn, AK	1
Farrar, J; Simmons, C	1
Thomson, R; von Itzstein, M	1
Traynor, K	1
Hayden, F	1
Balish, A; Bright, RA; Deyde, VM; Gubareva, LV; Klimov, AI; Lindstrom, S; Nguyen, T; Shu, B	1
Falahee, ML; Vallerand, AH; Vantine, M	1
Cooper, K; Jackson, R; Nicholson, K; Read, R; Rees, A; Simpson, E; Tappenden, P	1
Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T	1
Couzin-Frankel, J	1
Aramini, JM; Krug, RM	1
Bauer, K; Richter, M; Schmidtke, M; Wutzler, P	1
Jefferson, T	1
Oxford, JS	1
Ruf, BR; Szucs, T	1
Barr, IG; Besselaar, TG; Birch, C; Buchy, P; Chittaganpitch, M; Chiu, SC; D'Souza, H; Deng, YM; Dwyer, D; Ernest, J; Guigon, A; Harrower, B; Hurt, AC; Iannello, P; Kei, IP; Kelso, A; Kok, T; Komadina, N; Lin, C; McPhie, K; Mohd, A; Olveda, R; Panayotou, T; Rawlinson, W; Scott, L; Shaw, R; Smith, D	1
Temte, JL	2
Garcia-Bournissen, F; Ito, S; Koren, G; Murashima, A; Nakajima, K; Tanaka, T	1
Magano, J	1
Agarwal, N; Arya, SC	1
Agarwal, SK; Gupta, A; Ignatius, A; Khaira, A	1
Barr, IG; Holien, JK; Hurt, AC; Kelso, A; Parker, M	1
Gu, Y; Kamiya, H; Komiya, N; Matsui, T; Okabe, N; Yahata, Y; Yasui, Y	1
Buttery, JP; Cheng, AC; Dwyer, DE; Jenkins, CR; Johnson, PD; Korman, TM; Kotsimbos, AT; Krause, VL; Starr, M	1
Bravata, DM; Gould, MK; Holty, JE; Khazeni, N; Stave, CD; Uyeki, TM	1
Burch, J; Corbett, M; Duffy, S; Elliot, AJ; Nicholson, K; Palmer, S; Stewart, L; Stock, C; Westwood, M	1
Harnden, A; Heneghan, C; Mant, D; Perera, R; Shun-Shin, M; Thompson, M	1
Brown, LE; Doherty, PC; Kelso, A; Turner, SJ	1
Jiang, H; Li, N; Liu, H; Luo, C; Ma, J; Qin, G; Shen, X; Wang, Q; Xu, Z; Yang, C; Yu, K; Zhu, W	1
Hacker, J	1
Koopmans, MP; van den Wijngaard, CC; van der Sande, MA; van Steenbergen, JE	1
Ami, O; Donnadieu, AC; Dupont-Bernabé, C; Fernandez, H; Frydman, R; Guillet, M; Martinez, V; Picone, O; Senat, MV; Trichot, C; Vauloup-Fellous, C	1
Belshe, RB; Fang, F; Gubareva, LV; Hedlund, M; Klimov, AI; Larson, JL; Moss, RB; Triana-Baltzer, GB; Wurtman, DF	1
Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T; Maeda, T; Matsuura, S; Nishimura, M; Tanaka, O; Yamauchi, S	1
Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Xu, X	1
Ariano, RE; Smith, JR; Toovey, S	1
Barr, IG; Holien, JK; Hurt, AC; Parker, MW	1
Nayak, JL; Treanor, JJ	1
Clardy, BH; Payne, EM; Spradlin, TL; Vinson, J	1
Bagga, B; Barman, S; Bhojwani, D; Flynn, PM; Gaur, AH; Hayden, R; Hoffman, JM; Lamptey, A; Tuomanen, E; Webby, R	1
Chan, CH; Chen, CL; Su, ZY; Wang, YT	1
Du, GH; Liu, AL; Wang, HD; Yang, F	1
Caram, LB; Cunningham, CK; Cunningham, HM; Hendershot, EF; Lopez-Marti, MG; Purdy, WK; Sangvai, DG; Tsalik, EL; Woods, CW	1
Eagel, BA	1
Nakamura-Uchiyama, F; Ohnishi, K	1
Bozzo, P; Djokanovic, N; Koren, G	1
Kiatboonsri, C; Kiatboonsri, S; Theerawit, P	1
Chee, JJ; Chong, CY; Lim, ML; Lim, WY; Tee, WS	1
Del Mar, C; Dooley, L; Doshi, P; Foxlee, R; Jefferson, T; Jones, M	1
Abiko, C; Aoki, Y; Itagaki, T; Katsushima, Y; Matsuzaki, Y; Mizuta, K; Obuchi, M; Odagiri, T; Sanjoh, K; Sugawara, K; Suto, A; Takashita, E; Tashiro, M; Ujike, M	1
Baranovich, T; Dapat, C; Dapat, IC; Hasegawa, G; Kyaw, Y; Lin, N; Myint, YY; Naito, M; Nishikawa, M; Oo, HN; Oo, KY; Saito, R; Saito, T; Suzuki, H; Suzuki, Y; Win, N; Zaraket, H	1
Kung, YM	1
Bouscambert-Duchamp, M; Escuret, V; Ferraris, O; Lina, B; Morfin, F	1
Haas, W	1
Colombo, C; Daccò, V; Daleno, C; Esposito, S; Lackenby, A; Molteni, CG; Principi, N	1
Härter, G; Kern, P; Maier, L; Mertens, T; Schubert, A; Wöhrle, J; Zimmermann, O	1
Ohashi, Y; Sugaya, N	1
Davey, RT; Fang, F; Moss, RB; Steigbigel, RT	1
Chappell, JD; Creech, CB; Denison, MR; Domm, J; Dulek, DE; Frangoul, HA; Schulert, AK; Williams, JV	1
Lecumberri, J; Montané, E; Pedro-Botet, ML	1
Han, J; Liu, H; Wang, C; Yao, X	1
Baranovich, T; Dapat, C; Dapat, IC; Ishitani, N; Matsuda, R; Oguma, T; Saito, R; Sato, I; Suzuki, H; Suzuki, Y; Zaraket, H	1
Aardema, H; Boucher, CA; de Jager, CM; Riezebos-Brilman, A; Tulleken, JE; van den Biggelaar, RJ; Wolters, BA	1
Fujita, N; Horikawa, H; Kageyama, T; Kato, Y; Kishida, N; Mochizuki, K; Obuchi, M; Odagiri, T; Shimabukuro, K; Shirakura, M; Tashiro, M; Ujike, M; Yamashita, K	1
Baranovich, T; Caperig-Dapat, I; Dapat, C; Dbaibo, GS; Medlej, F; Reda, M; Saito, R; Suzuki, H; Suzuki, Y; Tabet, C; Wakim, R; Zaraket, H	1
Peppercorn, AF; Steel, HM	1
Prosenc, K; Socan, M; Tevz-Cizej, N	1
Bilgin, H; Odabas, D; Sert, A; Yazar, A	1
Dohna-Schwake, C; Felderhoff-Müser, U; Fiedler, M; Gerner, P; Hoyer, PF; Kaiser, GM; Lainka, E; Paul, A; Schweiger, B	1
Moura, FE	1
DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG	1
Cayley, WE	1
Lundgren, J; Madsen, L; Nielsen, A	1
Sinha, M	1
Boyko, Y; Jensen, R; Nielsen, LP; Severinsen, IK; Storgaard, M; Terp, K	1
Beekmann, SE; Dharan, NJ; Finelli, L; Fiore, A; Fry, AM; Polgreen, PM; Uyeki, TM	1
Albrecht, RA; García-Sastre, A; Kaminski, M; Kochs, G; Medina, RA; Palese, P; Philipp, J; Rubbenstroth, D; Schwalm, F; Seibert, CW; Staeheli, P; Stertz, S	1
Tsukahara, Y	1
Watanabe, A	2
Ishii, H; Kadota, J; Tokimatsu, I; Yoshioka, D	1
Allenet, B; Bussières, JF; Ferreira, E; Skalli, S	1
Choi, SH; Hong, EH; Kim, MN; Kim, MS; Kim, SH; Kim, YS; Lee, JH; Lee, SO; Park, KH; Woo, JH; Yi, H	1
Reece, PA	2
Boucher, CA; Stelma, FF; van der Vries, E	1
Chang, SC; Chu, DW; Kim, MJ; Ohashi, Y; Watanabe, A	1
Cooper, KL; Jackson, RJ; Nicholson, KG; Read, RC; Rees, A; Simpson, EL; Tappenden, P	1
Heikkinen, T; Heinonen, S; Lehtinen, P; Silvennoinen, H; Vainionpää, R	1
Calistri, A; Chillemi, C; Cusinato, R; Da Dalt, L; Franchin, E; Gambino, A; Palù, G; Salata, C; Sgarabotto, D; Toscano, G	1
Birkner, P; Duwe, SC; Schweiger, B; Wedde, M	1
Andreoletti, L; Blanchon, T; Bouscambert-Duchamp, M; Charlois-Ou, C; Duval, X; Enouf, V; Leport, C; Lina, B; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; van der Werf, S; Vincent, C	1
Alonso, M; Bouza, E; Catalán, P; García de Viedma, D; Gayoso, J; Giannella, M; López Bernaldo de Quirós, JC; Rodríguez-Sánchez, B	1
Biagioni, E; Busani, S; Girardis, M; Pasetto, A; Sambri, V	1
Anraku, M; Husain, S; Mazulli, T; Pierre, AF	1
Yamashita, M	1
Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Maeda, T; Matsuura, S; Nishimura, M; Tanaka, O; Yamauchi, S	1
Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A	1
Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Trujillo, AA	1
Das, RR	1
Bellomo, R; Charles, PG; Gordon, CL; Grayson, ML; Hart, GK; Johnson, PD; Langan, K; Torresi, J	1
Bornhäuser, M; Duwe, S; Ehninger, G; Pöhlmann, C; Schetelig, J; Schweiger, B; Shayegi, N	1
Biatto, JF; Costa, EL; Deheinzelin, D; Kallás, EG; Pastore, L; Schettino, G	1
Dolin, R	1
Ichikawa, M; Kawakami, C; Kawakami, E; Kawaoka, Y; Kiso, M; Mitamura, K; Ozawa, M; Shimizu, H; Sugaya, N; Takano, R; Tamura, D; Uehara, R; Yamazaki, M	1
Day, NP; Farrar, J; Hanpithakpong, W; Hien, TT; Kamanikom, B; Lindegardh, N; Singhasivanon, P; White, NJ	1
Kakuta, M; Kubo, S; Yamashita, M	1
Alcantara-Perez, P; Alpuche-Aranda, C; Barrera-Badillo, G; Cordova Villalobos, JA; Cortez-Ortiz, I; Díaz-Quiñonez, JA; Gatell-Ramírez, HL; Gonzalez-Duran, E; Gubareva, L; Hernández-Avila, M; Lezana-Fernández, MA; Lopez-Martinez, I; Nguyen, H; Olivera-Diaz, H; Ramirez-Gonzalez, JE; Wong-Arambula, C	1
Ellermann-Eriksen, S; Gubbels, S; Ilkjær, S; Jensen-Fangel, S; Keld, DB; Lindskov, C; Petersen, E	1
Chambers, CD; Jones, KL; Louik, C; Mitchell, AA; Schatz, M	1
Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ	1
Al-Hegelan, MS; Cheifetz, IM; Noble, PW; Ozment, CP; Peters, MA; Peterson-Carmichael, SL; Rehder, KJ; Turner, DA; Williford, WL	1
Hankins, RW; Hattori, H; Iida, H; Miyachi, K; Takano, T; Ukai, H; Watanabe, A	1
Bailey, AL; Bennink, JR; Das, SR; Gibbs, JS; Hensley, SE; Schmidt, LM; Yewdell, JW	1
Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K	1
Gupta, SK; Lai, X; Rahman, Q; Schmitz, U; Smita, S; Srivastava, M; Vera, J; Wolkenhauer, O	1
Geyer, H; McKimm-Breschkin, JL; Mohr, PG	1
Ejima, M; Kageyama, T; Konomi, N; Nakauchi, M; Oba, K; Obuchi, M; Odagiri, T; Takashita, E; Takayama, I; Tashiro, M; Ujike, M	1
Devroey, D; Semaille, P; Van De Vijver, E; Vandevoorde, J; Vansintejan, J	1
Nishiura, H; Oshitani, H	1
Barr, IG; Caldwell, N; Cui, L; Deng, YM; Freeman, K; Hurt, AC; Kelso, A; Komadina, N; Leang, SK; Lee, RT; Lin, RT; Maurer-Stroh, S; Phuah, SP; Smith, D; Speers, D	1
Bowkalow, S; Brauer, M; Gross, W; Schleussner, E	1
Finelli, L; Fry, AM; Pérez, A	1
Dwyer, DE	1
Granath, F; Kieler, H; Stephansson, O; Svensson, T	1
Al'khovskiĭ, SV; Aristova, VA; Bazarova, MV; Burtseva, EI; Chuchalin, AG; Fediakina, IT; Kolobukhina, LV; Malyshev, NA; Maslov, AM; Merkulova, LN; Morozova, TN; Ponomarenko, RA; Prilipov, AG; Proshina, ES; Samokhvalov, EI; Shchelkanov, MIu; Sutochnikova, OA	1
Angeles-Garay, U; Arias-Flores, R; Gayosso Rivera, JA; Rechy-Luna, M; Terrazas Estrada, JJ; Zacate-Palacios, Y	1
Alexander, DC; Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, Y; Low, DE; Patel, SN; Sarabia, A; Savchenko, A; Stojios, PJ	1
Hirayama, T; Ikeda, K; Ito, H; Iwasaki, Y; Kano, O; Kawabe, K; Nakamura, Y; Yoshii, Y	1
Chan, K; Chua, YY; Cui, L; Tan, BH; Wijaya, L	1
Chiang, VW; Chung, EY	1
Beersma, MF; Boucher, CA; de Jong, MD; Fouchier, RA; Fraaij, PL; Horrevorts, AM; Houmes, RJ; Koopmans, MP; Kroes, AC; Niesters, HG; Osterhaus, AD; Reis Miranda, D; Ridwan, BU; Riezebos-Brilman, A; van der Eijk, AA; van der Vries, E; van Dissel, JT; Wolfhagen, MJ	1
Ohuchi, M; Ushirogawa, H	1
Razonable, RR	1
Ikematsu, H; Kawai, N	1
Arnold, K; Baumbach, J; Bennett, NM; Doshi, S; Finelli, L; Fry, AM; Gershman, K; Hancock, EB; Kamimoto, L; Lynfield, R; Morin, C; Perez, A; Reingold, A; Ryan, P; Schaffner, W; Thomas, A; Yousey-Hindes, K; Zansky, S	1
Ito, T; Tokura, Y	1
Hama, R; Hayashi, K; Jones, M; Kitao, M; Noda, N; Okushima, H; Sakaguchi, K	1
Palmer, R	1
Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R	1
Gill, P; Harnden, A; Perera, R; Shun-Shin, M; Wang, K	2
Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Jefferson, T; Jones, MA; Thompson, MJ	1
Blanchon, T; Bouscambert, M; Carrat, F; Charlois-Ou, C; Dornic, Q; Duval, X; Enouf, V; Leport, C; Mentré, F; Mosnier, A	1
Andronikou, S; Lundy, CT; Martinez-Alier, N; McDougall, M; Siddiqui, A; Tang, SS	1
Ajisaka, K; Ikematsu, H; Kashiwagi, K; Kashiwagi, S; Masui, S; Nabeshima, S; Takeoka, H	1
Baumeister, E; Campos, AM; Pontoriero, A; Savy, VL	1
Ikematsu, H; Kashiwagi, S; Kawai, N	1
Dzhibladze, KM; Nakashidze, IM; Potskhishvili, ShN; Tsintsadze, NG	1
Cash, HL; Fujita, J; Higa, F; Sunagawa, S; Tateyama, M; Uno, T	1
Gubareva, LV; Hurt, AC; Okomo-Adhiambo, M	2
Bastien, N; Beniprashad, M; Chong-King, E; Gubbay, JB; Higgins, RR; Li, Y; Low, DE	1
Hannongbua, S; Malaisree, M; Mulholland, AJ; Pattarapongdilok, N; Sompornpisut, P; Woods, CJ	1
Ito, H; Katsumi, Y; Kidowaki, S; Matsui, F; Mibayashi, A; Otabe, O; Tsuma, Y	1
Hasegawa, N; Iwata, S; Shinjoh, M; Sugaya, N; Takahashi, T; Takano, Y	1
Dapat, C; Dapat, IC; Kawashima, T; Kondo, H; Saito, K; Saito, R; Sato, I; Shobugawa, Y; Suzuki, H; Suzuki, Y	1
Borders-Hemphill, V; Mosholder, A	1
Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M	1
Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T; Ukai, H	1
Blanchon, T; Bouscambert-Duchamp, M; Boutitie, F; Cornu, C; Duval, X; Enouf, V; Escuret, V; Gaillard, S; Gueyffier, F; Leport, C; Lina, B; Mosnier, A; Van Der Werf, S	1
Blanchon, T; Carrat, F; Duval, X; Flahault, A; Leport, C; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; Van der Werf, S	1
Cao, B; Chen, BY; Dong, JP; Gao, Y; Hu, K; Li, XL; Pu, ZH; Shu, YL; Song, SF; Wang, C; Wang, DY; Wang, J; Wei, LQ; Xu, Q; Yu, XM; Yu, YS	1
Kamei, T; Mazda, O; Murata, K; Suzuki, N; Takahashi, I; Toriumi, Y	1
Barbas, CF; Carrillo, N; Crowe, JE; Hayakawa, M; Thornburg, NJ; Toda, N	1
Boivin, G; DePasse, JV; Fitch, A; Ghedin, E; Hamelin, ME; Holmes, EC; Papenburg, J; Pinilla, LT	1
Adams, O; Borkhardt, A; Ghosh, S; Meisel, R; Schuster, FR	1
Bhatt, B; Smee, DF; Tarbet, EB; von Itzstein, M	1
Boucher, CA; Collins, PJ; Gamblin, SJ; Haire, LF; Hay, AJ; Liu, J; Martin, SR; Osterhaus, AD; Schutten, M; Skehel, JJ; Vachieri, SG; van der Vries, E; Walker, PA; Xiong, X	1
Gillissen, A	1
Hurt, AC; Kelso, A	1
Kashiwagi, S; Mitsui, N; Shiosakai, K; Shiozawa, T; Tanigawa, M; Yamaguchi, F; Yamaguchi, H; Yamanouchi, N; Yoshida, S	1
Fraaij, PL; Osterhaus, AD; van der Vries, E	1
Birnkrant, DB; Chan-Tack, KM; Gao, A; Himaya, AC; Singer, ME; Thompson, EG; Uyeki, TM	1
Azuma, T; Nakada, N; Tanaka, H; Yamashita, N	1
Anekthananon, T; Charunwatthana, P; Day, N; Fukuda, C; Jittamala, P; Lawpoolsri, S; Lindegardh, N; Pukritayakamee, S; Pukrittayakamee, S; Puthavathana, P; Ratanasuwan, W; Sapchookul, P; Stepniewska, K; Suwanagool, S; Tarning, J; Taylor, WR; Werarak, P; White, NJ	1
Chen, J; Haldar, J; Klibanov, AM; Lee, CM; Wang, L; Weight, AK	1
Cheng, Y; Gubareva, LV; Huang, W; Klimov, AI; Levine, M; Li, X; Nguyen, HT; Shu, Y; Sleeman, K; Tan, M; Wang, D; Xing, X; Xu, X	1
Cantu, J; Tita, AT	1
Horton, J; Mehta, N; Tisdale, M; Yates, PJ	1
Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A; Rhéaume, C	1
Cordonnier, C; de la Camara, R; Engelhard, D; Ljungman, P; Mohty, B	1
Eda, H; Fukushima, M; Nakano, T; Niwa, S; Okumura, A; Tanabe, T; Tsutsumi, H; Yonemochi, R	1
Prober, CG	1
Englund, JA	1
Leong, MA; Simmen, KA; Wagaman, PC	1
Fleming, DM	4
Clements, DA; Hamilton, JD; Huber, J; Lee, PY; Matchar, DB; Peterson, ED	1
Davidson, HE; Gravenstein, S	1
Bower, DJ; Slawson, JG	1
Sugaya, N	6
Uyeki, T; Winquist, A	1
Asano, T; Fukunaga, Y; Hayakawa, J; Maeda, M; Migita, M; Ueda, T	1
Roberts, MS; Smith, KJ	1
Dumyati, G; Falsey, AR	1
Bonham, J; Conly, J; Gardam, M; Hawkins, K; Hirji, Z; Law, L; Mak, M; Mazzulli, T; O'Grady, S; Takata-Shewchuk, J	2
Blanckenberg, SJ; Cooper, C; Fleming, DM; Kerr, C; Monto, AS; Pichichero, ME; Ruuskanen, O	1
Vogel, GE	3
Gillissen, A; Höffken, G	1
Schmidt, RE	1
Ajene, AN; Alfredson, TD; Cole, JA; Cook, SE; Loughlin, JE; Rosenberg, DM; Walker, AM	1
Ajene, AN; Cole, JA; Cook, SE; Loughlin, JE; Rosenberg, DM; Walker, AM	1
Noyola, DE	1
Wutzler, P	1
Carrat, F; Housset, B; Schwarzinger, M	1
Da Silva, PR; Hayward, AC; Nguyen, VT	1
Kudoh, S; Matsumoto, K; Sugaya, N; Suzuki, H	2
Lange, W; Vogel, GE	1
Bazin, H; Cavallo, JD; Hernandez, E; Lhonneux, A; Noury, J; Ramisse, F	1
Dempsey, M; Jormanainen, V; Kerr, C; Lehti, H; Puhakka, T; Pulkkinen, M; Ring, CJ; Sharp, S; Tisdale, M; Vainionpää, R; Ward, C	1
Balasingam, S; Bossuyt, S; Lambkin, R; Mann, A; Novelli, P; Oxford, JS	1
Mitamura, K	2
Calfee, DP; Hayden, FG; Hussey, EK; Lobo, M; Peng, AW	1
Abrams, KR; Cooper, NJ; Nicholson, KG; Sutton, AJ; Turner, D; Wailoo, A	1
Hansen, L	3
Imuta, F; Toyoda, M; Toyoda, T	1
Kirkbride, HA; Watson, J	1
Drinka, PJ; Krause, P; Nest, L	1
Harnden, A; Matheson, NJ; Sheikh, A; Shepperd, S; Symmonds-Abrahams, M	1
Elliott, M; Gnann, JW; Hayden, FG; Ison, MG; Nagy-Agren, S; Paya, C; Steigbigel, R; Treannor, J; Weiss, HL	1
Bellantonio, S; Rose, DN; Rothberg, MB	1
Myers, JW	1
Phillips, TG	1
Ikematsu, H	1
Kashiwagi, S	3
Kaji, M	2
Liedholm, H	1
Pegram, PS; Williamson, JC	2
Cheer, SM; Wagstaff, AJ	2
Beyer, WE; de Jong, JC; Fouchier, RA; Osterhaus, AD; Rimmelzwaan, GF	1
Lu, Q	1
Bauer, TT; Rohde, G; Schultze-Werninghaus, G	1
Barclay, WS; Thompson, CI; Zambon, MC	1
Eichelberger, MC; Ottolini, MG; Prince, GA	1
Szucs, TD	1
Barr, IG; Hampson, AW; Hurt, AC; Komadina, N	1
Klimov, A; Mungall, BA; Xu, X	1
Di Natale, R; Guy, RJ; Hampson, AW; Kelly, HA; Lambert, SB; Robinson, PM; Tallis, G; Tobin, S	1
Kossow, KD; Lode, H; Ruf, BR; Scholz, H; Vogel, GE; Wutzler, P	1
Barr, IG; Durrant, CJ; Hampson, AW; Hurt, AC; Shaw, RP; Sjogren, HM	1
Fagan, HB; Moeller, AH	1
Faughnan, ME; Langley, JM	1
Suzuki, H	1
McKimm-Breschkin, JL	2
Bergemann, R; Gyldmark, M; Hayden, FG; Morris, J; Mueller, E; Sander, B	1
Abbott, A	1
Colman, PM	2
Ferraris, O; Kessler, N; Lina, B	1
Goto, H; Guo, CT; Hidari, KI; Kawaoka, Y; Miyamoto, D; Suzuki, T; Suzuki, Y; Takahashi, T	1
Moscona, A	2
Hosoya, M; Kato, K; Sato, M; Suzuki, H	1
Goto, H; Horimoto, T; Kawaoka, Y; Kiso, M; Le, QM; Muramoto, Y; Nguyen, KH; Nguyen, TH; Ngyen, HH; Pham, ND; Sakai, YT; Someya, K; Suzuki, T; Suzuki, Y; Takada, A; Yamada, S	1
Groeneveld, K; van der Noordaa, J	1
Buchholz, U	1
Bradley, D	1
Amyard, M; Hampson, A; Hay, A; Hayden, F; Klimov, A; Macken, C; McKimm-Breschkin, J; Monto, A; Tashiro, M; Webster, RG; Zambon, M	1
Mayor, S	1
Aguado, JM; Díaz-Pedrochea, C; Escalante, F; Folgueira, D; Grande, C; Lizasoain, M; López-Medrano, F; Lumbreras, C; Sanz-Gallardo, I	1
Gupta, RK; Nguyen-Van-Tam, JS	1
Barr, IG; Hampson, AW; Hurt, AC; Iannello, P; Jachno, K; Komadina, N; McKimm-Breschkin, JL	1
Davies, T	1
Suzuki, T; Suzuki, Y; Takahashi, T	1
Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V	1
Aymard, M; Hampson, AW; Hay, A; Hayden, FG; Klimov, A; Macken, C; McKimm-Breschkin, JL; Monto, AS; Tashiro, M; Webster, RG; Zambon, M	1
Baccam, P; Beauchemin, C; Hayden, FG; Macken, CA; Perelson, AS	1
Demicheli, V; Di Pietrantonj, C; Jefferson, TO; Jones, M; Rivetti, D	1
Monto, AS; Ohmit, SE	1
Del Mar, C; Jones, M	1
Eng, P; Lam, WK; Liam, CK; Seto, WH; Shim, YS; Tsang, KW; Wong, TK	1
Barr, IG; Deed, N; Hurt, AC; Iannello, P; Komadina, N; Tomasov, C	1
Nau, JY	1
Halloran, ME; Hayden, FG; Longini, IM; Monto, AS; Yang, Y	1
Barr, IG; Brown, L; Hurt, AC; Komadina, N; Selleck, P; Shaw, R	1
Dwyer, DE; Emery, S; Harrod, ME	1
Mossad, SB	3
Hayden, FG; Pavia, AT	1
Monto, AS; Whitley, RJ	1
Harnden, AR; Matheson, NJ; Perera, R; Sheikh, A; Symmonds-Abrahams, M	1
Brydak, LB; Gawryluk, D; Machała, M; Wiatr, E	1
Gras-Masse, H; Willand, N	1
Martini, B	1
Lynch, JP; Walsh, EE	1
Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Tanaka, O; Yamanishi, Y	1
Hayden, FG; Ong, AK	1
Wiwanitkit, V	1
Lorin, V; Manuguerra, JC; Medeiros, R; Naffakh, N; Rameix-Welti, MA; Ribaud, P; Scieux, C; Socie, G; van der Werf, S	1
Carrat, F; El Sawi, A; Gaillat, J; Grandmottet, G; Schlemmer, C	1
Sun, XL	1
Bettis, R; Hampel, FC; Harris, J; Henderson, FW; Kudule, L; LaForce, C; Man, CY; McElhaney, JE; Tisdale, M; Webster, A; Yates, P	1
Hirotsu, N; Horii, S; Ikematsu, H; Iwaki, N; Kanazawa, H; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T; Maeda, T; Nagai, T; Tanaka, O; Yamauchi, S	1
Crusat, M; de Jong, MD	1
Wesseling, G	1
von Itzstein, M	1
Bouscambert-Duchamp, M; Escuret, V; Ferraris, O; Frobert, E; Grog, I; Lina, B; Morfin, F; Sabatier, M; Valette, M	1
Worrall, G	1
Panknin, HT; Trautmann, M	1
Bovin, NV; Govorkova, EA; Gray, TE; Ilyushina, NA; Webster, RG	1
Cheng, YS; Fang, JM; Jeng, KS; Shie, JJ; Su, CY; Temperton, NJ; Wang, SY; Wong, CH	1
Collins, PJ; Gamblin, SJ; Haire, LF; Hay, AJ; Lin, YP; Liu, J; Martin, SR; Russell, RJ; Skehel, JJ; Walker, PA	1
Moyad, MA; Robinson, LE	1
Bethell, RC; Coates, JA; Healy, N; Hiscox, SA; Pearson, BA; Ryan, DM; Ticehurst, J; Tilling, J; Walcott, SM; Woods, JM	1
Dyason, JC; Jin, B; Kok, GB; Oliver, SW; Pegg, MS; Smythe, ML; Van Phan, T; von Itzstein, M; White, HF; Wu, WY	1
Jack, DB	1
Aoki, FY; Bohnen, AM; Fleming, DM; Hayden, FG; Hirst, HM; Keene, O; Nicholson, KG; Osterhaus, AD; Treanor, JJ; Wightman, K	1
Couch, RB	2
Wade, RC	1
Hayden, FG; Hussey, EK; Montalvo, A; Treanor, JJ; Walker, JB	1
Adelman, A	1
Matsumoto, K	2
Bailey, KW; Barnard, DL; Huffman, JH; Kim, CU; Morrison, A; Sidwell, RW; Syndergaard, T; Wong, MH	1
Bethell, R; Daniel, M; Dines, GD	1
Ambrozaitis, A; Drinka, P; Gravenstein, M; Gravenstein, S; Jones, HH; Krause, P; Povinelli, L; Powers, D; Schilling, M; Shult, P	1
Bethell, RC; Brenner, MK; Gubareva, LV; Matrosovich, MN; Webster, RG	1
Hughes, J; Ostroff, S	1
Calfee, DP; Hayden, FG	1
Bethell, RC; Gubareva, LV; McCullers, JA; Webster, RG	1
Stephenson, J	2
Read, RC	1
Heinzl, S	1
Bricaire, F	1
Silagy, CA	1
Dove, A	1
Calfee, DP; Cass, LM; Hayden, FG; Lobo, M; Peng, AW	1
de Groot, R; Elliott, M; Fleming, DM; Henry, D; Keene, ON; Klein, T; Makela, M; Man, CY; Monto, AS	1
Crisp, A; Elliott, MJ; Herlocher, ML; Hinson, JM; Monto, AS; Robinson, DP	1
Patriarca, PA	1
Aoki, FY; Hayden, FG	1
Alvord, WG; Calfee, DP; Cass, LM; Fritz, RS; Hayden, FG; Peng, AW; Straus, SE; Strober, W	1
Miller, JL	1
Elliott, M; Freund, B; Gravenstein, S; Miller, I	1
Yamey, G	2
Hayden, FG	3
Dunn, CJ; Goa, KL	1
Campion, K; Silagy, CA	1
Deeks, J; Demicheli, V; Jefferson, T; Rivetti, D	2
Le Moing, V	1
Kelly, GD; Laver, WG	1
Barza, M	1
Robb-Nicholson, C	1
Green, ST	1
Koopmans, PP; Simonian, S; van Loon, FP; Voordouw, AC	1
Goldman, MP; Long, JK; Mossad, SB	1
Vallée, JP	1
Arakawa, M; Kashiwagi, S; Kawakami, Y; Kudoh, S; Matsumoto, K; Nagatake, T; Nakajima, S; Nerome, K; Numazaki, Y; Ogawa, N; Shimokata, K; Shirato, K; Yamakido, M	1
Hussey, EK; Moore, KH; Peng, AW	1
Gubareva, LV; Hayden, FG; Kaiser, L	1
Thomas, PD	1
Flack, NP; Hayden, FG; Henry, D; Kaiser, L; Keene, O	1
Anderson, SR	1
Lemon, M; Meade, F	1
Fleming, DM; Keene, ON; Mäkelä, MJ; Man, CY; Pauksens, K; Rostila, T; Webster, A	1
Aoki, F; Boivin, G; Goyette, N; Hardy, I; Trottier, S; Wagner, A	1
Nkoghe, D; Scheen, AJ	1
Barzilai, A; Behre, U; Hammond, J; Hedrick, JA; Henderson, FW; Keene, O; Reilly, L	1
Chapple, KJ; Hendrick, AE; McCarthy, MW	1
Zambon, MC	1
Keene, O; Monto, AS; Webster, A	1
Aoki, FY; Edmundson, S; Fleming, DM; Griffin, AD; Lacey, LA	1
Cates, SC; Griffin, AD; Lamb, SC; Mauskopf, JA; Neighbors, DM; Rutherford, C	1
Elliot, MJ; Gubareva, LV; Hammond, JM; Hayden, FG; Klein, TC; Monto, AS; Ossi, MJ; Sharp, SJ	1
Wright, P	1
Vogel, G; Wutzler, P	1
Elliott, M; Hammond, JM; Hayden, FG; Kaiser, L; Keene, ON	1
Colopy, M; Elliott, M; Gravenstein, S; Monto, AS; Schweinle, J	1
Fearon, M; Lee, C; Li, Y; Loeb, M; Mazzulli, T; McArthur, MA; McGeer, A; Nesbitt, J; Phillips, A; Smith, K	1
Caserta, MT; Hall, CB	1
Monto, AS; Moult, AB; Sharp, SJ	1
Ashley, JV; Gum, KD; Montalto, NJ	1
Conly, JM; Lim, S; Richardson, D	1
Rosen, DS	1
Campion, K; Keene, O; Lalezari, J; Silagy, C	1
Snell, J	1
Briganti, E; Calza, L; Chiodo, F; Manfredi, R	1
McNicholl, IR; McNicholl, JJ	1
Bernsen, RM; van Bentveld, RD; van der Wouden, JC	1
Feder, HM	1
Osterhaus, A; Penn, CR	1
Diggory, P; Fernandez, C; Humphrey, A; Jones, V; Murphy, M	1
Westergren, T	1
Fleming, DM; Griffin, AD; Perry, AS	1
Brocavich, J; Dreitlein, WB; Maratos, J	1
Abad-Santos, F; Gallego Sandín, S; Gálvez Múgica, MA; Martínez Sancho, E; Novalbos Reina, J	1
Groman, E; Hartl, HK; Kunze, U; Vymazal, K	1
Hayden, FG; Zambon, M	1
Cross, J; Wedekind, CA	1
Hall, GH	1
Tooley, P	1
Garman, E; Laver, G	1
Hays, J; Keene, O; Newman, R; Webster, A; Zambon, M	1
Preboth, M	1
Holdiness, MR	1
Aoki, F; Macaulay, A; Martin, B; Orr, P; Van Caeseele, P	1
Gravenstein, S; Johnston, SL; Loeschel, E; Webster, A	1
Elliott, M	1
Barnett, D	1
Roberts, NA	1
Collier, J	1
Pasanen, M; Tokola, O	1
Carrington, D; Clark, A; Johny, AA; Marks, DI; Oakhill, A; Price, N	1
MacConnachie, AM	1
Senior, K	1
Farr, BM; Hall, KK; Hayden, FG; Salgado, CD	1
Pitts, SR	1
Bridges, CB; Cox, NJ; Fukuda, K; Singleton, JA; Uyeki, TM	1
Boivin, G; Goyette, N	1
Bryan, S; Burls, A; Clark, W; Fry-Smith, A; Jefferson, T; Preston, C; Stewart, T	1

Reviews

195 review(s) available for zanamivir and Grippe

Article	Year
Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022, Volume: 28, Issue:2 Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Network Meta-Analysis; Neuraminidase; Oseltamivir; Zanamivir	2022
Antiviral Treatments for Influenza. Seminars in respiratory and critical care medicine, 2021, Volume: 42, Issue:6 Topics: Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2021
The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review. European journal of medicinal chemistry, 2022, Dec-05, Volume: 243 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Glycoside Hydrolases; Guanidines; Humans; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Zanamivir	2022
Antiviral therapies for influenza. Current opinion in infectious diseases, 2023, 04-01, Volume: 36, Issue:2 Topics: Antiviral Agents; COVID-19; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2023
Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors. European journal of medicinal chemistry, 2023, Jul-05, Volume: 255 Topics: Antiviral Agents; Cyclohexenes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir	2023
Influenza management with new therapies. Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:3 Topics: Adrenal Cortex Hormones; Amides; Antiviral Agents; Critical Care; Critical Illness; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; Respiration, Artificial; Triazines; Zanamivir	2020
Antivirals Targeting the Neuraminidase. Cold Spring Harbor perspectives in medicine, 2022, 01-04, Volume: 12, Issue:1 Topics: Antibodies, Monoclonal; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2022
Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials. European journal of internal medicine, 2021, Volume: 86 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir	2021
Antiviral use in healthcare workers-A systematic review. Infection control and hospital epidemiology, 2022, Volume: 43, Issue:4 Topics: Antiviral Agents; Enzyme Inhibitors; Health Personnel; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2022
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral research, 2021, Volume: 194 Topics: Animals; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Knowledge; Morpholines; Neuraminidase; Oseltamivir; Pyridones; SARS-CoV-2; Triazines; Virus Replication; Zanamivir	2021
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. JAMA network open, 2021, 08-02, Volume: 4, Issue:8 Topics: Adolescent; Adult; Antiviral Agents; Child; Dibenzothiepins; Endonucleases; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Morpholines; Network Meta-Analysis; Neuraminidase; Pyridones; Randomized Controlled Trials as Topic; Seasons; Triazines; Young Adult; Zanamivir	2021
A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Antiviral therapy, 2018, Volume: 23, Issue:2 Topics: Administration, Inhalation; Antiviral Agents; Betainfluenzavirus; Disease Management; Drug Therapy, Combination; Guanidines; Humans; Influenza A virus; Influenza, Human; Post-Exposure Prophylaxis; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2018
Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. The Journal of antimicrobial chemotherapy, 2017, Nov-01, Volume: 72, Issue:11 Topics: Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pneumonia; Zanamivir	2017
Prevalence of human influenza virus in Iran: Evidence from a systematic review and meta-analysis. Microbial pathogenesis, 2018, Volume: 115 Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Iran; Male; Oseltamivir; Prevalence; Zanamivir	2018
Treatment of influenza with neuraminidase inhibitors. Current opinion in infectious diseases, 2018, Volume: 31, Issue:6 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir	2018
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:14 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Half-Life; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2019
Influenza virus resistance to neuraminidase inhibitors. Antiviral research, 2013, Volume: 98, Issue:2 Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir	2013
Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiolo Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31, Issue:8 Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Cross Infection; Disease Management; Drug Resistance, Viral; Humans; Influenza Vaccines; Influenza, Human; Organ Transplantation; Oseltamivir; Postoperative Complications; Superinfection; Zanamivir	2013
Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31, Issue:8 Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Cross Infection; Diagnosis, Differential; Disease Management; Drug Resistance, Viral; HN Protein; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Inpatients; Kidney Diseases; Organ Transplantation; Oseltamivir; Outpatients; Pneumonia; Postoperative Complications; Superinfection; Zanamivir	2013
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PloS one, 2013, Volume: 8, Issue:4 Topics: Antibiotic Prophylaxis; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir	2013
Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infectious disorders drug targets, 2013, Volume: 13, Issue:1 Topics: Adult; Antibiotic Prophylaxis; Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Viral Proteins; Zanamivir	2013
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral research, 2013, Volume: 100, Issue:2 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir	2013
Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza and other respiratory viruses, 2013, Volume: 7 Suppl 2 Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Influenza, Human; Oseltamivir; Survival Analysis; Treatment Outcome; Zanamivir	2013
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study. Influenza and other respiratory viruses, 2013, Volume: 7 Suppl 2 Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Survival Analysis; Treatment Outcome; Viral Proteins; Zanamivir	2013
Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert review of anti-infective therapy, 2013, Volume: 11, Issue:11 Topics: Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2013
Antiviral drugs for influenza 2013-2014. The Medical letter on drugs and therapeutics, 2014, Jan-20, Volume: 56, Issue:1434 Topics: Animals; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir	2014
Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A(H7N9). Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Animals; Antiviral Agents; China; Commerce; Communicable Disease Control; Communicable Diseases, Emerging; Disease Outbreaks; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Food Supply; Hong Kong; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Poultry; Reverse Transcriptase Polymerase Chain Reaction; Taiwan; Zanamivir; Zoonoses	2014
Influenza viruses: update on epidemiology, clinical features, treatment and vaccination. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Animals; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Male; Pandemics; Poultry; Seasons; Sentinel Surveillance; Sequence Analysis, DNA; Viral Vaccines; Zanamivir	2014
Neuraminidase inhibitors for preventing and treating influenza in adults and children. The Cochrane database of systematic reviews, 2014, 04-10, Issue:4 Topics: Adult; Antiviral Agents; Child; Drug Evaluation; Enzyme Inhibitors; Europe; Health Status; Humans; Influenza, Human; Japan; Legislation, Drug; Neuraminidase; Oseltamivir; Pneumonia; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir	2014
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ (Clinical research ed.), 2014, Apr-09, Volume: 348 Topics: Adult; Antiviral Agents; Child; Humans; Influenza, Human; Randomized Controlled Trials as Topic; Treatment Outcome; Zanamivir	2014
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:5 Topics: Adolescent; Adult; Antiviral Agents; Child; Enzyme Inhibitors; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pandemics; Proportional Hazards Models; Treatment Outcome; Young Adult; Zanamivir	2014
[Multisystem failure: the story of antinfluenza drugs]. Recenti progressi in medicina, 2014, Volume: 105, Issue:5 Topics: Antiviral Agents; Clinical Trials as Topic; Evidence-Based Medicine; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Neuraminidase; Oseltamivir; Pandemics; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Zanamivir	2014
From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Future medicinal chemistry, 2014, Volume: 6, Issue:7 Topics: Animals; Antiviral Agents; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Molecular Targeted Therapy; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Zanamivir	2014
Antivirals--current trends in fighting influenza. Acta biochimica Polonica, 2014, Volume: 61, Issue:3 Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Viral Matrix Proteins; Zanamivir	2014
Influenza viruses resistant to neuraminidase inhibitors. Acta biochimica Polonica, 2014, Volume: 61, Issue:3 Topics: Adult; Aged; Antiviral Agents; Child; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2014
Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. Current opinion in infectious diseases, 2014, Volume: 27, Issue:6 Topics: Animals; Antiviral Agents; Birds; Enzyme Inhibitors; Humans; Immunologic Factors; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Population Surveillance; Public Health; Randomized Controlled Trials as Topic; Zanamivir	2014
Antiviral drugs for seasonal influenza 2014-2015. The Medical letter on drugs and therapeutics, 2014, Volume: 56, Issue:1457 Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Seasons; Zanamivir	2014
Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014). Antiviral therapy, 2015, Volume: 20, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Investigational New Drug Application; Male; Middle Aged; Oseltamivir; Pregnancy; Retrospective Studies; United States; Young Adult; Zanamivir	2015
Optimizing antiviral therapy for influenza: understanding the evidence. Expert review of anti-infective therapy, 2015, Volume: 13, Issue:4 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; RNA-Dependent RNA Polymerase; Sialic Acids; Viral Matrix Proteins; Viral Proteins; Zanamivir	2015
Antiviral medications for influenza. Canadian family physician Medecin de famille canadien, 2015, Volume: 61, Issue:4 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir	2015
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives. Expert review of anti-infective therapy, 2015, Volume: 13, Issue:11 Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir	2015
Treatment and prophylaxis of influenza and the problem of resistance to neuraminidase inhibitors. Postepy higieny i medycyny doswiadczalnej (Online), 2015, Sep-20, Volume: 69 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir	2015
Influenza and its treatment during pregnancy: A review. Journal of neonatal-perinatal medicine, 2015, Volume: 8, Issue:4 Topics: Animals; Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Membrane Transport Proteins; Oseltamivir; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Vaccination; Zanamivir	2015
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health technology assessment (Winchester, England), 2016, Volume: 20, Issue:42 Topics: Adult; Antiviral Agents; Asthma; Child; Dose-Response Relationship, Drug; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir	2016
Antiviral therapy for respiratory viral infections in immunocompromised patients. Expert review of anti-infective therapy, 2017, Volume: 15, Issue:4 Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir	2017
Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. The Journal of antimicrobial chemotherapy, 2017, 06-01, Volume: 72, Issue:6 Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Disease Outbreaks; Enzyme Inhibitors; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Neuraminidase; Observational Studies as Topic; Oseltamivir; Pandemics; Pneumonia; Young Adult; Zanamivir	2017
Clinical Mimics: An Emergency Medicine-Focused Review of Influenza Mimics. The Journal of emergency medicine, 2017, Volume: 53, Issue:1 Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Child, Preschool; Cyclopentanes; Emergency Medicine; Guanidines; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Risk Factors; United States; Zanamivir	2017
[Influenza]. La Revue du praticien, 2008, Feb-29, Volume: 58, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Amantadine; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Diagnosis, Differential; Female; Follow-Up Studies; France; Humans; Infant; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Seasons; Time Factors; Treatment Outcome; Zanamivir	2008
[Antiviral treatment of influenza in humans]. Therapeutische Umschau. Revue therapeutique, 2007, Volume: 64, Issue:11 Topics: Amantadine; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Virus Replication; Virus Shedding; Zanamivir	2007
Modifying clinical practices to manage influenza in children effectively. The Pediatric infectious disease journal, 2008, Volume: 27, Issue:8 Topics: Adolescent; Animals; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H2N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2008
[Neuraminidase inhibitors in prophylaxis and treatment of influenza]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 25, Issue:145 Topics: Antiviral Agents; Disease Outbreaks; Drug Administration Schedule; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2008
Anti-influenza drugs: the development of sialidase inhibitors. Handbook of experimental pharmacology, 2009, Issue:189 Topics: Animals; Antiviral Agents; Drug Design; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Zanamivir	2009
Developing new antiviral agents for influenza treatment: what does the future hold? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jan-01, Volume: 48 Suppl 1 Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cyclopentanes; Drug Discovery; Drug Resistance, Viral; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Pyrazines; Recombinant Fusion Proteins; Zanamivir	2009
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:11 Topics: Amantadine; Antiviral Agents; Cost-Benefit Analysis; Humans; Influenza, Human; Models, Economic; Oseltamivir; Practice Guidelines as Topic; Premedication; Randomized Controlled Trials as Topic; Seasons; Treatment Outcome; Zanamivir	2009
Emerging antiviral targets for influenza A virus. Trends in pharmacological sciences, 2009, Volume: 30, Issue:6 Topics: Animals; Antiviral Agents; Drug Delivery Systems; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins; Zanamivir	2009
Influenza. BMJ clinical evidence, 2009, Mar-12, Volume: 2009 Topics: Acute Disease; Administration, Inhalation; Humans; Incidence; Influenza Vaccines; Influenza, Human; Oseltamivir; Rimantadine; Zanamivir	2009
Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza and other respiratory viruses, 2007, Volume: 1, Issue:1 Topics: Amantadine; Antiviral Agents; Chemoprevention; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Rimantadine; Zanamivir	2007
Reducing the burden of influenza-associated complications with antiviral therapy. Infection, 2009, Volume: 37, Issue:3 Topics: Age Factors; Antiviral Agents; Cost of Illness; Enzyme Inhibitors; Health Care Costs; Humans; Influenza, Human; Neuraminidase; Risk Factors; Treatment Outcome; Zanamivir	2009
Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Jul-07, Volume: 181, Issue:1-2 Topics: Breast Feeding; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lactation; Neuraminidase; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Viral Vaccines; Zanamivir	2009
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chemical reviews, 2009, Volume: 109, Issue:9 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2009
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Annals of internal medicine, 2009, Oct-06, Volume: 151, Issue:7 Topics: Antiviral Agents; Disease Outbreaks; Drug Administration Schedule; Humans; Influenza A virus; Influenza, Human; Nausea; Neuraminidase; Oseltamivir; Risk Factors; Vomiting; Zanamivir	2009
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. The Lancet. Infectious diseases, 2009, Volume: 9, Issue:9 Topics: Adult; Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Treatment Outcome; United Kingdom; Zanamivir	2009
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ (Clinical research ed.), 2009, Aug-10, Volume: 339 Topics: Anti-Bacterial Agents; Antiviral Agents; Asthma; Bias; Child; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Otitis Media; Randomized Controlled Trials as Topic; Risk Factors; Zanamivir	2009
[Pandemic influenza A H1N1 2009 flu during pregnancy: Epidemiology, diagnosis and management]. Journal de gynecologie, obstetrique et biologie de la reproduction, 2009, Volume: 38, Issue:8 Topics: Antiviral Agents; Disease Outbreaks; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nasopharynx; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Zanamivir	2009
The use of antiviral agents for the management of severe influenza. Critical care medicine, 2010, Volume: 38, Issue:4 Suppl Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Length of Stay; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Risk Factors; Viral Load; Zanamivir	2010
Antiviral treatment and prophylaxis of influenza virus in children. Pediatric annals, 2009, Volume: 38, Issue:12 Topics: Amantadine; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Zanamivir	2009
[Research progress of neuraminidase inhibitors for anti-influenza]. Yao xue xue bao = Acta pharmaceutica Sinica, 2009, Volume: 44, Issue:9 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2009
Neuraminidase inhibitors for preventing and treating influenza in healthy adults. The Cochrane database of systematic reviews, 2010, Feb-17, Issue:2 Topics: Adult; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Post-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Zanamivir	2010
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections]. Pathologie-biologie, 2010, Volume: 58, Issue:2 Topics: Adult; Antiviral Agents; Child; Clinical Trials as Topic; Disease Outbreaks; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Influenza A virus; Influenza, Human; Male; Models, Molecular; Molecular Structure; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Protein Conformation; Viral Proteins; Zanamivir	2010
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:6 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Oseltamivir; Recombinant Fusion Proteins; Zanamivir	2010
[Influenza A, pregnancy and neuraminidase inhibitors]. Medicina clinica, 2011, May-28, Volume: 136, Issue:15 Topics: Animals; Antiviral Agents; Australia; Centers for Disease Control and Prevention, U.S.; Drug Evaluation, Preclinical; Drug Utilization; Europe; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; New Zealand; Oseltamivir; Pandemics; Practice Guidelines as Topic; Pregnancy; Pregnancy Outcome; Risk Assessment; United States; Viral Proteins; World Health Organization; Zanamivir	2011
Influenza in the tropics. Current opinion in infectious diseases, 2010, Volume: 23, Issue:5 Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Genetic Variation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Prevalence; Tropical Climate; Zanamivir	2010
Swine flu. Journal of infection and public health, 2009, Volume: 2, Issue:4 Topics: Antiviral Agents; Contact Tracing; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Travel; Zanamivir	2009
[Change of strategies for novel and seasonal flu during pregnancy]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:9 Topics: Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Zanamivir	2010
[Present and future in development of new anti-influenza drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:9 Topics: Amantadine; Antiviral Agents; DNA-Directed RNA Polymerases; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2010
[Current anti-influenza virus chemotherapy]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:9 Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Drug Utilization; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Japan; Oseltamivir; Pandemics; Zanamivir	2010
[Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?]. Annales pharmaceutiques francaises, 2010, Volume: 68, Issue:5 Topics: Adult; Antiviral Agents; Breast Feeding; Female; Fetus; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Zanamivir	2010
Treatment options for H5N1: lessons learned from the H1N1 pandemic. Postgraduate medicine, 2010, Volume: 122, Issue:5 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Pyrans; Severity of Illness Index; Sialic Acids; Zanamivir	2010
Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. The Journal of infection, 2011, Volume: 62, Issue:1 Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Post-Exposure Prophylaxis; Treatment Outcome; Viral Matrix Proteins; Zanamivir	2011
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antiviral chemistry & chemotherapy, 2010, Volume: 21, Issue:2 Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Guanidines; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pandemics; Prodrugs; Pyrans; Rats; Sialic Acids; Zanamivir	2010
[Research progress of anti-influenza virus agents]. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:3 Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Indoles; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrrolidines; Rimantadine; Structure-Activity Relationship; Viral Matrix Proteins; Zanamivir	2010
Influenza vaccination, diagnosis, and treatment in children. Pediatric emergency care, 2011, Volume: 27, Issue:8 Topics: Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Real-Time Polymerase Chain Reaction; Vaccination; Zanamivir	2011
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 2011, Volume: 86, Issue:10 Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir	2011
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert review of anti-infective therapy, 2011, Volume: 9, Issue:10 Topics: Administration, Inhalation; Adult; Animals; Antiviral Agents; Birds; Caprylates; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Viral Proteins; Virus Replication; Zanamivir	2011
Antiviral drugs for influenza. The Medical letter on drugs and therapeutics, 2012, Jan-09, Volume: 54, Issue:1381 Topics: Adult; Amantadine; Antiviral Agents; Child; Female; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Rimantadine; Zanamivir	2012
Neuraminidase inhibitors for preventing and treating influenza in children. The Cochrane database of systematic reviews, 2012, Jan-18, Volume: 1 Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2012
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. The Cochrane database of systematic reviews, 2012, Jan-18, Volume: 1 Topics: Adult; Antiviral Agents; Child; Drug Evaluation; Enzyme Inhibitors; Europe; Health Status; Humans; Influenza, Human; Japan; Legislation, Drug; Neuraminidase; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir	2012
Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Annals of internal medicine, 2012, Apr-03, Volume: 156, Issue:7 Topics: Administration, Inhalation; Administration, Oral; Amantadine; Antiviral Agents; Confounding Factors, Epidemiologic; Hospitalization; Humans; Influenza, Human; Oseltamivir; Rimantadine; Treatment Outcome; Zanamivir	2012
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). The Cochrane database of systematic reviews, 2012, Apr-18, Issue:4 Topics: Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2012
Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem, 2012, Volume: 7, Issue:9 Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2012
Antiviral drugs for influenza 2012-2013. The Medical letter on drugs and therapeutics, 2012, Dec-10, Volume: 54, Issue:1405 Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2012
Management of influenza in pregnancy. American journal of perinatology, 2013, Volume: 30, Issue:2 Topics: Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Isolation; Pregnancy; Pregnancy Complications, Infectious; Zanamivir	2013
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transplant infectious disease : an official journal of the Transplantation Society, 2013, Volume: 15, Issue:3 Topics: Acetamides; Antiviral Agents; Hematopoietic Stem Cell Transplantation; Humans; Influenza, Human; Leukemia; Oseltamivir; Practice Guidelines as Topic; Zanamivir	2013
Antiviral therapy for influenza virus infections. Seminars in pediatric infectious diseases, 2002, Volume: 13, Issue:1 Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Child; Clinical Trials as Topic; Global Health; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2002
Antiviral therapy of influenza. Seminars in pediatric infectious diseases, 2002, Volume: 13, Issue:2 Topics: Acetamides; Administration, Inhalation; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Drug Resistance, Viral; Guanidines; Humans; Infant; Influenza, Human; Orthomyxoviridae; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2002
The management of influenza in people of working age. Occupational medicine (Oxford, England), 2002, Volume: 52, Issue:5 Topics: Acetamides; Adolescent; Adult; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Middle Aged; Occupational Health; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Workplace; Zanamivir	2002
[A revolutionary change in the diagnosis and treatment of influenza]. Uirusu, 2002, Volume: 52, Issue:1 Topics: Acetamides; Antiviral Agents; Encephalitis, Viral; Enzyme Inhibitors; Guanidines; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Immunologic Tests; Influenza Vaccines; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Vaccines, Attenuated; Zanamivir	2002
Influenza. Clinical evidence, 2002, Issue:7 Topics: Acetamides; Administration, Inhalation; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Rimantadine; Sialic Acids; Treatment Outcome; Zanamivir	2002
Antivirals for influenza: what is their role in the older patient? Drugs & aging, 2002, Volume: 19, Issue:10 Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2002
Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors. Medical microbiology and immunology, 2002, Volume: 191, Issue:3-4 Topics: Administration, Oral; Age Factors; Antiviral Agents; Bacterial Infections; Chronic Disease; Double-Blind Method; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung Diseases; Pyrans; Risk Factors; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir	2002
Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy. Paediatric drugs, 2003, Volume: 5, Issue:2 Topics: Acetamides; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Otitis Media; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2003
Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. The Pediatric infectious disease journal, 2003, Volume: 22, Issue:2 Topics: Acetamides; Adolescent; Age Distribution; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child; Child, Preschool; DNA, Viral; Female; Fluorescent Antibody Technique, Direct; Follow-Up Studies; Guanidines; Humans; Incidence; Infant; Influenza, Human; Male; Orthomyxoviridae; Oseltamivir; Pyrans; Risk Assessment; Severity of Illness Index; Sex Distribution; Sialic Acids; Treatment Outcome; United States; Zanamivir	2003
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2003, Volume: 9, Issue:1 Topics: Acetamides; Amantadine; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Endemic Diseases; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Matrix Proteins; Zanamivir	2003
[Influenza]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 2 Topics: Acetamides; Amantadine; Antiviral Agents; Diagnosis, Differential; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Reagent Kits, Diagnostic; Sialic Acids; Vaccines, Attenuated; Zanamivir	2003
[Antiviral agents for influenza]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 2 Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Matrix Proteins; Zanamivir	2003
Zanamivir in the treatment of influenza. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:5 Topics: Adult; Animals; Antiviral Agents; Child; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Risk Factors; Sialic Acids; Zanamivir	2003
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed.), 2003, Jun-07, Volume: 326, Issue:7401 Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2003
Review of the use of neuraminidase inhibitors for prophylaxis of influenza. Communicable disease and public health, 2003, Volume: 6, Issue:2 Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Health Planning; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2003
Neuraminidase inhibitors for preventing and treating influenza in children. The Cochrane database of systematic reviews, 2003, Issue:3 Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2003
Influenza therapy. Southern medical journal, 2003, Volume: 96, Issue:8 Topics: Acetamides; Adult; Age Factors; Amantadine; Antiviral Agents; Child; Cost-Benefit Analysis; Creatine; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Kidney Failure, Chronic; Metabolic Clearance Rate; Oseltamivir; Patient Selection; Primary Prevention; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2003
[Clinical characteristic of the elderly in influenza infection]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:11 Topics: Age Factors; Aged; Amantadine; Antiviral Agents; Chromatography; Enzyme Inhibitors; Guanidines; Humans; Immunoenzyme Techniques; Influenza Vaccines; Influenza, Human; Neuraminidase; Pneumonia, Viral; Prognosis; Pyrans; Reagent Kits, Diagnostic; Risk; Sialic Acids; Zanamivir	2003
[Influenza virus infection in children]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:11 Topics: Acetamides; Age Factors; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2003
[Criteria for the use of anti-influenza agents]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:11 Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Prodrugs; Pyrans; Sialic Acids; Time Factors; Virus Latency; Zanamivir	2003
[Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:11 Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir	2003
Neuraminidase inhibitors in patients with underlying airways disease. American journal of respiratory medicine : drugs, devices, and other interventions, 2002, Volume: 1, Issue:2 Topics: Acetamides; Amantadine; Antiviral Agents; Asthma; Bronchial Spasm; Comorbidity; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Pyrans; Rimantadine; Risk Factors; Sialic Acids; Zanamivir	2002
Spotlight on zanamivir in influenza. American journal of respiratory medicine : drugs, devices, and other interventions, 2002, Volume: 1, Issue:2 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antiviral Agents; Child; Clinical Trials as Topic; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Placebos; Pyrans; Risk Factors; Severity of Illness Index; Sialic Acids; Zanamivir	2002
[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]. Nederlands tijdschrift voor geneeskunde, 2004, Jan-10, Volume: 148, Issue:2 Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Seasons; Sialic Acids; Zanamivir	2004
[Treatment for viral respiratory infections: Principles of action, strategies, and future prospects]. Der Internist, 2004, Volume: 45, Issue:4 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Practice Patterns, Physicians'; Pyrans; Respiratory Tract Infections; Sialic Acids; Treatment Outcome; Virus Diseases; Zanamivir	2004
Medical economics in the field of influenza--past, present and future. Virus research, 2004, Volume: 103, Issue:1-2 Topics: Adult; Antiviral Agents; Child; Child, Preschool; Cost of Illness; Cost-Benefit Analysis; Guanidines; Health Care Costs; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Vaccination; Zanamivir	2004
Neuraminidase inhibitors for treatment of influenza. American family physician, 2004, Jun-15, Volume: 69, Issue:12 Topics: Acetamides; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2004
What is the best antiviral agent for influenza infection? American family physician, 2004, Oct-01, Volume: 70, Issue:7 Topics: Acetamides; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Contraindications; Evidence-Based Medicine; Family Practice; Guanidines; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2004
Influenza. Clinical evidence, 2003, Issue:10 Topics: Acetamides; Adult; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2003
[Super pathogenic avian influenza]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Nov-10, Volume: 93, Issue:11 Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Chickens; Disease Outbreaks; Guanidines; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Poultry Diseases; Pyrans; Sialic Acids; Zanamivir; Zoonoses	2004
[Zanamivir, oseltamivir]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 12 Topics: Acetamides; Antiviral Agents; Biological Availability; Clinical Trials as Topic; Drug Monitoring; Enzyme Inhibitors; Guanidines; Half-Life; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2004
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treatments in respiratory medicine, 2005, Volume: 4, Issue:2 Topics: Acetamides; Animals; Drug Resistance; Enzyme Inhibitors; Guanidines; Hemagglutinins; Humans; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Zanamivir	2005
Influenza. Clinical evidence, 2004, Issue:12 Topics: Acetamides; Adult; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2004
Neuraminidase inhibitors for influenza. The New England journal of medicine, 2005, Sep-29, Volume: 353, Issue:13 Topics: Acetamides; Adamantane; Adult; Aged; Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2005
[Anti-virals for influenza virus infection]. Uirusu, 2005, Volume: 55, Issue:1 Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Drug Utilization; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; National Health Programs; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2005
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral therapy, 2005, Volume: 10, Issue:8 Topics: Acetamides; Computer Communication Networks; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir	2005
[Role of influenza virus sialidase]. Seikagaku. The Journal of Japanese Biochemical Society, 2006, Volume: 78, Issue:5 Topics: Acetamides; Antiviral Agents; Apoptosis; Caspase 3; Caspases; Disease Outbreaks; Guanidines; Humans; Hydrogen-Ion Concentration; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Viral Envelope Proteins; Zanamivir	2006
Neuraminidase inhibitors for preventing and treating influenza in healthy adults. The Cochrane database of systematic reviews, 2006, Jul-19, Issue:3 Topics: Acetamides; Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2006
Safety of neuraminidase inhibitors for influenza. Expert opinion on drug safety, 2006, Volume: 5, Issue:5 Topics: Acetamides; Adult; Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Nausea; Neuraminidase; Oseltamivir; Pyrans; Safety; Sialic Acids; Zanamivir	2006
Antiviral drugs prophylaxis and treatment of influenza. The Medical letter on drugs and therapeutics, 2006, Oct-23, Volume: 48, Issue:1246 Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2006
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. American journal of epidemiology, 2007, Jan-15, Volume: 165, Issue:2 Topics: Antiviral Agents; Disease Transmission, Infectious; Family Characteristics; Humans; Influenza, Human; Multicenter Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Zanamivir	2007
Antivirals in the management of an influenza pandemic. The Medical journal of Australia, 2006, 11-20, Volume: 185, Issue:S10 Topics: Amantadine; Antiviral Agents; Australia; Community-Acquired Infections; Disease Outbreaks; Drug Resistance, Viral; Government Programs; Humans; Infection Control; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization; Zanamivir	2006
Which agents should we use to treat and prevent influenza in 2006-2007? Cleveland Clinic journal of medicine, 2006, Volume: 73, Issue:11 Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Zanamivir	2006
Neuraminidase inhibitors for preventing and treating influenza in children. The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1 Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2007
[Neuraminidase inhibitors and risk of H5N1 influenza]. Annales pharmaceutiques francaises, 2007, Volume: 65, Issue:1 Topics: Animals; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2007
Antiviral therapy and prophylaxis for influenza in children. Pediatrics, 2007, Volume: 119, Issue:4 Topics: Adamantane; Amantadine; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infant; Influenza, Human; Male; Oseltamivir; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Rimantadine; Risk Assessment; Severity of Illness Index; Treatment Outcome; Zanamivir	2007
[Antiviral agents for influenza]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1 Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Zanamivir	2007
Influenza: evolving strategies in treatment and prevention. Seminars in respiratory and critical care medicine, 2007, Volume: 28, Issue:2 Topics: Aged; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child, Preschool; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Rimantadine; United States; Zanamivir	2007
[Threat from newly emerging influenza]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Apr-10, Volume: 96, Issue:4 Topics: Animals; Antiviral Agents; Birds; Communicable Diseases, Emerging; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Zanamivir	2007
Current research on drugs and vaccines for fighting bird flu. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, Volume: 101, Issue:12 Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Zanamivir	2007
Neuraminidase inhibitor resistance in influenza viruses. Journal of medical virology, 2007, Volume: 79, Issue:10 Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir	2007
Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches. Current medicinal chemistry, 2007, Volume: 14, Issue:21 Topics: Animals; Antiviral Agents; Hemagglutinins, Viral; Humans; Influenza, Human; Molecular Mimicry; Neuraminidase; Oligosaccharides; Orthomyxoviridae; Virus Attachment; Zanamivir	2007
Neuraminidase inhibitors and their role in avian and pandemic influenza. Antiviral therapy, 2007, Volume: 12, Issue:4 Pt B Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Influenza in Birds; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Zanamivir	2007
Occasional review: influenza in COPD: pathogenesis, prevention, and treatment. International journal of chronic obstructive pulmonary disease, 2007, Volume: 2, Issue:1 Topics: Amantadine; Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Rimantadine; Zanamivir	2007
The war against influenza: discovery and development of sialidase inhibitors. Nature reviews. Drug discovery, 2007, Volume: 6, Issue:12 Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2007
[Countermeasures for newly-emerging influenza]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Nov-10, Volume: 96, Issue:11 Topics: Antiviral Agents; Communicable Diseases, Emerging; Disease Outbreaks; Enzyme Inhibitors; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2007
Lessons learned from the 2007-2008 cold and flu season: what worked and what was worthless. Urologic nursing, 2008, Volume: 28, Issue:2 Topics: Antiviral Agents; Causality; Common Cold; Diagnosis, Differential; Dietary Supplements; Hand Disinfection; Hospitalization; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Morbidity; Nonprescription Drugs; Oseltamivir; Seasons; United States; Vaccination; Zanamivir	2008
'Flu' and structure-based drug design. Structure (London, England : 1993), 1997, Sep-15, Volume: 5, Issue:9 Topics: Amines; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1997
[Emerging infectious diseases--influenza]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1997, Nov-10, Volume: 86, Issue:11 Topics: Animals; Antiviral Agents; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Orthomyxoviridae; Pyrans; Serotyping; Sialic Acids; Zanamivir	1997
Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Drug safety, 1998, Volume: 19, Issue:3 Topics: Administration, Inhalation; Animals; Antiviral Agents; Dogs; Drug Evaluation, Preclinical; Female; Guanidines; Humans; Influenza, Human; Injections, Intravenous; Male; Mice; Pyrans; Rats; Rats, Wistar; Sialic Acids; Zanamivir	1998
New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs, 1998, Volume: 56, Issue:4 Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1998
Underused options for preventing and treating influenza. Cleveland Clinic journal of medicine, 1999, Volume: 66, Issue:1 Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Drug Administration Routes; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Orthomyxoviridae; Pyrans; Ribavirin; Rimantadine; Sialic Acids; Zanamivir	1999
Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Clinical pharmacokinetics, 1999, Volume: 36 Suppl 1 Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1999
Zanamivir: a review of clinical safety. Drug safety, 1999, Volume: 21, Issue:4 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Interactions; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	1999
Update on influenza and rhinovirus infections. Advances in experimental medicine and biology, 1999, Volume: 458 Topics: Acetamides; Amines; Antiviral Agents; Common Cold; Guanidines; Humans; Influenza, Human; Intercellular Adhesion Molecule-1; Neuraminidase; Oseltamivir; Oxadiazoles; Oxazoles; Picornaviridae Infections; Pyrans; Recombinant Proteins; Rhinovirus; Sialic Acids; Zanamivir	1999
Zanamivir: a review of its use in influenza. Drugs, 1999, Volume: 58, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	1999
Effectiveness and role of zanamivir in the treatment of influenza infection. Annals of medicine, 1999, Volume: 31, Issue:5 Topics: Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Prognosis; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	1999
Prevention and early treatment of influenza in healthy adults. Vaccine, 2000, Jan-06, Volume: 18, Issue:11-12 Topics: Adolescent; Adult; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2000
Measures for control of influenza. PharmacoEconomics, 1999, Volume: 16 Suppl 1 Topics: Amantadine; Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	1999
[Critical review of anti-influenza drugs]. Nederlands tijdschrift voor geneeskunde, 2000, Jan-22, Volume: 144, Issue:4 Topics: Acetamides; Adult; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Netherlands; Neuraminidase; Oseltamivir; Public Health; Pyrans; Sialic Acids; Zanamivir	2000
Antiviral agents for treating influenza. Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:2 Topics: Acetamides; Amantadine; Antiviral Agents; Drug Administration Schedule; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2000
[symbol: see text] Zanamivir for influenza. Drug and therapeutics bulletin, 1999, Volume: 37, Issue:11 Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	1999
Influenza virus neuraminidase inhibitors. Lancet (London, England), 2000, Mar-04, Volume: 355, Issue:9206 Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir	2000
Neuraminidase inhibitors for preventing and treating influenza in healthy adults. The Cochrane database of systematic reviews, 2000, Issue:2 Topics: Adult; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2000
Zanamivir in the treatment and prevention of influenza. The Annals of pharmacotherapy, 2000, Volume: 34, Issue:6 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2000
Epidemiology and pathogenesis of influenza. The Journal of antimicrobial chemotherapy, 1999, Volume: 44 Suppl B Topics: Animals; Antigenic Variation; Antiviral Agents; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1999
A novel approach to antiviral therapy for influenza. The Journal of antimicrobial chemotherapy, 1999, Volume: 44 Suppl B Topics: Animals; Antiviral Agents; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1999
Neuraminidase inhibitors in the treatment of influenza A and B--overview and case reports. Infection, 2000, Volume: 28, Issue:5 Topics: Acetamides; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bronchitis; Clinical Trials as Topic; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pericarditis; Pyrans; Sialic Acids; Zanamivir	2000
Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Archives of internal medicine, 2000, Nov-27, Volume: 160, Issue:21 Topics: Acute Disease; Administration, Inhalation; Administration, Intranasal; Adolescent; Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Prescriptions; Guanidines; Humans; Incidence; Influenza, Human; Middle Aged; Multicenter Studies as Topic; Pyrans; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Risk Factors; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir	2000
Updated treatment for influenza A and B. American family physician, 2000, Dec-01, Volume: 62, Issue:11 Topics: Acetamides; Amantadine; Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Treatment Outcome; Zanamivir	2000
Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. Vaccine, 2000, Dec-08, Volume: 19 Suppl 1 Topics: Acetamides; Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Eustachian Tube; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Interferon-beta; Oseltamivir; Otitis Media; Otitis Media with Effusion; Picornaviridae Infections; Piperidines; Pressure; Pyrans; Pyridazines; Respiratory Tract Infections; Rhinovirus; Rimantadine; Sialic Acids; Superinfection; Virus Replication; Zanamivir	2000
Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Archives of internal medicine, 2001, Jan-22, Volume: 161, Issue:2 Topics: Administration, Inhalation; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Pyrans; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sialic Acids; Zanamivir	2001
[Influenza]. Recenti progressi in medicina, 2000, Volume: 91, Issue:12 Topics: Acetamides; Amantadine; Antiviral Agents; Disease Outbreaks; Guanidines; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Influenza, Human; Italy; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; United States; Zanamivir	2000
Neuraminidase inhibitors: zanamivir and oseltamivir. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:1 Topics: Acetamides; Antiviral Agents; Clinical Trials as Topic; Diarrhea; Enzyme Inhibitors; Guanidines; Headache; Humans; Influenza, Human; Nausea; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2001
Prophylactic and symptomatic treatment of influenza. Current and developing options. Postgraduate medicine, 2001, Volume: 109, Issue:1 Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir	2001
[Antiinfluenza-drugs and the standard of the use]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:11 Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2000
[Neuraminidase inhibitor]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:11 Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2000
Zanamivir: a rational approach to influenza B. Scandinavian journal of infectious diseases, 2001, Volume: 33, Issue:1 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2001
Why not [symbol: see text]zanamivir? Drug and therapeutics bulletin, 2001, Volume: 39, Issue:2 Topics: Adult; Aged; Antiviral Agents; Guanidines; Humans; Influenza, Human; Middle Aged; Patient Selection; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2001
Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clinical therapeutics, 2001, Volume: 23, Issue:3 Topics: Acetamides; Animals; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2001
[Efficacy of inhaled zanamivir in the treatment and prevention of influenza]. Anales de medicina interna (Madrid, Spain : 1984), 2001, Volume: 18, Issue:2 Topics: Administration, Inhalation; Antiviral Agents; Clinical Trials as Topic; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2001
Managing influenza: amantadine, rimantadine and beyond. International journal of clinical practice, 2001, Volume: 55, Issue:3 Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2001
Position statement: global neuraminidase inhibitor susceptibility network. Antiviral research, 2001, Volume: 49, Issue:3 Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2001
Adverse cutaneous reactions to influenza vaccinations and chemotherapy. International journal of dermatology, 2001, Volume: 40, Issue:7 Topics: Acetamides; Amantadine; Antiviral Agents; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Orthomyxoviridae; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Skin; Zanamivir	2001
Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug safety, 2001, Volume: 24, Issue:15 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Controlled Clinical Trials as Topic; Guanidines; Humans; Influenza, Human; Middle Aged; Nursing Homes; Product Surveillance, Postmarketing; Pyrans; Risk Factors; Sialic Acids; Zanamivir	2001
Perspectives on antiviral use during pandemic influenza. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001, Dec-29, Volume: 356, Issue:1416 Topics: Acetamides; Amantadine; Antiviral Agents; Chemoprevention; Disease Outbreaks; Drug Resistance, Multiple, Viral; Drug Tolerance; Guanidines; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2001
Zanamivir: from drug design to the clinic. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001, Dec-29, Volume: 356, Issue:1416 Topics: Animals; Antiviral Agents; Chemoprevention; Clinical Trials as Topic; Drug Design; Drug Interactions; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2001
Treatment of influenza with neuraminidase inhibitors: virological implications. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001, Dec-29, Volume: 356, Issue:1416 Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2001
Zanamivir: an update of its use in influenza. Drugs, 2002, Volume: 62, Issue:1 Topics: Animals; Antiviral Agents; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2002
Neuraminidase inhibitors for the treatment and prevention of influenza. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:2 Topics: Acetamides; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; Zanamivir	2002
Influenza in the acute hospital setting. The Lancet. Infectious diseases, 2002, Volume: 2, Issue:3 Topics: Acetamides; Amantadine; Antiviral Agents; Cross Infection; Disease Outbreaks; Guanidines; Hospitals; Humans; Influenza Vaccines; Influenza, Human; Nursing Staff, Hospital; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Vaccination; Virginia; Zanamivir	2002
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2002, Volume: 6, Issue:9 Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; United Kingdom; Zanamivir	2002

Trials

67 trial(s) available for zanamivir and Grippe

Article	Year
Lessons from resistance analysis in clinical trials of IV zanamivir. Virus research, 2023, Volume: 325 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2023
Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2020, Volume: 54, Issue:2 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Zanamivir	2020
Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial. BMJ open, 2017, Jul-10, Volume: 7, Issue:7 Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Double-Blind Method; Female; France; Humans; Influenza, Human; Kaplan-Meier Estimate; Lost to Follow-Up; Male; Medication Adherence; Multivariate Analysis; Oseltamivir; Proportional Hazards Models; Treatment Outcome; Zanamivir	2017
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017, Volume: 23, Issue:9 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antiviral Agents; Child; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Pregnancy; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Treatment Outcome; Young Adult; Zanamivir	2017
Intravenous Zanamivir in Hospitalized Patients With Influenza. Pediatrics, 2017, Volume: 140, Issue:5 Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Influenza, Human; Infusions, Intravenous; Male; Neutropenia; Viral Load; Zanamivir	2017
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan. Expert review of anti-infective therapy, 2018, Volume: 16, Issue:2 Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir	2018
Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7 Topics: Adolescent; Adult; Aged; Antiviral Agents; Creatinine; Female; Humans; Influenza, Human; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Renal Insufficiency; Young Adult; Zanamivir	2013
Safety, tolerability and pharmacokinetics of orally inhaled zanamivir: a randomized study comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in healthy adults. Antiviral therapy, 2013, Volume: 18, Issue:6 Topics: Administration, Inhalation; Adult; Antiviral Agents; Female; Healthy Volunteers; Humans; Influenza, Human; Male; Young Adult; Zanamivir	2013
Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Disease Transmission, Infectious; Double-Blind Method; Family Characteristics; Female; Guanidines; Humans; Infant; Influenza, Human; Male; Middle Aged; Placebos; Post-Exposure Prophylaxis; Pyrans; Sialic Acids; Zanamivir	2013
Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. The Journal of infectious diseases, 2014, Feb-15, Volume: 209, Issue:4 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Treatment Outcome; Viral Load; Zanamivir	2014
The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Fever; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Pyrans; Sialic Acids; Young Adult; Zanamivir	2014
Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy, 2013, Volume: 59, Issue:5 Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Outpatients; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Young Adult; Zanamivir	2013
Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:12 Topics: Antiviral Agents; Child; Disease Outbreaks; Female; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2014
Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. Antiviral therapy, 2015, Volume: 20, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Injections, Intravenous; Male; Middle Aged; Neuraminidase; Patient Safety; Treatment Outcome; Viral Proteins; Zanamivir	2015
Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial. Influenza and other respiratory viruses, 2015, Volume: 9, Issue:2 Topics: Adult; Antiviral Agents; Canada; Female; Hemagglutination Inhibition Tests; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Pilot Projects; Seasons; Young Adult; Zanamivir	2015
Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015, Volume: 21, Issue:11 Topics: Antiviral Agents; Child; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Inhibitory Concentration 50; Male; Pyrans; Sialic Acids; Zanamivir	2015
Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 08-01, Volume: 63, Issue:3 Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Child; Double-Blind Method; Enzyme Inhibitors; Family Characteristics; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Post-Exposure Prophylaxis; Pyrans; Sialic Acids; Young Adult; Zanamivir	2016
Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects. Antiviral research, 2016, Volume: 134 Topics: Administration, Intravenous; Adult; Drug Resistance, Viral; Genotype; Hemagglutinins; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Phenotype; Sequence Analysis, DNA; Zanamivir	2016
Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial. Infectious diseases (London, England), 2017, Volume: 49, Issue:5 Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2017
Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children. Pediatrics, 2016, Volume: 138, Issue:6 Topics: Administration, Inhalation; Age Factors; Antiviral Agents; Child; Child, Preschool; Communicable Disease Control; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Family Characteristics; Follow-Up Studies; Guanidines; Humans; Influenza, Human; Japan; Monitoring, Physiologic; Pyrans; Risk Assessment; Sialic Acids; Treatment Outcome; Zanamivir	2016
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Female; Hospitalization; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir	2017
Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Virus Shedding; Zanamivir	2010
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Nov-15, Volume: 51, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir	2010
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS medicine, 2010, Nov-02, Volume: 7, Issue:11 Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Zanamivir	2010
A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:4 Topics: Adult; Antiviral Agents; Cytokines; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Statistics, Nonparametric; Treatment Outcome; Zanamivir	2012
Effect of a single inhalation of laninamivir octanoate in children with influenza. Pediatrics, 2012, Volume: 129, Issue:6 Topics: Administration, Inhalation; Adolescent; Child; Child, Preschool; Female; Fever; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir	2012
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:6 Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir	2012
A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:1 Topics: Adult; Aged; Antiviral Agents; Asthma; Chronic Disease; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2013
Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antiviral research, 2012, Volume: 96, Issue:2 Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nasal Mucosa; Oseltamivir; Treatment Outcome; Virus Shedding; Young Adult; Zanamivir	2012
Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antiviral therapy, 2012, Volume: 17, Issue:6 Topics: Adolescent; Adult; Aged; Antiviral Agents; Cough; Drug Therapy, Combination; Enzyme Inhibitors; Family Characteristics; Female; Fever; Follow-Up Studies; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Time Factors; Young Adult; Zanamivir	2012
Utility of Maoto in an influenza season where reduced effectiveness of oseltamivir was observed - a clinical, non-randomized study in children. Forschende Komplementarmedizin (2006), 2012, Volume: 19, Issue:4 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Age Factors; Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Seasons; Treatment Outcome; Zanamivir	2012
Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:3 Topics: Administration, Inhalation; Adult; Antiviral Agents; Chemoprevention; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Placebos; Thailand; Young Adult; Zanamivir	2013
Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:4 Topics: Amino Acid Substitution; Drug Resistance, Viral; Humans; Influenza, Human; Molecular Sequence Data; Mutation; Neuraminidase; Polymerase Chain Reaction; Viral Proteins; Zanamivir	2013
Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population. Infection control and hospital epidemiology, 2002, Volume: 23, Issue:10 Topics: Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Cross Infection; Disease Outbreaks; Female; Guanidines; Hospital Bed Capacity, 500 and over; Hospital Units; Hospitals, Urban; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Long-Term Care; Male; Middle Aged; Ontario; Premedication; Pyrans; Rehabilitation Centers; Safety; Sialic Acids; Zanamivir	2002
Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. The Journal of infectious diseases, 2002, Dec-01, Volume: 186, Issue:11 Topics: Adolescent; Adult; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Disease Transmission, Infectious; Double-Blind Method; Family Characteristics; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Microbial Sensitivity Tests; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2002
Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice. Medical microbiology and immunology, 2002, Volume: 191, Issue:3-4 Topics: Acetamides; Aged; Ambulatory Care; Antiviral Agents; Child; Enzyme Inhibitors; Fibrinogen; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2002
Drug under test: influenza--Relenza in daily practice. Experience during the influenza season 1999/2000. Medical microbiology and immunology, 2002, Volume: 191, Issue:3-4 Topics: Antiviral Agents; Drug Tolerance; Fever; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Pharyngitis; Pyrans; Respiratory Tract Infections; Risk; Seasons; Sialic Acids; Treatment Outcome; Zanamivir	2002
Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scandinavian journal of infectious diseases, 2003, Volume: 35, Issue:1 Topics: Administration, Oral; Adult; Base Sequence; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Finland; Follow-Up Studies; Guanidines; Humans; Influenza, Human; Male; Military Personnel; Molecular Sequence Data; Orthomyxoviridae; Polymerase Chain Reaction; Probability; Pyrans; Reference Values; RNA, Viral; Severity of Illness Index; Sialic Acids; Treatment Outcome; Viral Load; Zanamivir	2003
Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antiviral therapy, 1999, Volume: 4, Issue:3 Topics: Administration, Intranasal; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Pyrans; Sialic Acids; Zanamivir	1999
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral therapy, 2003, Volume: 8, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Nebulizers and Vaporizers; Pyrans; Respiratory Therapy; Rimantadine; Sialic Acids; Zanamivir	2003
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. The Pediatric infectious disease journal, 2005, Volume: 24, Issue:10 Topics: Acetamides; Animals; Antiviral Agents; Cell Line; Child; Child, Preschool; Chlorocebus aethiops; Guanidines; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Vero Cells; Virus Shedding; Zanamivir	2005
Zanamivir treatment is equally effective for both influenza A and influenza B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jun-15, Volume: 44, Issue:12 Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Treatment Outcome; Zanamivir	2007
Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clinical therapeutics, 2007, Volume: 29, Issue:8 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Europe; Female; Humans; Influenza, Human; Male; Middle Aged; North America; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Zanamivir	2007
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. The Journal of infection, 2008, Volume: 56, Issue:1 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Female; Fever; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Male; Oseltamivir; Treatment Outcome; Zanamivir	2008
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. The New England journal of medicine, 1997, Sep-25, Volume: 337, Issue:13 Topics: Administration, Inhalation; Administration, Intranasal; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Nose; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir	1997
Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. The Journal of infectious diseases, 1997, Volume: 176, Issue:6 Topics: Administration, Intranasal; Adult; Antiviral Agents; Double-Blind Method; Ear Diseases; Ear, Middle; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Nasal Lavage Fluid; Pressure; Pyrans; Sialic Acids; Zanamivir	1997
Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine, 1998, Volume: 16, Issue:18 Topics: Aged; Antiviral Agents; Disease Outbreaks; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Nursing Homes; Prospective Studies; Pyrans; Random Allocation; Rimantadine; Sialic Acids; Treatment Outcome; Wisconsin; Zanamivir	1998
Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet (London, England), 1998, Dec-12, Volume: 352, Issue:9144 Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Pyrans; Safety; Sialic Acids; Treatment Outcome; Zanamivir	1998
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:7 Topics: Adolescent; Adult; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Nasal Mucosa; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1999
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. The Journal of infectious diseases, 1999, Volume: 180, Issue:2 Topics: Adult; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Neuraminidase; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	1999
Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA, 1999, Jul-07, Volume: 282, Issue:1 Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir	1999
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. The Journal of infectious diseases, 1999, Volume: 180, Issue:3 Topics: Antiviral Agents; Body Temperature; Chemokines; Cytokines; Double-Blind Method; Guanidines; Humans; Influenza A virus; Influenza, Human; Injections, Intravenous; Male; Nasal Lavage Fluid; Neuraminidase; Placebos; Pyrans; Sialic Acids; Time Factors; Zanamivir	1999
[Flu and antiviral agents....]. Presse medicale (Paris, France : 1983), 2000, Jan-22, Volume: 29, Issue:2 Topics: Acetamides; Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Placebos; Pyrans; Risk Factors; Sialic Acids; Zanamivir	2000
Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antiviral therapy, 1999, Volume: 4, Issue:2 Topics: Adult; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1999
A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. Journal of clinical pharmacology, 2000, Volume: 40, Issue:3 Topics: Administration, Inhalation; Administration, Intranasal; Adult; Algorithms; Antiviral Agents; Double-Blind Method; Female; Guanidines; Humans; Influenza, Human; Male; Models, Biological; Pyrans; Sialic Acids; Zanamivir	2000
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30, Issue:3 Topics: Administration, Inhalation; Administration, Intranasal; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2000
Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. The Journal of infection, 2000, Volume: 40, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2000
Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. The Journal of infectious diseases, 2000, Volume: 181, Issue:4 Topics: Administration, Inhalation; Adult; Antiviral Agents; Canada; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2000
Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. The Pediatric infectious disease journal, 2000, Volume: 19, Issue:5 Topics: Administration, Inhalation; Antiviral Agents; Child; Child, Preschool; Double-Blind Method; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Patient Compliance; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2000
Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. The Journal of antimicrobial chemotherapy, 1999, Volume: 44 Suppl B Topics: Antiviral Agents; Double-Blind Method; Fever; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Nebulizers and Vaporizers; Prospective Studies; Pyrans; Sialic Acids; Zanamivir	1999
Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. PharmacoEconomics, 2000, Volume: 17, Issue:2 Topics: Adult; Antiviral Agents; Double-Blind Method; Efficiency; Female; Guanidines; Health Care Rationing; Health Status; Humans; Influenza, Human; Male; Pyrans; Sialic Acids; Zanamivir	2000
Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. PharmacoEconomics, 2000, Volume: 17, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Guanidines; Health Care Costs; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2000
Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. The New England journal of medicine, 2000, Nov-02, Volume: 343, Issue:18 Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Disease Transmission, Infectious; Double-Blind Method; Drug Resistance, Microbial; Family Health; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Neuraminidase; Prospective Studies; Pyrans; RNA, Viral; Sequence Analysis, RNA; Sialic Acids; Zanamivir	2000
Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing-care population. Canada communicable disease report = Releve des maladies transmissibles au Canada, 2001, Feb-01, Volume: 27, Issue:3 Topics: Administration, Inhalation; Aged; Antiviral Agents; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Pyrans; Sialic Acids; Zanamivir	2001
Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ (Clinical research ed.), 2001, Mar-10, Volume: 322, Issue:7286 Topics: Administration, Inhalation; Aged; Aged, 80 and over; Antiviral Agents; Drug Delivery Systems; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Powders; Pyrans; Sialic Acids; Zanamivir	2001
Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Archives of internal medicine, 2001, Sep-24, Volume: 161, Issue:17 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antibodies, Viral; Community-Acquired Infections; Double-Blind Method; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Predictive Value of Tests; Pyrans; Reverse Transcriptase Polymerase Chain Reaction; Sialic Acids; Virus Cultivation; Zanamivir	2001
The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone marrow transplantation, 2002, Volume: 29, Issue:2 Topics: Adolescent; Adult; Antiviral Agents; Female; Guanidines; Hematologic Neoplasms; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Myelodysplastic Syndromes; Pyrans; Sialic Acids; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Zanamivir	2002

Other Studies

471 other study(ies) available for zanamivir and Grippe

Article	Year
Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities. Bioorganic & medicinal chemistry letters, 2006, Oct-01, Volume: 16, Issue:19 Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Pyrans; Sialic Acids; Structure-Activity Relationship; Triazoles; Zanamivir	2006
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Amides; Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Oseltamivir; Oxygen; Pyrazines; Survival Analysis; Virus Replication	2007
Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir). Bioorganic & medicinal chemistry letters, 2007, Sep-01, Volume: 17, Issue:17 Topics: Administration, Oral; Animals; Cell Line; Disease Models, Animal; Dogs; Drug Design; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Infusions, Parenteral; Inhibitory Concentration 50; Mice; Ribavirin; Zanamivir	2007
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; Dogs; HeLa Cells; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Neuraminidase; Prodrugs; Zanamivir	2009
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Antiviral Agents; Cells, Cultured; Child, Preschool; Drug Resistance, Viral; Genetic Testing; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Molecular Sequence Data; Neuraminidase; Oseltamivir; Point Mutation; Sequence Analysis, DNA	2010
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9 Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir	2010
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir. Bioorganic & medicinal chemistry, 2011, Aug-15, Volume: 19, Issue:16 Topics: Administration, Oral; Antiviral Agents; Carbon Dioxide; Cell Line; Drug Evaluation, Preclinical; Enzyme Inhibitors; Esters; Guanidine; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A virus; Influenza, Human; Ions; Molecular Structure; Naphthols; Neuraminidase; Oseltamivir; Prodrugs; Zanamivir	2011
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. Journal of medicinal chemistry, 2016, 06-09, Volume: 59, Issue:11 Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Neuraminidase; Rabbits; Structure-Activity Relationship	2016
Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Alkaloids; Animals; Antiviral Agents; Boronic Acids; Cell Line; Female; Humans; Indoles; Influenza A virus; Influenza, Human; Mice; NF-kappa B; Orthomyxoviridae Infections; Quinolines; Signal Transduction	2017
Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives. Journal of medicinal chemistry, 2018, 03-08, Volume: 61, Issue:5 Topics: Antiviral Agents; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Structure-Activity Relationship	2018
Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp). Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5 Topics: Animals; Antiviral Agents; Humans; Hydrazines; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; RNA-Dependent RNA Polymerase; Virus Replication	2022
Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan. Pharmacoepidemiology and drug safety, 2022, Volume: 31, Issue:6 Topics: Antiviral Agents; Communicable Diseases; Dibenzothiepins; Employment; Humans; Incidence; Influenza, Human; Insurance, Health; Japan; Morpholines; Oseltamivir; Outpatients; Pyridones; Retrospective Studies; Triazines; Zanamivir	2022
Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019. Influenza and other respiratory viruses, 2022, Volume: 16, Issue:3 Topics: Antiviral Agents; Compassionate Use Trials; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2022
Genetic and biological properties of H10N3 avian influenza viruses: A potential pandemic candidate? Transboundary and emerging diseases, 2022, Volume: 69, Issue:5 Topics: Animals; Chick Embryo; Chickens; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Mammals; Mice; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Poultry; Rodent Diseases; Zanamivir	2022
Inhaled Zanamivir vs Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8 Topics: Antiviral Agents; Cohort Studies; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2022
Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors. Antiviral research, 2022, Volume: 200 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2022
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022, Volume: 28, Issue:7 Topics: Antiviral Agents; Fever; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Neuraminidase; Pyrans; Seasons; Sialic Acids; Zanamivir	2022
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-29, Volume: 75, Issue:6 Topics: Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Outpatients; Zanamivir	2022
Response to "Inhaled Zanamivir versus Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-29, Volume: 75, Issue:9 Topics: Antiviral Agents; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2022
In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance. Molecules (Basel, Switzerland), 2022, Sep-12, Volume: 27, Issue:18 Topics: Acids, Carbocyclic; Antiviral Agents; Arginine; Benserazide; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Zanamivir	2022
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020-2021. Communicable diseases intelligence (2018), 2022, Sep-26, Volume: 46 Topics: Antiviral Agents; Australia; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization; Zanamivir	2022
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023, Volume: 28, Issue:4 Topics: Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Hospital Mortality; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir	2023
Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014-2019/2020 seasons in Japan: an o BMC infectious diseases, 2023, Mar-29, Volume: 23, Issue:1 Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Outpatients; RNA, Viral; Seasons; Zanamivir	2023
Dual-Action Heteromultivalent Glycopolymers Stringently Block and Arrest Influenza A Virus Infection Nano letters, 2023, 06-14, Volume: 23, Issue:11 Topics: Alphainfluenzavirus; Antiviral Agents; Glycosylation; Humans; Influenza, Human; Polymers; Zanamivir	2023
A five-day treatment course of zanamivir for the flu with a single, self-administered, painless microneedle array patch: Revolutionizing delivery of poorly membrane-permeable therapeutics. International journal of pharmaceutics, 2023, Jun-25, Volume: 641 Topics: Animals; Antiviral Agents; Gelatin; Humans; Influenza, Human; Rats; Swine; Trehalose; Zanamivir	2023
Targeting the Human Influenza a Virus: The Methods, Limitations, and Pitfalls of Virtual Screening for Drug-like Candidates Including Scaffold Hopping and Compound Profiling. Viruses, 2023, 04-26, Volume: 15, Issue:5 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Prospective Studies; Zanamivir	2023
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections. Science immunology, 2023, 06-23, Volume: 8, Issue:84 Topics: Animals; Humans; Immunoglobulin Light Chains; Influenza, Human; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Zanamivir	2023
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses. Antiviral research, 2023, Volume: 217 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidine; Guanidines; Herpesvirus 1, Cercopithecine; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2023
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022. Communicable diseases intelligence (2018), 2023, Jul-27, Volume: 47 Topics: Animals; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Female; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; World Health Organization; Zanamivir	2023
Antiviral drugs for influenza for 2023-2024. The Medical letter on drugs and therapeutics, 2023, 11-13, Volume: 65, Issue:1689 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2023
Comparison chart: Antiviral drugs for influenza for 2023-2024. The Medical letter on drugs and therapeutics, 2023, 11-13, Volume: 65, Issue:1689 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2023
Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series. BMC infectious diseases, 2019, Oct-16, Volume: 19, Issue:1 Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Zanamivir	2019
Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. Clinical and translational science, 2020, Volume: 13, Issue:1 Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Datasets as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glomerular Filtration Rate; Healthy Volunteers; Hospitalization; Humans; Infant; Influenza A virus; Influenza, Human; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neuraminidase; Renal Elimination; Time Factors; United States; Viral Load; Young Adult; Zanamivir	2020
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient. Antiviral therapy, 2019, Volume: 24, Issue:8 Topics: Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Transplant Recipients; Zanamivir	2019
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews. Scientific reports, 2020, 02-20, Volume: 10, Issue:1 Topics: Acids, Carbocyclic; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza, Human; Internet; Male; Middle Aged; Neuraminidase; Odds Ratio; Oseltamivir; Patient Participation; Pyrans; Risk Factors; Sialic Acids; United States; United States Food and Drug Administration; Young Adult; Zanamivir	2020
Association of moderately abnormal behavior and administered neuraminidase inhibitors. Drug discoveries & therapeutics, 2020, Mar-08, Volume: 14, Issue:1 Topics: Acids, Carbocyclic; Adolescent; Antiviral Agents; Child; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Illness Behavior; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Young Adult; Zanamivir	2020
Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 10-23, Volume: 71, Issue:7 Topics: Amides; Antiviral Agents; Child; Humans; Influenza, Human; Pyrazines; Zanamivir	2020
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018. Communicable diseases intelligence (2018), 2020, Mar-16, Volume: 44 Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Phylogeny; World Health Organization; Zanamivir	2020
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2020
Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone. Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2020
Topology-Matching Design of an Influenza-Neutralizing Spiky Nanoparticle-Based Inhibitor with a Dual Mode of Action. Angewandte Chemie (International ed. in English), 2020, 09-01, Volume: 59, Issue:36 Topics: Animals; Antiviral Agents; Dogs; Drug Design; Glycerol; Humans; Influenza A virus; Influenza, Human; Lactose; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Molecular Structure; Nanoparticles; Particle Size; Polymers; Sialic Acids; Surface Properties; Virus Replication; Zanamivir	2020
Detection of a Peramivir-Resistant Influenza B/Yamagata-Lineage Virus Imported from Indonesia in Aichi, Japan, March 2019. Japanese journal of infectious diseases, 2020, Sep-24, Volume: 73, Issue:5 Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Guanidines; Humans; Indonesia; Influenza B virus; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Morpholines; Mutation; Neuraminidase; Pyrans; Pyridones; Sialic Acids; Triazines; Zanamivir	2020
[Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia]. Terapevticheskii arkhiv, 2019, Nov-15, Volume: 91, Issue:11 Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Russia; Zanamivir	2019
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea. Virology journal, 2020, 07-06, Volume: 17, Issue:1 Topics: Acids, Carbocyclic; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oropharynx; Oseltamivir; Phylogeny; Republic of Korea; Sequence Analysis, DNA; Zanamivir	2020
Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLoS pathogens, 2020, Volume: 16, Issue:8 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Rimantadine; Viral Matrix Proteins; Zanamivir	2020
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019. Virology, 2020, Volume: 549 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Microbial Sensitivity Tests; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Reassortant Viruses; Viral Proteins; Zanamivir	2020
Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza. The Annals of pharmacotherapy, 2021, Volume: 55, Issue:6 Topics: Antiviral Agents; Critical Illness; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2021
Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. Transplant infectious disease : an official journal of the Transplantation Society, 2021, Volume: 23, Issue:3 Topics: Alphainfluenzavirus; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyridones; Triazines; Zanamivir	2021
Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season. The Journal of antimicrobial chemotherapy, 2021, 03-12, Volume: 76, Issue:4 Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Female; France; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Prescriptions; Prospective Studies; Seasons; Zanamivir	2021
Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections. Bioconjugate chemistry, 2021, 08-18, Volume: 32, Issue:8 Topics: Animals; Enzyme Inhibitors; HEK293 Cells; Humans; Influenza A virus; Influenza, Human; Mice; Neuraminidase; Optical Imaging; Orthomyxoviridae Infections; Viral Proteins; Zanamivir	2021
The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:10 Topics: Administration, Inhalation; Antiviral Agents; Child, Preschool; Guanidines; Humans; Influenza, Human; Neuraminidase; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Zanamivir	2021
Adverse events of prophylactic anti-influenza agents in medical staffs. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017, Volume: 23, Issue:10 Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Influenza, Human; Medical Staff; Middle Aged; Oseltamivir; Post-Exposure Prophylaxis; Retrospective Studies; Zanamivir	2017
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antiviral research, 2017, Volume: 146 Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; World Health Organization; Zanamivir	2017
Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015. Communicable diseases intelligence quarterly report, 2017, Jun-30, Volume: 41, Issue:2 Topics: Africa; Annual Reports as Topic; Antigens, Viral; Antiviral Agents; Asia; Australia; Drug Resistance, Viral; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Phylogeny; World Health Organization; Zanamivir	2017
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. The Journal of infectious diseases, 2017, 09-15, Volume: 216, Issue:suppl_4 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Databases, Genetic; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Recombinant Proteins; Sialic Acids; Viral Proteins; Zanamivir	2017
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes. Journal of virology, 2018, 01-01, Volume: 92, Issue:1 Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mutagenesis; Neuraminidase; Orthomyxoviridae; Oseltamivir; Reverse Genetics; Zanamivir	2018
The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. Respiratory investigation, 2017, Volume: 55, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Clarithromycin; Cohort Studies; Comorbidity; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phosphorous Acids; Pneumonia; Prospective Studies; Treatment Outcome; Zanamivir	2017
Oseltamivir Treatment of Influenza in Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 05-02, Volume: 66, Issue:10 Topics: Child; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir	2018
Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2018, Volume: 102 Topics: Animals; Antiviral Agents; Defective Viruses; Denmark; Dogs; Drug Resistance, Viral; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Respiratory System; RNA-Dependent RNA Polymerase; RNA, Viral; Sequence Deletion; Treatment Outcome; Viral Proteins; Zanamivir	2018
A Sulfonozanamivir Analogue Has Potent Anti-influenza Virus Activity. ChemMedChem, 2018, 04-23, Volume: 13, Issue:8 Topics: Antiviral Agents; Arylsulfonates; Catalytic Domain; Crystallography, X-Ray; Humans; Influenza A virus; Influenza, Human; Molecular Docking Simulation; Neuraminidase; Virus Replication; Zanamivir	2018
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:6 Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir	2018
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections. Pediatric pulmonology, 2018, Volume: 53, Issue:6 Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Female; Guanidines; Hospitalization; Humans; Infant; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2018
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza. BMC health services research, 2018, 05-02, Volume: 18, Issue:1 Topics: Adult; Antiviral Agents; Attitude of Health Personnel; Glycoside Hydrolase Inhibitors; Hospitalization; Humans; Influenza, Human; Medical Staff, Hospital; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Research Personnel; Surveys and Questionnaires; United Kingdom; Zanamivir	2018
Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice. Archives of virology, 2018, Volume: 163, Issue:9 Topics: Animals; Antiviral Agents; Clarithromycin; Drug Approval; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Flufenamic Acid; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interleukin-1beta; Lung; Mice; Mice, Inbred BALB C; Tumor Necrosis Factor-alpha; United States; United States Food and Drug Administration; Zanamivir	2018
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:9 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Female; Fever; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Pyrans; Seasons; Sialic Acids; Young Adult; Zanamivir	2018
Humoral immunity to influenza in an at-risk population and severe influenza cases in Russia in 2016-2017. Archives of virology, 2018, Volume: 163, Issue:10 Topics: Animals; Antibodies, Viral; Antiviral Agents; Birds; Epidemics; Humans; Immunity, Herd; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H5N8 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Oseltamivir; Poultry; Poultry Diseases; Russia; Zanamivir	2018
Antigenic and genetic characterization of influenza viruses isolated in Mozambique during the 2015 season. PloS one, 2018, Volume: 13, Issue:7 Topics: Animals; Antiviral Agents; Child; Child, Preschool; Dogs; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Mozambique; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Zanamivir	2018
Outpatient influenza antivirals in a distributed data network for influenza surveillance. Influenza and other respiratory viruses, 2018, Volume: 12, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Utilization; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Outpatients; Prescriptions; Young Adult; Zanamivir	2018
Characteristics and mortality of severe influenza cases treated with parenteral aqueous zanamivir, United Kingdom, October 2009 to January 2011. Influenza and other respiratory viruses, 2019, Volume: 13, Issue:1 Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza, Human; Infusions, Parenteral; Male; Middle Aged; Pandemics; Retrospective Studies; Treatment Outcome; United Kingdom; Young Adult; Zanamivir	2019
Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency. Antiviral research, 2018, Volume: 160 Topics: Antiviral Agents; Child; Cord Blood Stem Cell Transplantation; Drug Resistance, Viral; Genetic Variation; Humans; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Severe Combined Immunodeficiency; Viral Load; Viral Proteins; Zanamivir	2018
Intravenous zanamivir for influenza myocarditis and enteral malabsorption. Critical care (London, England), 2018, 12-04, Volume: 22, Issue:1 Topics: Administration, Intravenous; Adult; Antiviral Agents; Catecholamines; Female; Humans; Influenza, Human; Malabsorption Syndromes; Middle Aged; Myocarditis; Oseltamivir; Zanamivir	2018
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka. Osaka city medical journal, 2016, Volume: 62, Issue:2 Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir	2016
Mobility-Based Quantification of Multivalent Virus-Receptor Interactions: New Insights Into Influenza A Virus Binding Mode. Nano letters, 2019, 03-13, Volume: 19, Issue:3 Topics: Cell Membrane; G(M1) Ganglioside; Hemagglutinins; Humans; Influenza A virus; Influenza, Human; Lipid Bilayers; Neuraminidase; Receptors, Virus; Zanamivir	2019
Association of severe abnormal behavior and acetaminophen with/without neuraminidase inhibitors. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:6 Topics: Acetaminophen; Adolescent; Age Factors; Antiviral Agents; Behavioral Symptoms; Child; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Incidence; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Sialic Acids; Zanamivir	2019
Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:7 Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Oseltamivir; Pneumonia, Viral; Treatment Outcome; Virus Shedding; Zanamivir	2019
Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate. Internal medicine (Tokyo, Japan), 2019, Sep-01, Volume: 58, Issue:17 Topics: Adolescent; Antiviral Agents; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Guanidines; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Influenza A virus; Influenza, Human; Jaundice; Pyrans; Sialic Acids; Zanamivir	2019
Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:12 Topics: Administration, Inhalation; Adult; Antiviral Agents; Bronchoalveolar Lavage; Female; Glucocorticoids; Guanidines; Humans; Influenza A virus; Influenza, Human; Lung; Neuraminidase; Pneumonia; Pyrans; Respiration, Artificial; Sialic Acids; Tomography, X-Ray Computed; Treatment Outcome; Viral Proteins; Young Adult; Zanamivir	2019
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017 Communicable diseases intelligence (2018), 2019, Jun-17, Volume: 43 Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Dogs; Drug Resistance, Viral; Eggs; Female; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Phylogeny; World Health Organization; Zanamivir	2019
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts. Virology journal, 2019, 07-02, Volume: 16, Issue:1 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Chickens; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Virus Replication; Zanamivir	2019
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:5 Topics: Animals; Antiviral Agents; Catalytic Domain; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Japan; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir	2013
Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug metabolism and pharmacokinetics, 2013, Volume: 28, Issue:5 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Sialic Acids; Zanamivir	2013
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza and other respiratory viruses, 2013, Volume: 7, Issue:5 Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oceania; Oseltamivir; Pyrans; Seasons; Sentinel Surveillance; Sialic Acids; South America; Zanamivir	2013
Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. American journal of obstetrics and gynecology, 2013, Volume: 209, Issue:2 Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiviral Agents; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Time Factors; Zanamivir	2013
Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. PloS one, 2013, Volume: 8, Issue:4 Topics: Absorption; Administration, Oral; Animals; Biological Availability; Biological Transport; Caco-2 Cells; Cell Membrane Permeability; Enzyme Inhibitors; Humans; Influenza, Human; Male; Neuraminidase; Orthomyxoviridae Infections; Rats; Rats, Sprague-Dawley; Time Factors; Zanamivir	2013
Value of pharmacy-based influenza surveillance - Ontario, Canada, 2009. MMWR. Morbidity and mortality weekly report, 2013, May-24, Volume: 62, Issue:20 Topics: Adolescent; Adult; Antiviral Agents; Drug Prescriptions; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Ontario; Oseltamivir; Population Surveillance; Reproducibility of Results; Retrospective Studies; Time Factors; Young Adult; Zanamivir	2013
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection. Pediatrics international : official journal of the Japan Pediatric Society, 2013, Volume: 55, Issue:6 Topics: Child; Early Medical Intervention; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Zanamivir	2013
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Antiviral research, 2013, Volume: 99, Issue:3 Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Microbial Sensitivity Tests; Neuraminidase; Pandemics; Pyrans; Seasons; Sialic Acids; Viral Proteins; Zanamivir	2013
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio, 2013, Jul-16, Volume: 4, Issue:4 Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Coinfection; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Plaque Assay; Viral Proteins; Zanamivir	2013
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Assays; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Kinetics; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir	2013
Should neuraminidase inhibitors be prescribed for patients with influenza? Annals of emergency medicine, 2014, Volume: 63, Issue:1 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2014
Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza and other respiratory viruses, 2014, Volume: 8, Issue:2 Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Chromatography, Affinity; Female; Fever; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Prospective Studies; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir	2014
Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model. Antiviral research, 2013, Volume: 100, Issue:1 Topics: Administration, Intravenous; Animals; Antiviral Agents; Disease Models, Animal; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Mice; Mice, Inbred BALB C; Pyrans; Sialic Acids; Zanamivir	2013
Therapy of H7N9 pneumonia: current perspectives. Expert review of anti-infective therapy, 2013, Volume: 11, Issue:11 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pulmonary Ventilation; Zanamivir	2013
Anti-influenza activity of Alchemilla mollis extract: possible virucidal activity against influenza virus particles. Drug discoveries & therapeutics, 2013, Volume: 7, Issue:5 Topics: Alchemilla; Animals; Antiviral Agents; Chickens; Dogs; Drug Synergism; Erythrocytes; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Medicine, Traditional; Orthomyxoviridae; Plant Extracts; Virus Replication; Zanamivir	2013
Neuraminidase inhibitors for critically ill children with influenza. Pediatrics, 2013, Volume: 132, Issue:6 Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; California; Child; Child, Preschool; Critical Care; Critical Illness; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pandemics; Population Surveillance; Treatment Outcome; Zanamivir	2013
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Child; Child, Preschool; Cohort Studies; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Retrospective Studies; Treatment Outcome; Young Adult; Zanamivir	2014
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity. Scientific reports, 2013, Dec-20, Volume: 3 Topics: Acids, Carbocyclic; Antiviral Agents; Computational Biology; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir	2013
Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir. The Pediatric infectious disease journal, 2014, Volume: 33, Issue:7 Topics: Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Nasal Cavity; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zanamivir	2014
Critics attack chief medical officer's advice to use antivirals for flu. BMJ (Clinical research ed.), 2014, Feb-12, Volume: 348 Topics: Antiviral Agents; Evidence-Based Medicine; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; State Medicine; United Kingdom; Zanamivir	2014
Department of Health's misguided alert recommending neuraminidase inhibitors for flu. BMJ (Clinical research ed.), 2014, Feb-19, Volume: 348 Topics: England; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Zanamivir	2014
Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG : an international journal of obstetrics and gynaecology, 2014, Volume: 121, Issue:7 Topics: Adolescent; Adult; Antiviral Agents; Epidemiological Monitoring; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; United Kingdom; Young Adult; Zanamivir	2014
Study claiming Tamiflu saved lives was based on "flawed" analysis. BMJ (Clinical research ed.), 2014, Mar-18, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir. The European respiratory journal, 2014, Volume: 44, Issue:2 Topics: Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Pneumonia, Viral; Respiration Disorders; Time Factors; Treatment Outcome; Zanamivir	2014
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection. PloS one, 2014, Volume: 9, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Orthomyxoviridae; Pyrans; Sialic Acids; Vaccination; Young Adult; Zanamivir	2014
Cochrane review questions effectiveness of neuraminidase inhibitors. BMJ (Clinical research ed.), 2014, Apr-09, Volume: 348 Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Zanamivir	2014
Multisystem failure: the story of anti-influenza drugs. BMJ (Clinical research ed.), 2014, Apr-10, Volume: 348 Topics: Antiviral Agents; Drug and Narcotic Control; Evidence-Based Medicine; History, 20th Century; History, 21st Century; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Policy Making; Zanamivir	2014
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza and other respiratory viruses, 2014, Volume: 8, Issue:2 Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Asia; Cyclopentanes; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Pyrans; Sialic Acids; Viral Proteins; Zanamivir	2014
Tamiflu report comes under fire. Nature, 2014, Apr-24, Volume: 508, Issue:7497 Topics: Antiviral Agents; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Observational Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Strategic Stockpile; Zanamivir	2014
Editor in chief's reply to Nguyen-Van-Tam. BMJ (Clinical research ed.), 2014, Apr-29, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Principal author of PRIDE study responds to news story in The BMJ claiming that the study was based on "flawed" analysis. BMJ (Clinical research ed.), 2014, Apr-29, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Authors' reply to Mark Jones's second critique of the study by Muthuri and colleagues reported in The BMJ. BMJ (Clinical research ed.), 2014, Apr-30, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Authors' reply to Mark Jones's critique of the study by Muthuri and colleagues reported in The BMJ. BMJ (Clinical research ed.), 2014, Apr-30, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Mark Jones's reply to Myles and Leonardi-Bee's response to his critique of their paper reported in The BMJ. BMJ (Clinical research ed.), 2014, Apr-30, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Tug of war for antiviral drugs data. BMJ (Clinical research ed.), 2014, Apr-09, Volume: 348 Topics: Antiviral Agents; Clinical Trials as Topic; Dissent and Disputes; Drug Industry; Humans; Influenza, Human; Information Dissemination; Oseltamivir; Research Design; Zanamivir	2014
Neuraminidase inhibitors for influenza. BMJ (Clinical research ed.), 2014, Apr-09, Volume: 348 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Risk Assessment; Zanamivir	2014
Effectiveness of neuraminidase inhibitors for severe influenza. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:5 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Antiviral therapy, 2015, Volume: 20, Issue:1 Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pyrans; Severity of Illness Index; Sialic Acids; Time Factors; Treatment Outcome; Viral Proteins; Virus Shedding; Zanamivir	2015
Antivirals for influenza: where now for clinical practice and pandemic preparedness? Lancet (London, England), 2014, Aug-02, Volume: 384, Issue:9941 Topics: Antiviral Agents; Child; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Was the flu drug zanamivir a breakthrough or money for old rope? BMJ (Clinical research ed.), 2014, Jun-02, Volume: 348 Topics: Antiviral Agents; Drug Approval; Drugs, Investigational; Enzyme Inhibitors; Humans; Influenza, Human; United States; United States Food and Drug Administration; Zanamivir	2014
Anti-viral drugs in flu: not that good? Archives of disease in childhood, 2014, Volume: 99, Issue:8 Topics: Adult; Antiviral Agents; Child, Preschool; Humans; Influenza, Human; Oseltamivir; Treatment Outcome; Zanamivir	2014
Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults. BMC infectious diseases, 2014, Jun-10, Volume: 14 Topics: Adult; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pregnancy; Turkey; Zanamivir	2014
Primarily oseltamivir-resistant influenza A (H1N1pdm09) virus evolving into a multidrug-resistant virus carrying H275Y and I223R neuraminidase substitutions. Antiviral therapy, 2015, Volume: 20, Issue:1 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Mutation; Myelodysplastic Syndromes; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir	2015
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7 Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2014
Oseltamivir and zanamivir have limited effect on symptoms and do not reduce hospitalisation or serious complications of influenza. Evidence-based medicine, 2014, Volume: 19, Issue:6 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2014
Neuraminidase-producing oral mitis group streptococci potentially contribute to influenza viral infection and reduction in antiviral efficacy of zanamivir. Cellular and molecular life sciences : CMLS, 2015, Volume: 72, Issue:2 Topics: Analysis of Variance; Antiviral Agents; Blotting, Western; Fluorescent Antibody Technique, Indirect; Humans; Influenza, Human; Neuraminidase; Streptococcus mitis; Streptococcus oralis; Zanamivir	2015
Glycan based detection and drug susceptibility of influenza virus. Analytical chemistry, 2014, Aug-19, Volume: 86, Issue:16 Topics: Antiviral Agents; Biosensing Techniques; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Limit of Detection; Microarray Analysis; Microbial Sensitivity Tests; Oseltamivir; Polysaccharides; Zanamivir	2014
Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2014, Jul-10, Volume: 19, Issue:27 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Immunoenzyme Techniques; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pandemics; Phenotype; RNA, Viral; Seasons; Sequence Analysis, DNA; Spain; Viral Proteins; Zanamivir	2014
Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. Journal of medical virology, 2015, Volume: 87, Issue:1 Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Portugal; Viral Proteins; Zanamivir	2015
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral research, 2014, Volume: 110 Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2014
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Sao Paulo medical journal = Revista paulista de medicina, 2014, Volume: 132, Issue:4 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2014
Pregnancy outcomes of women exposed to laninamivir during pregnancy. Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:10 Topics: Adolescent; Adult; Antiviral Agents; Female; Guanidines; Humans; Infant, Newborn; Influenza, Human; Japan; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyrans; Retrospective Studies; Sialic Acids; Young Adult; Zanamivir	2014
Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico. International journal of data mining and bioinformatics, 2014, Volume: 9, Issue:3 Topics: Algorithms; Binding Sites; Computational Biology; Drug Design; Humans; Influenza, Human; Inhibitory Concentration 50; Least-Squares Analysis; Models, Molecular; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Quantitative Structure-Activity Relationship; Software; Technology, Pharmaceutical; Zanamivir	2014
Zanamivir for influenza in adults and children shows limited benefit for treatment of symptomatic influenza and no effect on relevant complications. Evidence-based medicine, 2015, Volume: 20, Issue:1 Topics: Antiviral Agents; Humans; Influenza, Human; Zanamivir	2015
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:12 Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fatal Outcome; Female; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A Virus, H3N2 Subtype; Influenza, Human; Leukemia, B-Cell; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Transplantation, Homologous; Viral Proteins; Zanamivir	2014
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir]. Bing du xue bao = Chinese journal of virology, 2014, Volume: 30, Issue:4 Topics: Antiviral Agents; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir	2014
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015, Volume: 21, Issue:1 Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Madin Darby Canine Kidney Cells; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir	2015
Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons. Intervirology, 2014, Volume: 57, Issue:6 Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pyrans; Sialic Acids; Zanamivir	2014
Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958. Angewandte Chemie (International ed. in English), 2014, Dec-08, Volume: 53, Issue:50 Topics: Antiviral Agents; Catalysis; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2014
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations. Annals of internal medicine, 2014, Oct-21, Volume: 161, Issue:8 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2014
Do we need a replacement medication for influenza with good efficacy? Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2014, Dec-16, Volume: 22 Topics: Antiviral Agents; Drug Combinations; Drug Synergism; Humans; Indoles; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Plant Extracts; Treatment Outcome; Zanamivir	2014
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. The European respiratory journal, 2015, Volume: 45, Issue:6 Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Beijing; Cohort Studies; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Protective Factors; Respiratory Insufficiency; Retrospective Studies; Risk Factors; Singapore; Superinfection; Young Adult; Zanamivir	2015
A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir. Journal of molecular recognition : JMR, 2015, Volume: 28, Issue:9 Topics: Animals; Antiviral Agents; Cell Line; Enzyme Inhibitors; Humans; Influenza, Human; Inhibitory Concentration 50; Insecta; Mutation; Neuraminidase; Oseltamivir; Surface Plasmon Resonance; Zanamivir	2015
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. The Journal of infectious diseases, 2015, Oct-15, Volume: 212, Issue:8 Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir	2015
E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. The Journal of infectious diseases, 2015, Dec-01, Volume: 212, Issue:11 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Nasal Cavity; Neuraminidase; Stem Cell Transplantation; Zanamivir	2015
Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 68 Topics: Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child; Child, Preschool; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Nasal Cavity; Oseltamivir; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Zanamivir	2015
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015, Volume: 21, Issue:9 Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Young Adult; Zanamivir	2015
Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study. The Journal of infectious diseases, 2016, Jan-15, Volume: 213, Issue:2 Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Infant; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir	2016
WHO Global Influenza Surveillance and Response System working group on surveillance of influenza antiviral susceptibility. Releve epidemiologique hebdomadaire, 2015, Aug-14, Volume: 90, Issue:33 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H10N7 Subtype; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Population Surveillance; Practice Guidelines as Topic; World Health Organization; Zanamivir	2015
[Susceptibility of human influenza A (H3N2) viruses to neuraminidase inhibitors isolated during 2011-2012 in China]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2015, Volume: 49, Issue:6 Topics: Antiviral Agents; China; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2015
Knowledge gaps about Tamiflu and Relenza for pandemic flu are blamed on research failure. BMJ (Clinical research ed.), 2015, Oct-08, Volume: 351 Topics: Antiviral Agents; Biomedical Research; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Zanamivir	2015
Influenza A H1N1 pdm09-associated myocarditis during zanamivir therapy. Pediatrics international : official journal of the Japan Pediatric Society, 2015, Volume: 57, Issue:6 Topics: Antiviral Agents; Child; DNA, Viral; Echocardiography; Electrocardiography; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Myocarditis; Zanamivir	2015
[Haut Conseil de la Santé Publique (HCSP). Guidance on the prioritization of antiviral drugs in case of seasonal influenza epidemics (March 3, 2015)]. Revue des maladies respiratoires, 2015, Volume: 32, Issue:8 Topics: Adult; Age Factors; Aged; Antiviral Agents; Child; Comorbidity; Disease Management; Disease Susceptibility; Drug Utilization; Epidemics; Female; France; Humans; Influenza Vaccines; Influenza, Human; Male; Meta-Analysis as Topic; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Seasons; Vulnerable Populations; Zanamivir	2015
Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. Influenza and other respiratory viruses, 2016, Volume: 10, Issue:2 Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Gene Deletion; Genetic Fitness; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae Infections; Pyrans; RNA, Viral; Sialic Acids; Virus Replication; Zanamivir	2016
Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2015, Volume: 20, Issue:45 Topics: Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Neuraminidase; Reverse Transcriptase Polymerase Chain Reaction; Viral Proteins; Zanamivir	2015
The accuracy and timeliness of neuraminidase inhibitor dispensing data for predicting laboratory-confirmed influenza. Epidemiology and infection, 2016, Volume: 144, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Utilization; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Quebec; Young Adult; Zanamivir	2016
Relenza-Induced Acute Myopia Change. Optometry and vision science : official publication of the American Academy of Optometry, 2016, Volume: 93, Issue:3 Topics: Acute Disease; Antiviral Agents; Female; Glucocorticoids; Histamine Antagonists; Humans; Influenza, Human; Middle Aged; Myopia; Refraction, Ocular; Zanamivir	2016
NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots. Antiviral research, 2016, Volume: 126 Topics: Antiviral Agents; Computer Graphics; Enzyme Assays; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Internet; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Zanamivir	2016
[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?]. MMW Fortschritte der Medizin, 2015, Oct-08, Volume: 157, Issue:17 Topics: Ambulatory Care; Antiviral Agents; Cause of Death; Evidence-Based Medicine; Germany; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Survival Analysis; Zanamivir	2015
Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2014. Communicable diseases intelligence quarterly report, 2015, Dec-31, Volume: 39, Issue:4 Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Epidemiological Monitoring; Hemagglutinins, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; International Cooperation; Oseltamivir; Phylogeny; Retrospective Studies; Zanamivir; Zygote	2015
Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School. The Tohoku journal of experimental medicine, 2016, Volume: 238, Issue:2 Topics: Antiviral Agents; Child; Demography; Female; Guanidines; Health; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Pyrans; RNA, Viral; Schools; Sialic Acids; Virus Shedding; Zanamivir	2016
ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation. Influenza and other respiratory viruses, 2016, Volume: 10, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; European Union; Expert Testimony; Health Policy; Humans; Influenza, Human; Meta-Analysis as Topic; Neuraminidase; Treatment Outcome; Zanamivir	2016
Clinical Pearls. Optometry and vision science : official publication of the American Academy of Optometry, 2016, Volume: 93, Issue:3 Topics: Acute Disease; Antiviral Agents; Humans; Influenza, Human; Myopia; Retina; Retinal Diseases; Tissue Adhesions; Vitreous Body; Vitreous Detachment; Zanamivir	2016
Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages. PloS one, 2016, Volume: 11, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Antibodies, Viral; Antiviral Agents; B-Lymphocytes; Cell Death; Epithelial Cells; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Models, Immunological; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Virulence; Zanamivir	2016
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season]. The Japanese journal of antibiotics, 2015, Volume: 68, Issue:6 Topics: Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; Medication Adherence; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir	2015
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors against clinical isolates of the influenza viruses circulating in the 2010-2011 to 2014-2015 Japanese influenza seasons. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2016, Volume: 22, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Product Surveillance, Postmarketing; Young Adult; Zanamivir	2016
ECDC public consultation on the use of neuraminidase inhibitors. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2016, Volume: 21, Issue:7 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2016
Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada. Influenza and other respiratory viruses, 2016, Volume: 10, Issue:6 Topics: Alberta; Antiviral Agents; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Nasopharynx; Neuraminidase; Oseltamivir; Seasons; Viral Load; Zanamivir	2016
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2016, Volume: 22, Issue:9 Topics: Administration, Inhalation; Antiviral Agents; Child; Female; Fever; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Kaplan-Meier Estimate; Male; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2016
Total Synthesis of Anti-Influenza Agents Zanamivir and Zanaphosphor via Asymmetric Aza-Henry Reaction. Organic letters, 2016, 09-02, Volume: 18, Issue:17 Topics: Antiviral Agents; Aza Compounds; Humans; Influenza, Human; Microbial Sensitivity Tests; Molecular Conformation; Orthomyxoviridae; Zanamivir	2016
Recommendations for Prevention and Control of Influenza in Children, 2016-2017. Pediatrics, 2016, Volume: 138, Issue:4 Topics: Antiviral Agents; Child; Drug Storage; Egg Hypersensitivity; Health Personnel; Hospitalization; Humans; Immunization Schedule; Infectious Disease Transmission, Patient-to-Professional; Infectious Disease Transmission, Professional-to-Patient; Influenza Vaccines; Influenza, Human; Oseltamivir; United States; Zanamivir	2016
Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies. Journal of medical virology, 2017, Volume: 89, Issue:4 Topics: Antiviral Agents; Codon; Drug Resistance, Viral; Genetic Variation; Genotyping Techniques; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Sensitivity and Specificity; Zanamivir	2017
Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017, Volume: 36, Issue:2 Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Greece; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir	2017
Fate of new three anti-influenza drugs and one prodrug in the water environment. Chemosphere, 2017, Volume: 169 Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Biodegradation, Environmental; Cyclopentanes; Environmental Monitoring; Fresh Water; Guanidines; Half-Life; Humans; Influenza, Human; Japan; Prodrugs; Pyrans; Pyrazines; Rivers; Seasons; Sewage; Sialic Acids; Water Pollutants, Chemical; Zanamivir	2017
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase. Journal of chemical theory and computation, 2016, Dec-13, Volume: 12, Issue:12 Topics: Antiviral Agents; Binding Sites; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrogen Bonding; Influenza A virus; Influenza, Human; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Neuraminidase; Oseltamivir; Protein Binding; Protein Structure, Quaternary; Static Electricity; Substrate Specificity; Thermodynamics; Zanamivir	2016
Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2017, Jan-19, Volume: 22, Issue:3 Topics: Antiviral Agents; Denmark; Drug Resistance, Viral; Genotype; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Zanamivir	2017
Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs. BMC bioinformatics, 2016, Dec-22, Volume: 17, Issue:Suppl 19 Topics: Antiviral Agents; Catalytic Domain; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Molecular Dynamics Simulation; Neuraminidase; Zanamivir	2016
Stockpile, use during outbreaks, restock, repeat. Canadian family physician Medecin de famille canadien, 2017, Volume: 63, Issue:2 Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Strategic Stockpile; Zanamivir	2017
In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein. Journal of biomolecular structure & dynamics, 2018, Volume: 36, Issue:4 Topics: Catalytic Domain; Computer Simulation; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Ligands; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir	2018
Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Aug-01, Volume: 47, Issue:3 Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Fever; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Retrospective Studies; Treatment Outcome; Zanamivir	2008
Editorial commentary: viral susceptibility and the choice of influenza antivirals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Aug-01, Volume: 47, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Practice Patterns, Physicians'; Zanamivir	2008
Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral research, 2008, Volume: 80, Issue:2 Topics: Animals; Antiviral Agents; Disease Models, Animal; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macaca; Male; Zanamivir	2008
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2008, Aug-08, Volume: 57, Issue:RR-7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Pregnancy; Seasons; United States; Zanamivir	2008
Statement on influenza vaccination for the 2008-2009 season. An Advisory Committee Statement (ACS). Canada communicable disease report = Releve des maladies transmissibles au Canada, 2008, Volume: 34, Issue:ACS-3 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Zanamivir	2008
Antivirals and influenza: frequency of resistance. The Pediatric infectious disease journal, 2008, Volume: 27, Issue:10 Suppl Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Zanamivir	2008
Insights into inflammation and influenza. The New England journal of medicine, 2008, Oct-09, Volume: 359, Issue:15 Topics: Animals; Antiviral Agents; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mesalamine; Mice; Orthomyxoviridae Infections; Pyrazoles; Sulfonamides; Zanamivir	2008
Antiinfluenza medication kits need work, FDA advisers conclude. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Dec-15, Volume: 65, Issue:24 Topics: Antiviral Agents; Disease Outbreaks; First Aid; Humans; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration; Zanamivir	2008
Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Amantadine; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Genetic Markers; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Rimantadine; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, RNA; Zanamivir	2009
Neuropsychiatric concerns related to influenza treatment. The Nurse practitioner, 2009, Volume: 34, Issue:2 Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mental Disorders; Nervous System Diseases; Oseltamivir; Zanamivir	2009
Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Apr-01, Volume: 48, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir	2009
Update: infections with a swine-origin influenza A (H1N1) virus--United States and other countries, April 28, 2009. MMWR. Morbidity and mortality weekly report, 2009, May-01, Volume: 58, Issue:16 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Middle Aged; Oseltamivir; Travel; United States; Zanamivir	2009
Swine flu outbreak. What role for antiviral drugs? Science (New York, N.Y.), 2009, May-08, Volume: 324, Issue:5928 Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir	2009
How severe will the flu outbreak be? Nature, 2009, May-07, Volume: 459, Issue:7243 Topics: Animals; Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Time Factors; Zanamivir	2009
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Antiviral research, 2009, Volume: 82, Issue:1 Topics: Animals; Cell Line; Dogs; Enzyme Inhibitors; Germany; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Zanamivir	2009
Zanamivir: new indication. Influenza: in children as in adults, symptom relief or vaccination. Prescrire international, 2008, Volume: 17, Issue:96 Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Europe; Humans; Influenza Vaccines; Influenza, Human; Zanamivir	2008
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral research, 2009, Volume: 83, Issue:1 Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Asia, Southeastern; Cluster Analysis; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; South Africa; Viral Proteins; Zanamivir	2009
Basic rules of influenza: how to combat the H1N1 influenza (swine flu) virus. American family physician, 2009, Jun-01, Volume: 79, Issue:11 Topics: Antiviral Agents; Disease Outbreaks; Health Planning; Humans; Infectious Disease Incubation Period; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; United States; Vaccination; Zanamivir	2009
Telephone triage of patients with influenza. American family physician, 2009, Jun-01, Volume: 79, Issue:11 Topics: Antiviral Agents; Clinical Protocols; Disease Outbreaks; Family Practice; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mass Screening; Nursing Care; Oseltamivir; Telephone; Triage; Zanamivir	2009
FDA notifications. EUA issued for treating novel 2009 H1N1 flu. AIDS alert, 2009, Volume: 24, Issue:6 Topics: Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration; Zanamivir	2009
Apropos "vaccines in a hurry". Vaccine, 2009, Aug-06, Volume: 27, Issue:36 Topics: Antiviral Agents; Disease Outbreaks; Drug Industry; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Microbial Sensitivity Tests; Oseltamivir; Zanamivir	2009
Swine influenza: nephrologist's perspective. Iranian journal of kidney diseases, 2009, Volume: 3, Issue:3 Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nephrology; Oseltamivir; Renal Insufficiency, Chronic; Zanamivir	2009
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. Journal of virology, 2009, Volume: 83, Issue:20 Topics: Animals; Antiviral Agents; Asia, Southeastern; Australasia; Cell Line; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2009
Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2009, Jul-23, Volume: 14, Issue:29 Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Reagent Kits, Diagnostic; Reverse Transcriptase Polymerase Chain Reaction; Schools; Sensitivity and Specificity; Treatment Outcome; Young Adult; Zanamivir	2009
Summary of the Australasian Society for Infectious Diseases and the Thoracic Society of Australia and New Zealand guidelines: treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents. The Medical journal of Australia, 2009, Aug-03, Volume: 191, Issue:3 Topics: Adult; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2009
Q&A: What have we found out about the influenza A (H1N1) 2009 pandemic virus? Journal of biology, 2009, Volume: 8, Issue:8 Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Immunity, Active; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Time Factors; Virulence; Zanamivir	2009
Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)? Cell research, 2009, Volume: 19, Issue:10 Topics: Antiviral Agents; Base Sequence; Binding Sites; Computer Simulation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Molecular Sequence Data; Oseltamivir; Zanamivir	2009
[Inquired of the President of the.Robert Koch Institute. How dangerous is Mexican influenza?]. MMW Fortschritte der Medizin, 2009, May-07, Volume: 151, Issue:19 Topics: Animals; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Orthomyxoviridae Infections; Oseltamivir; Swine; World Health Organization; Zanamivir	2009
[New influenza A (H1N1): advised indication and prescription of antiviral drugs]. Nederlands tijdschrift voor geneeskunde, 2009, Volume: 153 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Netherlands; Oseltamivir; Zanamivir	2009
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PloS one, 2009, Nov-06, Volume: 4, Issue:11 Topics: Animals; Antiviral Agents; Binding Sites; Caco-2 Cells; Cell Proliferation; Dogs; Humans; Influenza, Human; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Recombinant Fusion Proteins; Zanamivir	2009
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Dec-15, Volume: 49, Issue:12 Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Time Factors; Zanamivir	2009
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral research, 2010, Volume: 85, Issue:2 Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir	2010
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs, 2009, Volume: 69, Issue:18 Topics: Cross Infection; Drug Resistance, Viral; Global Health; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Population Surveillance; Rimantadine; Zanamivir	2009
H1N1 influenza in pregnancy: cause for concern. Obstetrics and gynecology, 2010, Volume: 115, Issue:1 Topics: Antiviral Agents; Compassionate Use Trials; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Zanamivir	2010
Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. The New England journal of medicine, 2010, Jan-07, Volume: 362, Issue:1 Topics: Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Investigational New Drug Application; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Zanamivir	2010
Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase. Biophysical chemistry, 2010, Volume: 147, Issue:1-2 Topics: Amino Acid Sequence; Binding Sites; Disaccharides; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Molecular Sequence Data; Neuraminidase; Oseltamivir; Plant Extracts; Sequence Alignment; Triterpenes; Zanamivir	2010
Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 47, Issue:3 Topics: Adolescent; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Time Factors; Treatment Outcome; United States; Zanamivir	2010
The truth about Tamiflu? Zanamivir should be inhaled, not nebulised. BMJ (Clinical research ed.), 2010, Jan-13, Volume: 340 Topics: Administration, Inhalation; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nebulizers and Vaporizers; Off-Label Use; Oseltamivir; Zanamivir	2010
Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1). Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2010, Volume: 16, Issue:1 Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir	2010
H1N1 influenza in pregnancy: risks, vaccines, and antivirals. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2009, Volume: 31, Issue:12 Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Zanamivir	2009
Fatal respiratory events caused by zanamivir nebulization. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Feb-15, Volume: 50, Issue:4 Topics: Adult; Equipment Failure; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nebulizers and Vaporizers; Oxygen; Pregnancy; Pregnancy Complications, Infectious; Ventilators, Mechanical; Zanamivir	2010
Influenza A/H1N1 (2009) infection in pregnancy--an Asian perspective. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Cohort Studies; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Prospective Studies; Singapore; Time Factors; Young Adult; Zanamivir	2010
A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virology journal, 2010, Mar-05, Volume: 7 Topics: Adolescent; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Child, Preschool; Dogs; Drug Resistance, Viral; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Epidemiology; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins; Virulence; Zanamivir	2010
Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerging infectious diseases, 2010, Volume: 16, Issue:3 Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Myanmar; Neuraminidase; Phylogeny; Sequence Analysis, DNA; Viral Matrix Proteins; Viral Proteins; Zanamivir	2010
A close-up view of flu. The Nurse practitioner, 2010, Volume: 35, Issue:4 Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Nurse Practitioners; Young Adult; Zanamivir	2010
[Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?]. MMW Fortschritte der Medizin, 2010, Jan-21, Volume: 152, Issue:3 Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Infant; Influenza A virus; Influenza, Human; Male; Meta-Analysis as Topic; Middle Aged; Neuraminidase; Oseltamivir; Pregnancy; Risk Factors; Seasons; Zanamivir	2010
Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:1 Topics: Antiviral Agents; Child; Cystic Fibrosis; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Oseltamivir; Pseudomonas aeruginosa; Pseudomonas Infections; Zanamivir	2010
Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, May-01, Volume: 50, Issue:9 Topics: Adult; Antiviral Agents; Critical Illness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intravenous; Male; Middle Aged; Pneumonia; Respiratory Distress Syndrome; Treatment Outcome; Zanamivir	2010
Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jun-01, Volume: 50, Issue:11 Topics: Antiviral Agents; Compassionate Use Trials; Critical Illness; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intravenous; Oseltamivir; Treatment Outcome; Viral Load; Zanamivir	2010
In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Molecular pharmaceutics, 2010, Jun-07, Volume: 7, Issue:3 Topics: Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Zanamivir	2010
Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. The Pediatric infectious disease journal, 2010, Volume: 29, Issue:10 Topics: Adolescent; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Fever; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Mutation, Missense; Nasopharynx; Neuraminidase; Oseltamivir; Treatment Outcome; Viral Proteins; Zanamivir	2010
[Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154 Topics: Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia; Zanamivir	2010
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerging infectious diseases, 2010, Volume: 16, Issue:6 Topics: Amantadine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Phylogeny; Seasons; Sequence Analysis, Protein; Time Factors; Viral Matrix Proteins; Zanamivir	2010
Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season. Journal of medical virology, 2010, Volume: 82, Issue:7 Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Child, Preschool; Dogs; Drug Resistance, Viral; Environmental Monitoring; Epidemiological Monitoring; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Male; Microbial Sensitivity Tests; Oseltamivir; Phylogeny; Seasons; Zanamivir	2010
Fatal respiratory events caused by zanamivir nebulization. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jul-01, Volume: 51, Issue:1 Topics: Administration, Inhalation; Adult; Antiviral Agents; Drug Compounding; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lactose; Nebulizers and Vaporizers; Pregnancy; Pregnancy Complications, Infectious; Product Labeling; Ventilators, Mechanical; Zanamivir	2010
Influenza A(H1N1) outbreak in a long-term care facility for severely handicapped residents, Slovenia, March-April 2009. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2010, May-27, Volume: 15, Issue:21 Topics: Adolescent; Adult; Antiviral Agents; Disabled Persons; Disease Outbreaks; Drug Resistance; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Residential Facilities; Severity of Illness Index; Slovenia; Young Adult; Zanamivir	2010
An unusual cause of fever in a neonate: influenza A (H1N1) virus pneumonia. Pediatric pulmonology, 2010, Volume: 45, Issue:7 Topics: Antiviral Agents; Fever; Gentamicins; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Zanamivir	2010
Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications. Transplantation, 2010, Jul-27, Volume: 90, Issue:2 Topics: Antiviral Agents; Child, Preschool; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Liver Transplantation; Respiratory Distress Syndrome; RNA, Viral; Treatment Outcome; Zanamivir	2010
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. Journal of virology, 2010, Volume: 84, Issue:19 Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir	2010
Neuraminidase inhibitors for influenza treatment and prevention in healthy adults. American family physician, 2010, Aug-01, Volume: 82, Issue:3 Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; Enzyme Inhibitors; Family; Female; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Primary Prevention; Zanamivir	2010
[Naturally occurring oseltamivir resistance in influenza A]. Ugeskrift for laeger, 2010, Aug-09, Volume: 172, Issue:32 Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Zanamivir	2010
Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008. Seton Hall law review, 2009, Volume: 39, Issue:4 Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; United States; Zanamivir	2009
[Influenza A H1N1v treated with extracorporeal membrane oxygenation]. Ugeskrift for laeger, 2010, Aug-23, Volume: 172, Issue:34 Topics: Adult; Antiviral Agents; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Zanamivir	2010
Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses. Antiviral research, 2010, Volume: 88, Issue:2 Topics: Adamantane; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Rimantadine; Seasons; Surveys and Questionnaires; Zanamivir	2010
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. Journal of virology, 2010, Volume: 84, Issue:21 Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Zanamivir	2010
Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus. Scandinavian journal of infectious diseases, 2011, Volume: 43, Issue:2 Topics: Acids, Carbocyclic; Administration, Inhalation; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Treatment Outcome; Virus Shedding; Zanamivir	2011
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. The New England journal of medicine, 2010, Sep-30, Volume: 363, Issue:14 Topics: Amino Acid Substitution; Antiviral Agents; Child, Preschool; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Fatal Outcome; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Viral Load; Zanamivir	2010
Feasibility of diagnosing influenza within 24 hours of symptom onset in children 1-3 years of age. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2011, Volume: 30, Issue:3 Topics: Antigens, Viral; Antiviral Agents; Child, Preschool; Early Diagnosis; Feasibility Studies; Fluoroimmunoassay; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Point-of-Care Systems; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Sensitivity and Specificity; Zanamivir	2011
Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir. Emerging infectious diseases, 2010, Volume: 16, Issue:11 Topics: Child, Preschool; Dosage Forms; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Nebulizers and Vaporizers; Oseltamivir; Pandemics; Zanamivir	2010
Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany. Antiviral research, 2011, Volume: 89, Issue:1 Topics: Adult; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Viral Proteins; Young Adult; Zanamivir	2011
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011, Volume: 50, Issue:2 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Virulence; Zanamivir	2011
Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection. American journal of respiratory and critical care medicine, 2010, Nov-15, Volume: 182, Issue:10 Topics: Acute Disease; Biological Products; Bronchoscopy; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Phospholipids; Pulmonary Surfactants; Respiratory Insufficiency; Zanamivir	2010
Peri-operative novel 2009 H1N1 influenza virus infection successfully treated with oseltamivir and zanamivir in a lung transplant recipient. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2011, Volume: 30, Issue:3 Topics: Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Transplantation; Oseltamivir; Perioperative Care; Treatment Outcome; Young Adult; Zanamivir	2011
Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antiviral Agents; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Seasons; Young Adult; Zanamivir	2011
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. The Journal of infectious diseases, 2011, Jan-01, Volume: 203, Issue:1 Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrrolidines; Recombination, Genetic; Viral Plaque Assay; Viral Proteins; Virus Replication; Zanamivir	2011
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Pyrrolidines; Sialic Acids; Viral Plaque Assay; Zanamivir	2010
Antivirals in treatment of H1N1 infection: are they really effective? European journal of pediatrics, 2011, Volume: 170, Issue:3 Topics: Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome; Zanamivir	2011
Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-01, Volume: 52, Issue:3 Topics: Adult; Antiviral Agents; Common Variable Immunodeficiency; Critical Illness; Female; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Pneumonia; Pregnancy; Salvage Therapy; Treatment Outcome; Zanamivir	2011
Antiviral treatment of influenza A (H1N1-09) guided by molecular resistance testing in aplasia after allo-SCT. Bone marrow transplantation, 2011, Volume: 46, Issue:11 Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Zanamivir	2011
Prone position ventilation, recruitment maneuver and intravenous zanamivir in severe refractory hypoxemia caused by influenza A (H1N1). Clinics (Sao Paulo, Brazil), 2010, Volume: 65, Issue:11 Topics: Antiviral Agents; Female; Humans; Hypoxia; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Prone Position; Respiration, Artificial; Zanamivir	2010
Resistance to neuraminidase inhibitors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4 Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Shedding; Zanamivir	2011
Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4 Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Influenza, Human; Male; Microbial Sensitivity Tests; Nasal Mucosa; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pharynx; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Virus Shedding; Zanamivir	2011
Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS. Bioanalysis, 2011, Volume: 3, Issue:2 Topics: Antiviral Agents; Chromatography, Liquid; Humans; Influenza, Human; Plasma; Reference Standards; Tandem Mass Spectrometry; Zanamivir	2011
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses]. The Japanese journal of antibiotics, 2010, Volume: 63, Issue:5 Topics: Administration, Intranasal; Animals; Antiviral Agents; Cells, Cultured; Delayed-Action Preparations; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Pandemics; Viral Load; Virus Replication; Zanamivir	2010
Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. Emerging infectious diseases, 2011, Volume: 17, Issue:2 Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pandemics; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Zanamivir	2011
Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scandinavian journal of infectious diseases, 2011, Volume: 43, Issue:6-7 Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Child; Critical Illness; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiration, Artificial; Time Factors; Treatment Failure; Virus Shedding; Zanamivir	2011
Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. American journal of obstetrics and gynecology, 2011, Volume: 204, Issue:6 Suppl 1 Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Case-Control Studies; Congenital Abnormalities; Female; Humans; Immunization; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; Risk Assessment; Societies, Medical; United States; Zanamivir	2011
Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A. Respiratory care, 2011, Volume: 56, Issue:7 Topics: Adolescent; Adult; Antiviral Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Oseltamivir; Respiratory Insufficiency; Retrospective Studies; Young Adult; Zanamivir	2011
Comparison of the efficacies of amantadine treatment of swine-origin influenza virus A H1N1 and seasonal influenza H1N1 and H3N2 in Japan (2008-2009). Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:4 Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Amino Acid Sequence; Analysis of Variance; Antiviral Agents; Body Temperature; Child; Child, Preschool; Disease Outbreaks; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Middle Aged; Molecular Sequence Data; Mutation; Oseltamivir; Seasons; Sequence Alignment; Treatment Outcome; Viral Matrix Proteins; Zanamivir	2011
Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PloS one, 2011, Feb-22, Volume: 6, Issue:2 Topics: Amino Acid Substitution; Antibodies, Viral; Antigenic Variation; Antiviral Agents; Drug Resistance, Viral; Hemagglutinins; Humans; Immune Evasion; Influenza A virus; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Zanamivir	2011
Real-time estimation and prediction for pandemic A/H1N1(2009) in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:4 Topics: Antiviral Agents; Databases, Factual; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Models, Statistical; Oseltamivir; Pandemics; Population Surveillance; Predictive Value of Tests; Zanamivir	2011
Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2011, Volume: 11, Issue:5 Topics: Antigens, Viral; Antiviral Agents; Computer Simulation; Genetic Drift; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Neuraminidase; Phylogeny; Zanamivir	2011
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors. Antiviral research, 2011, Volume: 91, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H2N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2011
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay. Journal of medical virology, 2011, Volume: 83, Issue:7 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Genetic Testing; Genotype; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Typing; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir	2011
Online monitoring of flu in Belgium. Influenza and other respiratory viruses, 2011, Volume: 5, Issue:5 Topics: Adolescent; Adult; Aged; Antiviral Agents; Belgium; Child; Child, Preschool; Disease Notification; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Online Systems; Oseltamivir; Pandemics; Population Surveillance; Young Adult; Zanamivir	2011
Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment. The Journal of international medical research, 2011, Volume: 39, Issue:2 Topics: Adolescent; Adult; Age Distribution; Antiviral Agents; Child; Child, Preschool; Family Characteristics; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Risk Factors; Time Factors; Young Adult; Zanamivir	2011
Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2011, Jun-09, Volume: 16, Issue:23 Topics: Antiviral Agents; Australia; Drug Resistance; Genetic Predisposition to Disease; Genetic Variation; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Population Surveillance; Risk Assessment; Risk Factors; Singapore; Zanamivir	2011
Severe H1N1-infection during pregnancy. Archives of gynecology and obstetrics, 2011, Volume: 284, Issue:5 Topics: Abortion, Spontaneous; Antiviral Agents; Extracorporeal Membrane Oxygenation; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Respiration, Artificial; Severity of Illness Index; Young Adult; Zanamivir	2011
Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance. JAMA, 2011, Jul-13, Volume: 306, Issue:2 Topics: Acids, Carbocyclic; Adult; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Inpatients; Middle Aged; Population Surveillance; Practice Patterns, Physicians'; United States; Zanamivir	2011
Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies. Vaccine, 2011, Jul-22, Volume: 29 Suppl 2 Topics: Adult; Age Distribution; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Population Surveillance; Seasons; Zanamivir	2011
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy. Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:10 Topics: Adult; Antiviral Agents; Cohort Studies; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Influenza, Human; Male; Maternal Age; Maternal-Fetal Exchange; Neuraminidase; Oseltamivir; Parity; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Risk Factors; Young Adult; Zanamivir	2011
[Etiotropic therapy of influenza: lessons from the last pandemic]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2011, Issue:5 Topics: Antiviral Agents; Communicable Diseases, Emerging; Drug Resistance, Viral; Early Diagnosis; Hemagglutination, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Pneumonia, Viral; Prognosis; Severity of Illness Index; Viral Interference; Viral Tropism; Zanamivir	2011
[Clinical features and contagiousness of influenza A(H1N1) in health care workers and hospitalized patients in a Mexico City hospital]. Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29, Issue:9 Topics: Adult; Aged; Antiviral Agents; Comorbidity; Contact Tracing; Cross Infection; Disease Outbreaks; Female; Hospital Mortality; Hospitals, Urban; Humans; Immunocompromised Host; Infectious Disease Transmission, Patient-to-Professional; Infectious Disease Transmission, Professional-to-Patient; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Male; Mexico; Middle Aged; Neoplasms; Occupational Diseases; Oseltamivir; Personnel, Hospital; Virulence; Zanamivir	2011
Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerging infectious diseases, 2011, Volume: 17, Issue:8 Topics: Adolescent; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Female; Humans; Immunocompetence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Zanamivir	2011
Influenza-associated monophasic neuromyelitis optica. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:15 Topics: Adolescent; Anti-Inflammatory Agents; Antiviral Agents; Aquaporin 4; Autoantibodies; Female; Humans; Influenza A virus; Influenza, Human; Magnetic Resonance Imaging; Methylprednisolone; Neuromyelitis Optica; Prednisolone; Zanamivir	2011
Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus. Singapore medical journal, 2011, Volume: 52, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Singapore; Survival Analysis; Zanamivir	2011
Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. The Journal of infectious diseases, 2011, Sep-01, Volume: 204, Issue:5 Topics: Adolescent; Adult; Child, Preschool; Critical Illness; Drug Therapy, Combination; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Middle Aged; Netherlands; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Zanamivir	2011
Novel antiviral activity of neuraminidase inhibitors against an avian influenza a virus. Virology journal, 2011, Aug-19, Volume: 8 Topics: Animals; Antiviral Agents; Cell Line; Chickens; Dogs; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Microscopy, Electron, Scanning; Neuraminidase; Oseltamivir; Virion; Virus Assembly; Zanamivir	2011
Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. The Journal of infectious diseases, 2011, Dec-15, Volume: 204, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Odds Ratio; Oseltamivir; Pandemics; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Infectious; Rimantadine; United States; Young Adult; Zanamivir	2011
Alopecia areata triggered or exacerbated by swine flu virus infection. The Journal of dermatology, 2012, Volume: 39, Issue:10 Topics: Adjuvants, Immunologic; Adolescent; Adult; Alopecia Areata; Antiviral Agents; Child; Child, Preschool; Cyclobutanes; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Zanamivir	2012
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. The International journal of risk & safety in medicine, 2011, Volume: 23, Issue:4 Topics: Adolescent; Adult; Age Distribution; Aged; Antiviral Agents; Child; Child, Preschool; Death, Sudden; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Middle Aged; Oseltamivir; Young Adult; Zanamivir	2011
Drugs: Lines of defence. Nature, 2011, Dec-07, Volume: 480, Issue:7376 Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2011
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3 Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir	2012
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2013, Volume: 19, Issue:2 Topics: Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Severity of Illness Index; Treatment Outcome; Viral Load; Young Adult; Zanamivir	2013
Acute encephalopathy in childhood associated with novel influenza a h1n1 virus infection: clinical and neuroimaging findings. The Ulster medical journal, 2011, Volume: 80, Issue:1 Topics: Antiviral Agents; Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukoencephalitis, Acute Hemorrhagic; Neuroimaging; Zanamivir	2011
Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008. Revista panamericana de salud publica = Pan American journal of public health, 2011, Volume: 30, Issue:6 Topics: Amantadine; Animals; Antiviral Agents; Argentina; Cell Line; Dogs; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Morbidity; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Population Surveillance; Seasons; Virus Cultivation; Zanamivir	2011
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:4 Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Zanamivir	2012
[Clinical trials and intensive therapy of the swine flu (H1N1)]. Georgian medical news, 2012, Issue:202 Topics: Administration, Inhalation; Adult; Aged; Bilirubin; Disease Outbreaks; Female; Georgia (Republic); Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Zanamivir	2012
Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza and other respiratory viruses, 2013, Volume: 7, Issue:1 Topics: Administration, Inhalation; Antiviral Agents; Epidemics; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2013
The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods in molecular biology (Clifton, N.J.), 2012, Volume: 865 Topics: Antiviral Agents; Biological Assay; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Luminescence; Luminescent Measurements; Neuraminidase; Oseltamivir; Sequence Analysis, RNA; Software; Viral Proteins; Zanamivir	2012
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods in molecular biology (Clifton, N.J.), 2012, Volume: 865 Topics: Antiviral Agents; Biological Assay; Drug Resistance, Viral; Enzyme Inhibitors; Fluorescence; Humans; Influenza, Human; Kinetics; Neuraminidase; Orthomyxoviridae; Oseltamivir; Sequence Analysis, RNA; Software; Spectrometry, Fluorescence; Viral Proteins; Zanamivir	2012
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient. Journal of clinical microbiology, 2012, Volume: 50, Issue:7 Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza B virus; Influenza, Human; Male; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; RNA, Viral; Sequence Analysis, DNA; Zanamivir	2012
Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus. Biochemistry, 2012, May-29, Volume: 51, Issue:21 Topics: Amino Acid Substitution; Antiviral Agents; Computer Graphics; Computer Simulation; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; History, 21st Century; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Pandemics; Point Mutation; Protein Conformation; Protein Structure, Secondary; Static Electricity; Zanamivir	2012
Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection. The Pediatric infectious disease journal, 2012, Volume: 31, Issue:11 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Health Personnel; Humans; Infant; Influenza, Human; Inpatients; Orthomyxoviridae; Oseltamivir; Young Adult; Zanamivir	2012
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and other respiratory viruses, 2012, Volume: 6, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; United States; Young Adult; Zanamivir	2012
Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B. Influenza and other respiratory viruses, 2013, Volume: 7, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Neuraminidase; Oseltamivir; Seasons; Severity of Illness Index; Treatment Outcome; Young Adult; Zanamivir	2013
An uncontrolled open-label, multicenter study to monitor the antiviral activity and safety of inhaled zanamivir (as Rotadisk via Diskhaler device) among Chinese adolescents and adults with influenza-like illness. Chinese medical journal, 2012, Volume: 125, Issue:17 Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Treatment Outcome; Zanamivir	2012
A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase. Chembiochem : a European journal of chemical biology, 2012, Oct-15, Volume: 13, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antiviral Agents; Click Chemistry; Fructose-Bisphosphate Aldolase; Humans; Immunoconjugates; Influenza A virus; Influenza, Human; Mice; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Zanamivir	2012
Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. The Journal of infectious diseases, 2012, Nov-15, Volume: 206, Issue:10 Topics: Adolescent; Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Zanamivir	2012
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study. PloS one, 2012, Volume: 7, Issue:9 Topics: Antiviral Agents; Enzyme Inhibitors; Geography; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Poisson Distribution; Regression Analysis; Socioeconomic Factors; World Health Organization; Zanamivir	2012
Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function. Transplant infectious disease : an official journal of the Transplantation Society, 2012, Volume: 14, Issue:6 Topics: Adolescent; Antineoplastic Agents; Antiviral Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Pandemics; Zanamivir	2012
Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:12 Topics: Administration, Intranasal; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; N-Acetylneuraminic Acid; Virus Replication; Zanamivir	2012
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS pathogens, 2012, Volume: 8, Issue:9 Topics: Adamantane; Amino Acid Substitution; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Protein Conformation; Zanamivir	2012
[Neuraminidase inhibitors: effects still unclear]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:41 Topics: Administration, Inhalation; Antiviral Agents; Bias; Conflict of Interest; Double-Blind Method; Drug Industry; Humans; Influenza, Human; Length of Stay; Neuraminidase; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; Research Design; Zanamivir	2012
The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters. Nature medicine, 2012, Volume: 18, Issue:10 Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir	2012
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:2 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Child; Female; Fever; Guanidines; Humans; Influenza, Human; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neuraminidase; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2013
Reply to Chan-Tack et al. The Journal of infectious diseases, 2013, Jan-01, Volume: 207, Issue:1 Topics: Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Zanamivir	2013
Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States. The Journal of infectious diseases, 2013, Jan-01, Volume: 207, Issue:1 Topics: Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Zanamivir	2013
Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. Environmental science & technology, 2012, Dec-04, Volume: 46, Issue:23 Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Rivers; Sewage; Water Pollutants, Chemical; Zanamivir	2012
Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, Dec-11, Volume: 109, Issue:50 Topics: Animals; Antiviral Agents; Dogs; Drug Synergism; Endocytosis; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Microscopy, Electron, Transmission; Neuraminidase; Orthomyxoviridae Infections; Peptides; Zanamivir	2012
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral research, 2013, Volume: 97, Issue:3 Topics: Antiviral Agents; China; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Zanamivir	2013
Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:4 Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neuraminidase; Viral Proteins; Virus Replication; Zanamivir	2013
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Scandinavian journal of infectious diseases, 2013, Volume: 45, Issue:6 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiviral Agents; Child; Delirium; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Pyrans; Sialic Acids; Syncope; Zanamivir	2013
Development of a novel influenza A antiviral assay. Journal of virological methods, 2002, Volume: 105, Issue:1 Topics: Animals; Antiviral Agents; Branched DNA Signal Amplification Assay; Cell Line; Dogs; Guanidines; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Nucleocapsid Proteins; Nucleoproteins; Oligonucleotide Probes; Pyrans; Rimantadine; RNA, Viral; Sialic Acids; Viral Core Proteins; Virus Replication; Zanamivir	2002
Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Annals of internal medicine, 2002, Aug-20, Volume: 137, Issue:4 Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Drug Costs; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Sensitivity and Specificity; Sialic Acids; Vaccination; Zanamivir	2002
Summaries for patients. Influenza vaccination or antiviral treatment for healthy working adults: an economic analysis. Annals of internal medicine, 2002, Aug-20, Volume: 137, Issue:4 Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Vaccination; Zanamivir	2002
Current strategies for management of influenza in the elderly population. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-15, Volume: 35, Issue:6 Topics: Acetamides; Aged; Aged, 80 and over; Chemoprevention; Complementary Therapies; Cost-Benefit Analysis; Disease Management; Guanidines; Health Services for the Aged; Humans; Influenza, Human; Institutionalization; Oseltamivir; Patient Compliance; Population Surveillance; Prevalence; Pyrans; Rimantadine; Sialic Acids; Vaccination; Zanamivir	2002
Influenza prevention 2002-2003. The Medical letter on drugs and therapeutics, 2002, Sep-02, Volume: 44, Issue:1138 Topics: Acetamides; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanidines; Headache; Humans; Infant; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Pyrans; Sialic Acids; Zanamivir	2002
Zanamivir in the prevention of influenza among healthy adults. The Journal of family practice, 1999, Volume: 48, Issue:10 Topics: Administration, Inhalation; Adult; Aged; Antiviral Agents; Evidence-Based Medicine; Guanidines; Humans; Influenza, Human; Middle Aged; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	1999
Zanamivir is an effective treatment for influenza in children undergoing therapy for acute lymphoblastic leukemia. Scandinavian journal of infectious diseases, 2002, Volume: 34, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Guanidines; Humans; Influenza, Human; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrans; Risk Assessment; Sialic Acids; Treatment Outcome; Zanamivir	2002
Cost-effectiveness of newer treatment strategies for influenza. The American journal of medicine, 2002, Volume: 113, Issue:4 Topics: Acetamides; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Diagnostic Tests, Routine; Drug Costs; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Monte Carlo Method; Neuraminidase; Oseltamivir; Pennsylvania; Pyrans; Quality-Adjusted Life Years; Sialic Acids; Zanamivir	2002
[Neuraminidase inhibitor permitted. The first pill against influenza]. MMW Fortschritte der Medizin, 2002, Oct-10, Volume: 144, Issue:41 Topics: Acetamides; Administration, Inhalation; Administration, Oral; Aged; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir	2002
Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clinical therapeutics, 2002, Volume: 24, Issue:11 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antiviral Agents; Bronchial Diseases; Child; Cohort Studies; Constriction, Pathologic; Emergency Service, Hospital; Female; Guanidines; Hospitalization; Humans; Influenza, Human; Insurance Claim Reporting; Male; Middle Aged; Pyrans; Retrospective Studies; Risk; Seasons; Sialic Acids; Zanamivir	2002
The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clinical therapeutics, 2002, Volume: 24, Issue:11 Topics: Adolescent; Adult; Aged; Antiviral Agents; Cardiovascular Diseases; Child; Child, Preschool; Cohort Studies; Female; Guanidines; Humans; Influenza, Human; Insurance Claim Reporting; Male; Middle Aged; Otitis Media; Pyrans; Respiratory Tract Diseases; Retrospective Studies; Risk; Seasons; Sialic Acids; Zanamivir	2002
[New diagnostic possibilities and medications. Fit for influenza?]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Acetamides; Administration, Inhalation; Administration, Oral; Aged; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir	2002
Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis. PharmacoEconomics, 2003, Volume: 21, Issue:3 Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Economics, Pharmaceutical; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Pyrans; Sialic Acids; Zanamivir	2003
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care. Journal of the Royal Society of Medicine, 2003, Volume: 96, Issue:2 Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Family Practice; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Patient Acceptance of Health Care; Pyrans; Sialic Acids; State Medicine; United Kingdom; Zanamivir	2003
[Patient assessment for zanamivir therapy (second report) -- a survey of patients with influenza who were prescribed zanamivir during the 2001/2002 season in Japan]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 2002, Volume: 76, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Infant; Influenza, Human; Male; Middle Aged; Patient Satisfaction; Pyrans; Sialic Acids; Zanamivir	2002
[Oral neuraminidase inhibitor and an early warning system. New weapons against influenza]. MMW Fortschritte der Medizin, 2003, Jan-23, Volume: 145, Issue:3-4 Topics: Acetamides; Adult; Aged; Antiviral Agents; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sentinel Surveillance; Sialic Acids; Zanamivir	2003
Compared protective effect of nasal immunoprophylaxis using a new human monoclonal IgM antibody, human polyclonal antibodies, F(ab')2, amantadine, and zanamivir for prophylaxis of influenza A virus pneumonia in mice. Military medicine, 2003, Volume: 168, Issue:3 Topics: Amantadine; Animals; Antibodies, Monoclonal; Antiviral Agents; Female; Guanidines; Humans; Immunization, Passive; Immunoglobulin Fab Fragments; Immunoglobulin M; Immunoglobulins, Intravenous; Influenza A virus; Influenza, Human; Mice; Mice, Inbred BALB C; Pneumonia, Viral; Pyrans; Sialic Acids; Zanamivir	2003
We need to determine who benefits most from flu treatments. BMJ (Clinical research ed.), 2003, Jun-07, Volume: 326, Issue:7401 Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2003
New application method of zanamivir with a straw. Pediatrics international : official journal of the Japan Pediatric Society, 2003, Volume: 45, Issue:3 Topics: Administration, Oral; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2003
Clinical features of influenza a virus infection in older hospitalized persons. Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:8 Topics: Aged; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza, Human; Inpatients; Pyrans; Sensitivity and Specificity; Sialic Acids; Zanamivir	2003
Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Annals of internal medicine, 2003, Sep-02, Volume: 139, Issue:5 Pt 1 Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Quality-Adjusted Life Years; Rimantadine; Sensitivity and Specificity; Sialic Acids; Zanamivir	2003
Summaries for patients. Cost-effective management of flu in adults older than 65 years of age. Annals of internal medicine, 2003, Sep-02, Volume: 139, Issue:5 Pt 1 Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Quality-Adjusted Life Years; Rimantadine; Sensitivity and Specificity; Sialic Acids; Zanamivir	2003
Neuraminidase inhibitors slightly beneficial for shortening flu symptoms. The Journal of family practice, 2003, Volume: 52, Issue:10 Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir	2003
[English meta-analysis on zanamivir and oseltamivir. Knowledge of effects of influenza agents still not sufficient]. Lakartidningen, 2003, Dec-11, Volume: 100, Issue:50 Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; Practice Guidelines as Topic; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2003
[Treatment of influenza in children]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2003, Volume: 41, Issue:2 Topics: Adamantane; Amantadine; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2003
Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. The Journal of antimicrobial chemotherapy, 2004, Volume: 53, Issue:5 Topics: Animals; Antiviral Agents; Cell Line; Chickens; Cloning, Molecular; Disease Progression; Enzyme Inhibitors; Guanidines; Hemagglutination Tests; Humans; Influenza A virus; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Plasmids; Pyrans; Reverse Transcriptase Polymerase Chain Reaction; Sialic Acids; Species Specificity; Turkeys; United Kingdom; Viral Plaque Assay; Zanamivir	2004
Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor. Virology, 2004, May-01, Volume: 322, Issue:2 Topics: Albuterol; Animals; Anti-Inflammatory Agents; Antiviral Agents; Bronchodilator Agents; Disease Models, Animal; Female; Glucocorticoids; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Neuraminidase; Pyrans; Respiration Disorders; Sialic Acids; Sigmodontinae; Triamcinolone Acetonide; Zanamivir	2004
A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses. Virus research, 2004, Volume: 103, Issue:1-2 Topics: Acetamides; Antiviral Agents; Fluorescence; Guanidines; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Virology; Zanamivir	2004
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus research, 2004, Volume: 103, Issue:1-2 Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Population Surveillance; Pyrans; Sialic Acids; Zanamivir	2004
Influenza outbreaks in aged-care facilities: staff vaccination and the emerging use of antiviral therapy. The Medical journal of Australia, 2004, Jun-21, Volume: 180, Issue:12 Topics: Acetamides; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Disease Outbreaks; Female; Guanidines; Homes for the Aged; Humans; Infection Control; Infectious Disease Transmission, Patient-to-Professional; Influenza A virus; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Vaccination; Victoria; Zanamivir	2004
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 31, Issue:2 Topics: Acetamides; Amantadine; Antiviral Agents; Drug Resistance, Viral; Germany; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Primary Health Care; Pyrans; Sialic Acids; Zanamivir	2004
Avian influenza should be ruffling our feathers. The Lancet. Infectious diseases, 2004, Volume: 4, Issue:10 Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Asia, Eastern; Asia, Southeastern; Birds; Disease Outbreaks; Guanidines; Humans; Influenza in Birds; Influenza Vaccines; Influenza, Human; International Cooperation; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; World Health Organization; Zanamivir	2004
Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Communicable diseases intelligence quarterly report, 2003, Volume: 27, Issue:4 Topics: Acetamides; Antiviral Agents; Australia; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Population Surveillance; Pyrans; Sialic Acids; Zanamivir	2003
Prevention of influenza in the general population: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Nov-09, Volume: 171, Issue:10 Topics: Acetamides; Aged; Canada; Guanidines; Health Policy; Humans; Infant; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Preventive Medicine; Public Health; Pyrans; Risk Factors; Sialic Acids; Zanamivir	2004
Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. The European journal of health economics : HEPAC : health economics in prevention and care, 2005, Volume: 6, Issue:3 Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Zanamivir	2005
Avian flu special: what's in the medicine cabinet? Nature, 2005, May-26, Volume: 435, Issue:7041 Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Humans; Influenza, Human; Internationality; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; World Health Organization; Zanamivir	2005
Zanamivir: an influenza virus neuraminidase inhibitor. Expert review of anti-infective therapy, 2005, Volume: 3, Issue:2 Topics: Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Pyrans; Sialic Acids; Zanamivir	2005
Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral research, 2005, Volume: 68, Issue:1 Topics: Acetamides; Enzyme Inhibitors; France; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2005
Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. Journal of virology, 2005, Volume: 79, Issue:18 Topics: Animals; Cell Line; Dogs; Endocytosis; Enzyme Inhibitors; Enzyme Stability; Guanidines; Humans; Hydrogen-Ion Concentration; Influenza A virus; Influenza, Human; Male; Mice; Mice, Inbred C57BL; Neuraminidase; Pyrans; Sialic Acids; Transfection; Virus Replication; Zanamivir	2005
Avian flu: isolation of drug-resistant H5N1 virus. Nature, 2005, Oct-20, Volume: 437, Issue:7062 Topics: Acetamides; Adolescent; Adult; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Mutation; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Pyrans; Sialic Acids; Zanamivir	2005
Use of antiviral agents and other measures in an influenza pandemic. The Netherlands journal of medicine, 2005, Volume: 63, Issue:9 Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza A virus; Influenza, Human; Netherlands; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Pyrans; Risk; Sialic Acids; Zanamivir	2005
[Influenza prevention in your practice (interview by Waldtraud Paukstadt)]. MMW Fortschritte der Medizin, 2005, Nov-17, Volume: 147, Issue:46 Topics: Acetamides; Adult; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir	2005
Star role for bacteria in controlling flu pandemic? Nature reviews. Drug discovery, 2005, Volume: 4, Issue:12 Topics: Acetamides; Animals; Antiviral Agents; Birds; Chemistry, Pharmaceutical; Disease Outbreaks; Drugs, Generic; Escherichia coli; Genetic Engineering; Global Health; Guanidines; Humans; Illicium; Influenza in Birds; Influenza, Human; Oseltamivir; Pyrans; Shikimic Acid; Sialic Acids; Technology, Pharmaceutical; Zanamivir	2005
Oseltamivir resistance--disabling our influenza defenses. The New England journal of medicine, 2005, Dec-22, Volume: 353, Issue:25 Topics: Acetamides; Binding Sites; Child; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pyrans; Self Administration; Sialic Acids; Zanamivir	2005
Review says oseltamivir and zanamivir should be kept for epidemics of flu. BMJ (Clinical research ed.), 2006, Jan-28, Volume: 332, Issue:7535 Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2006
[Nosocomial outbreak of influenza in high-risk hematological patients. Efficacy of control measures and the use of zanamivir]. Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:1 Topics: Antiviral Agents; Cross Infection; Guanidines; Hematologic Neoplasms; Humans; Immunocompromised Host; Infection Control; Influenza A virus; Influenza, Human; Pyrans; Risk Factors; Sialic Acids; Zanamivir	2006
Oseltamivir resistance in influenza A (H5N1) infection. The New England journal of medicine, 2006, Mar-30, Volume: 354, Issue:13 Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2006
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:5 Topics: Acetamides; Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Baculoviridae; Base Sequence; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Pyrans; Recombinant Proteins; Sialic Acids; Zanamivir	2006
Non-voluntary licensing of antivirals under patent: options the Australian Government should consider in light of a potential bird flu pandemic. Journal of law and medicine, 2006, Volume: 13, Issue:4 Topics: Acetamides; Animals; Antiviral Agents; Australia; Birds; Drugs, Generic; Guanidines; Health Services Needs and Demand; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Legislation, Drug; Oseltamivir; Patents as Topic; Public Health; Pyrans; Sialic Acids; Zanamivir	2006
Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:12 Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Kidney Failure, Chronic; Oseltamivir; Zanamivir	2006
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:7 Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Orthomyxoviridae; Population Surveillance; Pyrans; Sialic Acids; World Health Organization; Zanamivir	2006
Kinetics of influenza A virus infection in humans. Journal of virology, 2006, Volume: 80, Issue:15 Topics: Administration, Intranasal; Adult; Antiviral Agents; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Kinetics; Models, Theoretical; Nose; Pyrans; Sialic Acids; Zanamivir	2006
Symptomatic predictors of influenza virus positivity in children during the influenza season. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Sep-01, Volume: 43, Issue:5 Topics: Acetamides; Aging; Antiviral Agents; Child; Child, Preschool; Cough; Fever; Guanidines; Headache; Humans; Infant; Influenza, Human; Logistic Models; Muscular Diseases; Odds Ratio; Oseltamivir; Pyrans; Risk Factors; Seasons; Sialic Acids; Zanamivir	2006
Possible case scenarios and logistic issues in H5N1 pandemic. Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:5 Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Severe Acute Respiratory Syndrome; Zanamivir	2006
Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral research, 2007, Volume: 73, Issue:2 Topics: Adamantane; Antiviral Agents; Australia; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Rimantadine; Zanamivir	2007
[Avian influenza pandemic prevention - current research]. Revue medicale suisse, 2006, Aug-23, Volume: 2, Issue:76 Topics: Acetamides; Animals; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Models, Animal; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2006
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral research, 2007, Volume: 73, Issue:3 Topics: Acids, Carbocyclic; Amantadine; Animals; Antiviral Agents; Base Sequence; Birds; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2007
Antiviral management of seasonal and pandemic influenza. The Journal of infectious diseases, 2006, Nov-01, Volume: 194 Suppl 2 Topics: Amantadine; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Rimantadine; Seasons; Zanamivir	2006
Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. The Journal of infectious diseases, 2006, Nov-01, Volume: 194 Suppl 2 Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Clinical Trials as Topic; Disease Outbreaks; Enzyme Inhibitors; Female; Homes for the Aged; Humans; Immunocompromised Host; Infant; Influenza Vaccines; Influenza, Human; Leukemia; Middle Aged; Nursing Homes; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Rats; Risk; United States; Vaccination; Zanamivir	2006
[Significance of virological diagnostics for the effective treatment of hospitalized patients infected with influenza virus]. Pneumonologia i alergologia polska, 2006, Volume: 74, Issue:2 Topics: Adult; Amantadine; Antiviral Agents; Diagnosis, Differential; Fluorescent Antibody Technique; Hospitalization; Humans; Influenza A virus; Influenza, Human; Middle Aged; Oseltamivir; Respiratory Tract Diseases; Reverse Transcriptase Polymerase Chain Reaction; Rimantadine; Treatment Outcome; Zanamivir	2006
Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best. Prescrire international, 2007, Volume: 16, Issue:87 Topics: Amantadine; Antiviral Agents; Child; Drug Approval; Drug Resistance; Europe; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Vaccination; Zanamivir	2007
[Zanamivir for prevention of influenza and in children]. Medizinische Monatsschrift fur Pharmazeuten, 2007, Volume: 30, Issue:3 Topics: Adult; Animals; Antiviral Agents; Child; Disease Outbreaks; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Zanamivir	2007
Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Releve epidemiologique hebdomadaire, 2007, Apr-27, Volume: 82, Issue:17 Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir	2007
John F. Enders lecture 2006: antivirals for influenza. The Journal of infectious diseases, 2007, Jul-15, Volume: 196, Issue:2 Topics: Antiviral Agents; Drug Design; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir	2007
Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antiviral therapy, 2007, Volume: 12, Issue:4 Topics: Antiviral Agents; Bone Marrow Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Pneumonia, Viral; Recurrence; Treatment Failure; Zanamivir	2007
General practitioners' management of influenza with or without neuraminidase inhibitors. The European journal of general practice, 2007, Volume: 13, Issue:3 Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Enzyme Inhibitors; Female; France; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Physicians, Family; Practice Patterns, Physicians'; Prospective Studies; Time Factors; Zanamivir	2007
Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2008, Volume: 41, Issue:1 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Proteins; Zanamivir	2008
Influenza. Canadian family physician Medecin de famille canadien, 2008, Volume: 54, Issue:3 Topics: Amantadine; Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mass Vaccination; Oseltamivir; Rimantadine; Zanamivir	2008
[Influenza in children: what should be considered in prevention and treatment?]. Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege, 2008, Volume: 27, Issue:2 Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Female; Germany; Humans; Infant; Infectious Disease Transmission, Professional-to-Patient; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Seasons; Zanamivir	2008
Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses. PLoS pathogens, 2008, Apr-11, Volume: 4, Issue:4 Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Receptors, Virus; Recombination, Genetic; Respiratory Mucosa; Species Specificity; Viral Proteins; Virus Replication; Zanamivir	2008
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral research, 2008, Volume: 79, Issue:3 Topics: Animals; Antiviral Agents; Cell Line; Chick Embryo; Drug Evaluation, Preclinical; Enzyme Inhibitors; Genes, Reporter; Genetic Engineering; Hemagglutinins, Viral; Humans; Influenza, Human; Leukemia Virus, Murine; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Shedding; Zanamivir	2008
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature, 2008, Jun-26, Volume: 453, Issue:7199 Topics: Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kinetics; Models, Molecular; Molecular Conformation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir	2008
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:7 Topics: Animals; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Neuraminidase; Pyrans; Sialic Acids; Thymidine; Tritium; Viral Plaque Assay; Virus Replication; Zanamivir	1993
Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, Jun-03, Volume: 363, Issue:6428 Topics: Animals; Antiviral Agents; Cell Line; Computer-Aided Design; Disease Models, Animal; Drug Design; Female; Ferrets; Guanidines; Humans; Influenza A virus; Influenza, Human; Mice; Models, Molecular; Neuraminidase; Pyrans; Sheep; Sialic Acids; Viral Plaque Assay; Virus Replication; Zanamivir	1993
Getting ready for the next influenza pandemic. Lancet (London, England), 1996, May-04, Volume: 347, Issue:9010 Topics: Animals; Antigens, Viral; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Pyrans; Sialic Acids; Zanamivir	1996
A new antiviral agent for influenza--is there a clinical niche? The New England journal of medicine, 1997, Sep-25, Volume: 337, Issue:13 Topics: Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Pyrans; Rimantadine; Sialic Acids; Zanamivir	1997
Zanamivir for influenza virus infections. The Journal of family practice, 1998, Volume: 46, Issue:1 Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Guanidines; Humans; Influenza, Human; Male; Multicenter Studies as Topic; Pyrans; Randomized Controlled Trials as Topic; Reproducibility of Results; Sialic Acids; Treatment Outcome; Zanamivir	1998
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral research, 1998, Volume: 37, Issue:2 Topics: Acetamides; Administration, Intranasal; Administration, Oral; Amines; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung Diseases; Mice; Mice, Inbred BALB C; Molecular Structure; Neuraminidase; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Zanamivir	1998
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. The Journal of infectious diseases, 1998, Volume: 178, Issue:5 Topics: Amino Acid Substitution; Animals; Antiviral Agents; Bone Marrow Transplantation; Cell Line; Chlorocebus aethiops; Dogs; Drug Resistance, Microbial; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Ferrets; Guanidines; Hemagglutination Inhibition Tests; Humans; Immunosuppression Therapy; Infant; Influenza B virus; Influenza, Human; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Receptors, Virus; RNA, Viral; Sialic Acids; Vero Cells; Zanamivir	1998
New ways to tackle influenza highlighted at ICAAC. Interscience Conference on Antimicrobial Agents and Chemotherapy. Lancet (London, England), 1998, Oct-03, Volume: 352, Issue:9134 Topics: Adolescent; Amines; Child; Child, Preschool; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1998
Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. The Journal of infectious diseases, 1998, Volume: 178, Issue:6 Topics: Animals; Antiviral Agents; Chick Embryo; Female; Guanidines; Hong Kong; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Organ Specificity; Pyrans; Sialic Acids; Virulence; Virus Replication; Zanamivir	1998
Progress treating, preventing influenza. JAMA, 1998, Nov-25, Volume: 280, Issue:20 Topics: Amines; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1998
Treating influenza with zanamivir. Lancet (London, England), 1998, Dec-12, Volume: 352, Issue:9144 Topics: Administration, Inhalation; Adult; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1998
The relentless flu drug. Environmental health perspectives, 1998, Volume: 106, Issue:8 Topics: Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Pyrans; Sialic Acids; Zanamivir	1998
[A grip grippe?]. Medizinische Monatsschrift fur Pharmazeuten, 1998, Volume: 21, Issue:12 Topics: Antiviral Agents; Guanidines; Humans; Incidence; Influenza, Human; Pyrans; Sialic Acids; United States; Zanamivir	1998
[Influenza: new therapeutic perspectives]. Presse medicale (Paris, France : 1983), 1998, Volume: 27 Suppl 5 Topics: Administration, Intranasal; Animals; Antiviral Agents; Disease Models, Animal; Guanidines; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Mice; Prospective Studies; Pyrans; Rodentia; Sialic Acids; Vaccination; Zanamivir	1998
[HIV, hepatitis, influenza: new antiviral agents]. Deutsche medizinische Wochenschrift (1946), 1999, Jan-08, Volume: 124, Issue:1-2 Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiviral Agents; Child; Clinical Trials as Topic; Dideoxynucleosides; Enzyme Inhibitors; Guanidines; Hepatitis B; Humans; Influenza, Human; Lamivudine; Neuraminidase; Pyrans; Reverse Transcriptase Inhibitors; Sialic Acids; Zanamivir	1999
Treating influenza with zanamivir. Management of Influenza in the Southern Hemisphere Trialists. Lancet (London, England), 1999, Feb-20, Volume: 353, Issue:9153 Topics: Administration, Inhalation; Amantadine; Antiviral Agents; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Orthomyxoviridae; Pyrans; Rimantadine; Sialic Acids; Time Factors; Zanamivir	1999
Treating influenza with zanamivir. Lancet (London, England), 1999, Feb-20, Volume: 353, Issue:9153 Topics: Administration, Inhalation; Amantadine; Antiviral Agents; Biological Availability; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Orthomyxoviridae; Pyrans; Sialic Acids; Time Factors; Zanamivir	1999
Glaxo's antiviral ills not deemed contagious. Nature biotechnology, 1999, Volume: 17, Issue:4 Topics: Antiviral Agents; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; United States; United States Food and Drug Administration; Zanamivir	1999
New options for prevention and control of influenza. JAMA, 1999, Jul-07, Volume: 282, Issue:1 Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	1999
Zanamivir for influenza: a public health perspective. Its use will require careful management by GPs. BMJ (Clinical research ed.), 1999, Sep-11, Volume: 319, Issue:7211 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	1999
Inhaled zanamivir approved for influenza treatment. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Sep-01, Volume: 56, Issue:17 Topics: Administration, Inhalation; Antiviral Agents; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	1999
NICE to rule on influenza flu drug zanamivir. BMJ (Clinical research ed.), 1999, Oct-09, Volume: 319, Issue:7215 Topics: Academies and Institutes; Antiviral Agents; Guanidines; Humans; Influenza, Human; National Health Programs; Pyrans; Sialic Acids; Zanamivir	1999
Dobson backed NICE ruling on flu drug. BMJ (Clinical research ed.), 1999, Oct-16, Volume: 319, Issue:7216 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Legislation, Drug; Organizational Policy; Pyrans; Sialic Acids; Zanamivir	1999
Flu treatment. A new member of the armamentarium. Harvard health letter, 1999, Volume: 25, Issue:1 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	1999
A nasty start for NICE. Lancet (London, England), 1999, Oct-16, Volume: 354, Issue:9187 Topics: Aged; Antiviral Agents; Drug Approval; Drug Industry; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; State Medicine; United Kingdom; Zanamivir	1999
Two neuraminidase inhibitors for treatment of influenza. The Medical letter on drugs and therapeutics, 1999, Oct-08, Volume: 41, Issue:1063 Topics: Acetamides; Administration, Inhalation; Administration, Oral; Amantadine; Amines; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir	1999
[Neuraminidase inhibitors against influenza]. Medizinische Monatsschrift fur Pharmazeuten, 1999, Volume: 22, Issue:9 Topics: Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1999
NICE advises against prescribing zanamivir until further evidence emerges. Communicable disease report. CDR weekly, 1999, Oct-15, Volume: 9, Issue:42 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Practice Guidelines as Topic; Pyrans; Risk Factors; Sialic Acids; Zanamivir	1999
[New antivirals for respiratory tract viruses]. Presse medicale (Paris, France : 1983), 1999, Nov-27, Volume: 28 Suppl 3 Topics: Antiviral Agents; Drug Approval; France; Guanidines; Humans; Influenza, Human; Neuraminidase; Oxadiazoles; Oxazoles; Picornaviridae Infections; Pyrans; Respiratory Tract Infections; Sialic Acids; Zanamivir	1999
Influenza--a new problem? The Medical journal of Australia, 1999, Nov-01, Volume: 171, Issue:9 Topics: Amines; Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1999
Do the new flu drugs measure up? Health news (Waltham, Mass.), 1999, Nov-20, Volume: 5, Issue:14 Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1999
Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 1999, Dec-17, Volume: 48, Issue:RR-14 Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	1999
By the way, doctor. I am 68 years old and healthy. For the past two years, I've gotten a flu shot in October. Nonetheless, both winters I experienced what felt like influenza. I was thrilled to read about a new flu treatment. If I get the flu again this y Harvard women's health watch, 2000, Volume: 7, Issue:6 Topics: Aged; Antiviral Agents; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2000
Zanamivir. 4-guanidino Neu5Ac2en, GG 167, GR 121167, GR 121167X, Relenza. Drugs in R&D, 1999, Volume: 2, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Guanidines; Humans; Influenza, Human; Orthomyxoviridae; Pyrans; Sialic Acids; Zanamivir	1999
Zanamivir, influenza, and meningococcal disease. Zanamivir may help to fight potential flu epidemic. BMJ (Clinical research ed.), 2000, Feb-05, Volume: 320, Issue:7231 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2000
Respiratory distress associated with zanamivir. The New England journal of medicine, 2000, 03-02, Volume: 342, Issue:9 Topics: Antiviral Agents; Bronchial Spasm; Guanidines; Humans; Influenza, Human; Lung Diseases, Obstructive; Male; Middle Aged; Neuraminidase; Pyrans; Respiratory Insufficiency; Sialic Acids; Zanamivir	2000
Zanamivir, influenza, and meningococcal disease. NHS regulations are of questionable legality. BMJ (Clinical research ed.), 2000, Feb-05, Volume: 320, Issue:7231 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Legislation, Drug; Pyrans; Sialic Acids; State Medicine; United Kingdom; Zanamivir	2000
Implications of the Relenza ruling. Journal of the Royal Society of Medicine, 2000, Volume: 93, Issue:2 Topics: Antiviral Agents; Decision Making; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; State Medicine; United Kingdom; Zanamivir	2000
Neuraminidase inhibitors and relief of influenza symptoms. South Dakota journal of medicine, 2000, Volume: 53, Issue:3 Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2000
[Influenza: from vaccine prevention to antiviral therapy]. Revue medicale de Liege, 2000, Volume: 55, Issue:1 Topics: Administration, Inhalation; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2000
[New flu therapy. Progress or burden for the budget?]. MMW Fortschritte der Medizin, 2000, Feb-24, Volume: 142, Issue:8 Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2000
New influenza drug offers some help. Mayo Clinic health letter (English ed.), 1999, Volume: 17, Issue:11 Topics: Antiviral Agents; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	1999
Influenza in the family. The New England journal of medicine, 2000, Nov-02, Volume: 343, Issue:18 Topics: Administration, Inhalation; Antiviral Agents; Disease Transmission, Infectious; Family Health; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2000
Clinical signs and symptoms predicting influenza infection. Archives of internal medicine, 2000, Nov-27, Volume: 160, Issue:21 Topics: Adolescent; Adult; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cough; Diagnosis, Differential; Double-Blind Method; Female; Fever; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Pharyngitis; Predictive Value of Tests; Pyrans; Retrospective Studies; Sialic Acids; Time Factors; Zanamivir	2000
Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infection control and hospital epidemiology, 2000, Volume: 21, Issue:11 Topics: Activities of Daily Living; Administration, Inhalation; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Microbial; Guanidines; Homes for the Aged; Humans; Influenza A virus; Influenza, Human; Middle Aged; Nursing Homes; Ontario; Patient Compliance; Pyrans; Sialic Acids; Zanamivir	2000
Antiviral agents for influenza. Pediatric annals, 2000, Volume: 29, Issue:11 Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Guanidines; Guidelines as Topic; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; Zanamivir	2000
Effect of zanamivir on duration and resolution of influenza symptoms. Clinical therapeutics, 2000, Volume: 22, Issue:11 Topics: Administration, Inhalation; Adult; Aged; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir	2000
Guidance on the use of the anti-influenza drug, zanamivir. Communicable disease report. CDR weekly, 2000, Nov-24, Volume: 10, Issue:47 Topics: Adult; Enzyme Inhibitors; Female; Guanidines; Guidelines as Topic; Humans; Influenza, Human; Male; Pyrans; Sensitivity and Specificity; Sialic Acids; Treatment Outcome; United Kingdom; Zanamivir	2000
Influenza and the new antivirals: potential for misdiagnosis and possible misuse of antivirals. Canada communicable disease report = Releve des maladies transmissibles au Canada, 2000, Dec-01, Volume: 26, Issue:23 Topics: Antiviral Agents; Canada; Diagnostic Errors; Guanidines; Health Services Misuse; Humans; Influenza, Human; Male; Middle Aged; Pyrans; Sialic Acids; Zanamivir	2000
Study allays therapy concern, finds new flu drug safe for patients with asthma, COPD. JAMA, 2000, Dec-27, Volume: 284, Issue:24 Topics: Antiviral Agents; Asthma; Guanidines; Humans; Influenza, Human; Lung Diseases, Obstructive; Pyrans; Risk; Sialic Acids; Zanamivir	2000
Flu-fighting options: decisions, decisions.... Health news (Waltham, Mass.), 2000, Volume: 6, Issue:12 Topics: Acetamides; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pneumonia; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2000
Zanamivir. No noticeable progress against influenza. Canadian family physician Medecin de famille canadien, 2000, Volume: 46 Topics: Amantadine; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2000
Flu drugs. Have I got news for flu. The Health service journal, 2000, Jan-27, Volume: 110, Issue:5689 Topics: Acetamides; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Zanamivir	2000
Zanamivir to prevent influenza. The New England journal of medicine, 2001, Feb-15, Volume: 344, Issue:7 Topics: Antiviral Agents; Family; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2001
Zanamivir to prevent influenza. The New England journal of medicine, 2001, Feb-15, Volume: 344, Issue:7 Topics: Antiviral Agents; Cost-Benefit Analysis; Family; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Pyrans; Sialic Acids; Zanamivir	2001
[New preparations against influenza]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2001, Feb-10, Volume: 121, Issue:4 Topics: Antiviral Agents; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2001
Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. PharmacoEconomics, 2001, Volume: 19, Issue:3 Topics: Administration, Inhalation; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Pyrans; Sialic Acids; Zanamivir	2001
Does the availability of a neuraminidase inhibitor impair influenza vaccination? A report from Austria. Vaccine, 2001, Feb-28, Volume: 19, Issue:15-16 Topics: Antiviral Agents; Austria; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Vaccination; Zanamivir	2001
Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors. Medicine and health, Rhode Island, 2001, Volume: 84, Issue:6 Topics: Acetamides; Antiviral Agents; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sensitivity and Specificity; Sialic Acids; United States; Zanamivir	2001
Elderly people's technique in using dry powder inhalers. Zanamivir and unreason seem to go together. BMJ (Clinical research ed.), 2001, Jul-07, Volume: 323, Issue:7303 Topics: Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Nebulizers and Vaporizers; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2001
Unprepared for an influenza pandemic. Lancet (London, England), 2001, Aug-25, Volume: 358, Issue:9282 Topics: Acetamides; Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2001
Virology. The origin and control of pandemic influenza. Science (New York, N.Y.), 2001, Sep-07, Volume: 293, Issue:5536 Topics: Animals; Antiviral Agents; Chickens; Drug Industry; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; HN Protein; Hong Kong; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Protein Conformation; Pyrans; Reassortant Viruses; RNA, Viral; Sialic Acids; Zanamivir	2001
ACIP releases guidelines on the prevention and control of influenza. Advisory Committee on Immunization Practices. American family physician, 2001, Oct-01, Volume: 64, Issue:7 Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Drug Administration Schedule; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Selection; Pyrans; Rimantadine; Sialic Acids; Zanamivir	2001
[Patient assessment for zanamivir therapy--a survey of patients with influenza who were prescribed zanamivir during the 2000/2001 season in Japan]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 2001, Volume: 75, Issue:9 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antiviral Agents; Guanidines; Humans; Influenza, Human; Middle Aged; Patient Satisfaction; Pyrans; Sialic Acids; Surveys and Questionnaires; Zanamivir	2001
Rapid pharmacotherapeutic intervention for an influenza A outbreak in the Canadian Arctic: lessons from the Sanikiluaq experience. International journal of circumpolar health, 2001, Volume: 60, Issue:4 Topics: Adult; Aged; Antiviral Agents; Arctic Regions; Canada; Disease Outbreaks; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Middle Aged; Pregnancy; Pyrans; Reagent Kits, Diagnostic; Sialic Acids; Zanamivir	2001
Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001, Dec-29, Volume: 356, Issue:1416 Topics: Antiviral Agents; Evidence-Based Medicine; Government Agencies; Guanidines; Health Care Costs; Humans; Influenza, Human; Organizational Objectives; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; United Kingdom; Zanamivir	2001
Zanamivir: an alternative translation. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001, Dec-29, Volume: 356, Issue:1416 Topics: Antiviral Agents; Evidence-Based Medicine; Government Agencies; Guanidines; Humans; Influenza, Human; Practice Guidelines as Topic; Pyrans; Sialic Acids; United Kingdom; Zanamivir	2001
[Drug regulatory agency comments on the editorial about the new influenza drugs]. Duodecim; laaketieteellinen aikakauskirja, 2000, Volume: 116, Issue:6 Topics: Antiviral Agents; Drug Approval; Enzyme Inhibitors; Finland; Guanidines; Humans; Influenza, Human; Neuraminidase; Pyrans; Sialic Acids; Zanamivir	2000
Influenza vaccine, anti-influenza drugs, and rapid diagnosis in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2000, Volume: 6, Issue:2 Topics: Amantadine; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Neuraminidase; Pyrans; Reagent Kits, Diagnostic; Sialic Acids; Vaccination; Zanamivir	2000
Zanamivir (Relenza )--a new treatment for influenza. Intensive & critical care nursing, 1999, Volume: 15, Issue:6 Topics: Age Factors; Aged; Antiviral Agents; Child; Drug Prescriptions; Guanidines; Humans; Influenza, Human; Patient Selection; Public Health; Pyrans; Sialic Acids; United Kingdom; Vaccination; Zanamivir	1999
Are we ready for the next flu pandemic? The Lancet. Infectious diseases, 2001, Volume: 1, Issue:5 Topics: Acetamides; Adult; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2001
[Pneumonia diagnosis in the practice on the test-bench: how much diagnosis is necessary?]. Deutsche medizinische Wochenschrift (1946), 2002, Mar-15, Volume: 127, Issue:11 Topics: Acetamides; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Diagnosis, Differential; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pneumonia; Pyrans; Research; Sialic Acids; Time Factors; Zanamivir	2002
Evidence-based emergency medicine/systematic review abstract. Use of the neuraminidase inhibitor class of antiviral drugs for treatment of healthy adults with an acute influenza-like illness. Annals of emergency medicine, 2002, Volume: 39, Issue:5 Topics: Acetamides; Adolescent; Adult; Age Factors; Antiviral Agents; Confidence Intervals; Emergency Medicine; Enzyme Inhibitors; Evidence-Based Medicine; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Systematic Reviews as Topic; Time Factors; Treatment Outcome; Zanamivir	2002
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2002, Apr-12, Volume: 51, Issue:RR-3 Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Risk Factors; Sialic Acids; United States; Vaccination; Zanamivir	2002
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral research, 2002, Volume: 54, Issue:3 Topics: Acetamides; Acids, Carbocyclic; Canada; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fluorometry; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Luminescent Measurements; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir	2002